SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions June archived by invention type 06/08

20080152585 - Low viscosity liquid dosage forms: The present invention relates to liquid dosage forms of nanoparticulate active agents having very low viscosities.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20080152586 - High avidity polyvalent and polyspecific reagents: This invention provides polyvalent or polyspecific protein complexes, comprising three or more polypeptides which associate to form three or more functional target-binding regions (TBRs), and in which each individual polypeptide comprises two or more immunoglobulin-like domains which are covalently joined together, such that two Ig-like domains in a single polypeptide... Agent: Foley And Lardner LLP Suite 500

20080152587 - Targeted binding agents directed to upar and uses thereof: Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences... Agent: Knobbe Martens Olson & Bear LLP

20080152588 - Metal chelators and methods of their use: Metal chelators of formula (I) and formula (II) are disclosed or a farmaceutically acceptable salt thereof. Also disclosed are metal chelator-targeting moiety complexes, metal chelator-targeting moiety-metal conjugates, kits, and methods of their preparation and use in diagnosis and/or treatment of diseases and conditions, including, inter alia, cancer and thrombosis.... Agent: Woodcock Washburn LLP

20080152589 - Diagnostics and therapeutics of neurological disease: The present invention provides methods for diagnosing a neurological disease and/or for determining the predisposition of a subject to a neurological disease and/or for determining a subject at risk of developing a neurological disease, the method comprising detecting a marker in a glycogen synthase kinase 3β gene or expression product... Agent: Bozicevic, Field & Francis LLP

20080152590 - Engraftable neural progenitor and stem cells for brain tumor therapy: One of the impediments to the treatment of some human brain tumors (e.g. gliomas) has been the degree to which they expand, migrate widely, and infiltrate normal tissue. We demonstrate that a clone of multipotent neural progenitor stem cells, when implanted into an experimental glioma, will migrate along with and... Agent: David S. Resnick

20080152592 - Method of therapeutic drug monitoring: A method of using a diffusion-based, continuous-monitoring system to monitor the effectiveness of delivering a drug includes creating and maintaining a diffusion channel in an area of skin. The levels of the drug, metabolite, or affected substance of the drug are continuously monitored in the area of the skin for... Agent: Nixon Peabody LLP

20080152591 - Methods of screening agents for activity using teleosts: The present invention provides methods of screening an agent for activity using teleosts. Methods of screening an agent for angiogenesis activity, toxic activity and an effect cell death activity in teleosts are provided. Methods of screening an agent for an activity in the brain or central nervous system in zebrafish... Agent: Townsend And Townsend And Crew, LLP

20080152593 - Contrast agent: A contrast agent characterized in that each of carbon nanohorns forming a carbon nanohorn aggregate has an opening at the side wall or tip, wherein a metal M (at least one metal selected from among paramagnetic metals, ferromagnetic metals, and superparamagnetic metals) or a compound of the metal M is... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080152594 - Targeting vector-phospholipid conjugates: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in... Agent: Kramer Levin Naftalis & Frankel LLP

20080152595 - Methods and compositions for deterring abuse of orally administered pharmaceutical products: This invention relates to an abuse deterrent formulation of an oral dosage form of a therapeutically effective amount of any active drug substance that can be subject to abuse combined with a gel forming polymer, a nasal mucosal irritating surfactant and a flushing agent. Such a dosage form is intended... Agent: Morgan, Lewis & Bockius LLP

20080152596 - Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof: i

20080152597 - Dermal penetration enhancers and drug delivery systems involving the same: The invention relates to a method for treatment or prophylaxis of a disease or condition in an animal comprising administering to a mucosal membrane of said animal in need of such treatment a therapeutically effective amount of a drug delivery system comprising at least one physiologically active agent or prodrug... Agent: Foley And Lardner LLP Suite 500

20080152598 - Oral composition for stabilization, (re)calcification and (re)mineralization of tooth enamel and dentine: An oral composition for the stabilization, recalcification and remineralization of dental enamel, providing efficient protection from tooth decay. The oral composition uses the calcium form of zeolite, phosphate salts soluble in water, and matrix proteins of teeth. The efficiency of this solution is based on the adjustment of pH in... Agent: Katten Muchin Rosenman LLP

20080152599 - Oral care compositions: An oral care composition comprising from 0.01 to 0.3% by weight of a pigment having a hue angle, h, in the CIELAB system of from 220 to 320 degrees, characterized in that the composition further comprises a soluble deposition aid for said pigment.... Agent: Unilever Patent Group

20080152601 - Dual component dental composition containing enzyme: A two component desensitizing dentifrice composition is disclosed which comprises a first dentifrice component containing an enzyme such as papain and a second dentifrice component containing an ionic surfactant such as sodium lauryl sulfate, the first and second dentifrice components being maintained separate from the other until dispensed for application... Agent: Colgate-palmolive Company

20080152600 - Peptide-based oral care surface reagents for personal care: Peptides have been identified that bind to oral surfaces such as teeth and gums. Peptide based oral care reagents have been created by couple such peptides to oral care benefit agents such as whiteners.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080152602 - Anti-calculus dental composition and methods for using same: The present invention relates generally to an anti-calculus composition and method for treating subgingival calculus. The anti-calculus composition comprises a pyrophosphate and a tripolyphosphate in a pharmaceutically acceptable carrier. The composition may also comprise a fluoride providing compound.... Agent: Gordon & Rees LLP

20080152603 - Antioxidants: The present invention relates to the use of compounds of the formula (I), with radicals defined in the description, as antioxidants, to corresponding novel compounds and compositions, and to corresponding processes for the preparation of compounds and compositions.... Agent: Millen, White, Zelano & Branigan, P.c.

20080152604 - Skin-lightening compositions with an improved action: Cosmetic or dermatological preparations are comprised of from 0.01 to 5% by weight of a dicarboxylic acid selected from the group consisting of 8-hexadecene-1,16-dicarboxylic acid decanedioic acid nonanedioic acid and combinations thereof and from 0.01 to 5% by weight of ascorbic acid, salts of ascorbic acid, ascorbic acid derivatives and... Agent: Paul & Paul

20080152605 - Cosmetic compositions comprising at least one starch and at least one peg fatty diester, and uses thereof: from 0.1% to 1% by weight, relative to the total weight of the composition, of at least one diester of a carboxylic acid comprising 8 to 30 carbon atoms and of polyethylene glycol. The cosmetic compositions provides a fondant texture, and these compositions rinse out easily. Hair treated with this... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080152606 - Compositions for treating keratinous surfaces: A cosmetic composition comprising Acetyl Hexapeptide-3 in a cosmetically acceptable carrier, and use of such cosmetic compositions in improving skin conditions associated with aging such as wrinkles, fine lines, laxity, mottled pigmentation, and sallowness.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20080152607 - Polycondensate, composition containing a polycondensate, method of treatment, and method of preparation: c

20080152608 - Antiperspirant stick compositions: Antiperspirant stick compositions in the form of a water-in-oil emulsion comprising a dispersed aqueous solution of an astringent antiperspirant salt and a continuous oil phase solidified by a hydrocarbon wax comprising an intermediate molecular weight polyethylene wax, optionally together with a further hydrocarbon wax, exhibit desirable aesthetic properties, including low... Agent: Unilever Patent Group

20080152611 - Shampoo containing a gel network: The compositions of the present invention relate to improved shampoo compositions having from about from about 5 to about 50 weight percent of a detersive surfactant, at least about 0.05 weight percent of a fatty alcohol gel network and at least about 20.0 weight percent of an aqueous carrier.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080152612 - Peptide-based conditioners and colorants for hair, skin, and nails: Peptides have been identified that bind with high affinity to hair, skin, and nails. Peptide-based hair conditioners, hair colorants, skin conditioners, skin colorants, and nail colorants are described. The peptide-based hair conditioners and hair colorants consist of a hair-binding peptide coupled to a hair conditioning agent or a coloring agent,... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080152609 - Suppression of sulfer fumes by higher boiling point oils: A method is disclosed for suppressing low vapor pressure sulfurous fumes generated by sulfur-containing organic compounds, such as is found in personal hair care products. The method includes the step of applying a liquid with a higher vapor pressure temperature than the sulfur-containing compounds to materials contaminated with the sulfur-containing... Agent: Milde & Hoffberg, LLP

20080152610 - Aerosol foam composition: The present invention relates to aerosol foam composition for styling and conditioning keratin fibres especially human hair. The composition improves hair styling with excellent hold and especially conditions hair with excellent shine, combability, volume and body and also excellent elasticity. The inventors of the present invention have found out surprisingly... Agent: Norris, Mclaughlin & Marcus, P.a.

20080152613 - Method for manufacturing a skin care composition: A method for manufacturing a skin care composition may include blending a first phase of the skin care composition. The first phase of the skin care composition may include a predetermined percentage of water, between about 2% and 20% by weight glycerin and/or diglycerin, and between about 0.1% and 5%... Agent: Mark R. Malek, Esquire The Torpy Group, P.l.

20080152614 - Method and kit for skin lesion prevention and/or protection: A method for treatment or prevention of skin lesions, e.g., blisters, comprising: a) applying a liquid polymerizable foundation composition to a selected location on skin, e.g., an existing lesion or an area to be protected from formation of a lesion, b) at least partially polymerizing the foundation composition in situ... Agent: 3m Innovative Properties Company

20080152615 - Composition for adjuvant containing poly-gamma-glutamic acid: The present invention relates to a composition for an immunopotentiator (adjuvant) containing poly-gamma-glutamic acid and a composition for a vaccine containing the immunopotentiator, and more particularly, to an immunopotentiator containing poly-gamma-glutamic acid capable of enhancing antibody production rate by administering it to an animal together with antigen having low immunogenicity,... Agent: Intellectual Property / Technology Law

20080152616 - Amphiphilic block copolymer and polymeric compostition comprising the same for drug delivery: The present invention relates to an amphiphilic block copolymer of a hydrophilic block and a hydrophobic block with a terminal hydroxyl group wherein the terminal hydroxyl group of the hydrophobic bock is substituted with a tocopherol or cholesterol group. It also relates to polymeric compositions capable of forming stable micelles... Agent: Thorpe North & Western, LLP.

20080152617 - Composition for control of cockroaches: The present invention relates to a composition of a bait matrix and acetamiprid with high direct and improved secondary mortality characteristics when used to control cockroaches.... Agent: Patent Administrator Fmc Corporation

20080152618 - Identification and use of agents that modulate oncogenic transcription agent activity: Embodiments of the invention provides, among other things, methods for identifying agents that inhibit oncogenic transcription factors, induce apoptosis, inhibit the growth of transformed cells and cancer cells, and potentiate the effects of other agents that induce apoptosis and that inhibit the growth of transformed cells and cancer cells. Embodiments... Agent: Larry S. Millstein Holland & Knight LLP

20080152621 - Antiviral nucleosides: 4-Amino-1-((2R,3S,4S,5R)-5-azido-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one (22) and prodrugs thereof are hepatitis C (HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting HCV and treating HCV-mediated diseases, processes for making the compounds and synthetic intermediates employed in the process.... Agent: Roche Palo Alto Llc Patent Law Dept. M/s A2-250

20080152620 - Canine thymic stromal lymphopoietin protein and uses thereof: The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080152619 - Hepatitis c virus inhibitors: e

20080152622 - Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, Pc

20080152623 - Blockade of airway hyperresponsiveness and inflammation in a murine model of asthma by insulin-like growth factor binding protein-3 (igfbp-3): The physiological role of IGFBP-3 in respiratory inflammation and hyperresponsiveness is presently unknown. The present invention is based on the unexpected finding that both wild-type IGFBP-3 and the IGFBP-3 mutant GGG-IGFBP-3 inhibit tissue inflammation and hyperresponsiveness associated with obstructive respiratory disorders such as bronchial asthma. Provided herein are methods of... Agent: Troutman Sanders LLP

20080152631 - Cancer antigen peptides derived from wt1: The present invention relates to HLA-A26-binding cancer antigen peptides derived from WT1, polynucleotides encoding said peptide, CTL-inducers, and cancer vaccine comprising said peptide or polynucleotide.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080152633 - Flavivirus replicon constructs for tumor therapy: A flaviviral replicon-based construct is provided for delivery and expression of granulocyte-macrophage colony stimulating factor to facilitate tumour therapy. In particular, the replicon construct encodes a Kunjin virus replicon having one or more mutations in an NS2A non-structural protein that induce enhanced levels of cellular IFN that synergize with recombinant... Agent: Hoffmann & Baron, LLP

20080152634 - Means and methods for improving the development and maturation of eggs and/or sperm in fish using hormones produced by transplanted cells: The invention is concerned with means and methods for improving the development and/or maturation of eggs and/or sperm in fish using hormone administration comprising providing said fish with cells producing said hormone. Preferred hormones are fertility hormones such as luteinizing hormone (LH), follicle stimulating hormone (FSH)or chorionic gonadotropin (CG) or... Agent: Trask Britt

20080152635 - Methods and compositions for correction of cardiac conduction disturbances: The invention provides methods for establishing electrical coupling between cardiomyocytes and recombinant cells which have been genetically engineered to express a gap junction protein, e.g., a connexin protein such as connexin 43 (Cx43) protein. The invention is based on the discovery that genetic modification of skeletal muscle cells to express... Agent: Bozicevic, Field & Francis LLP

20080152632 - Promoter-reporter cells for determining drug metabolism, drug interactions, and the effects of allotype variation: This invention provides a system for rapid determination of pharmacologic effects on target tissue types in cell populations cultured in vitro. The cells contain a promoter-reporter construct that reflects a toxicologic or metabolic change caused by the agent being screened. The promoter is taken from a gene known to be... Agent: Geron Corporation

20080152628 - Augmentation and repair of spincter defects with cells including mesenchymal cells: An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or... Agent: Dardi & Associates, Pllc

20080152626 - Method for activating cd8 t cells: A method for activating a CD8 T cell includes separating CD8 T cells and cultivating them in vitro with a culture broth containing cytokines such as GM-CSF, IFN-γ, TNF-α, lectin, IL-2 and IL-4. Also provided is a therapeutic composition for preventing or treating infectious viral diseases, which includes the CD8... Agent: The Rafferty Patent Law Firm

20080152630 - Method of generation and expansion of tissue-progenitor cells and mature tissue cells from intact bone marrow or intact umbilical cord tissue: Disclosed are compositions and methods of generating and expanding tissue-progenitor cells or mature tissue cells in culture, comprising culturing intact bone marrow or intact umbilical cord tissue in a cell differentiation medium whereby tissue-progenitor cells or mature tissue cells are generated from mesenchymal stem cells and various progenitor cells present... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080152627 - Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same: The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080152629 - Placental stem cell populations: The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.... Agent: Jones Day

20080152625 - Swine population having low levels of porcine endogenous retrovirus and uses thereof: The invention relates to methods of selecting and maintaining a population of pigs having a low copy number of porcine endogenous retrovirus, and the use of such pigs as a source of cells, tissue and/or organs suitable for xenotransplantation. The invention further relates to methods for selecting cells, tissue and/or... Agent: Greenlee Winner And Sullivan P C

20080152624 - Tumor suppression using placental stem cells: The present invention provides methods of suppression of tumor cell proliferation and tumor growth using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of tumor suppression, and compositions comprising such cells and cell... Agent: Jones Day

20080152636 - Composition containing reduced coenzyme q10 and lysolecithin: The present invention provides a method of improving the absorbability of reduced coenzyme Q10, which includes affording a composition containing lysolecithin and reduced coenzyme Q10 in combination. The composition containing lysolecithin and reduced coenzyme Q10 of the present invention shows superior absorption of reduced coenzyme Q10 and can be utilized... Agent: Sughrue Mion, Pllc

20080152637 - Methods of treating and diagnosing parkinsons disease and related dysautonomic disorders: A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease... Agent: Kristina M. Grasso

20080152638 - Storage-stable glucose oxidase: The present invention provides methods and compositions comprising at least one glucose oxidase enzyme, wherein the glucose oxidase has improved storage stability. In some preferred embodiments, the glucose oxidase enzyme is stable after exposure to elevated temperatures. In some alternative preferred embodiments, the glucose oxidase has improved storage stability in... Agent: Elena E. Quertermous Danisco Us Inc., Genencor Division

20080152639 - Methods and compositions using compounds from fetal cells and tissues to improve condition of skin: Compositions comprising one or more compounds expressed by fetal tissues for modulating skin conditions, methods of identifying the compounds, and methods of making and using the compounds are provided.... Agent: Squire, Sanders & Dempsey L.l.p.

20080152642 - Aiolos, helios, daedalos and ikaros: genes, polypeptides, regulatory elements and uses thereof: Provided herein are (a) Aiolos gene, Aiolos polypeptides, Aiolos homodimers, Aiolos/Ikaros heterodimers and methods of using Aiolos nucleic acids and polypeptides; (b) Helios gene, Helios polypeptides, Helios homodimers, Helios/Ikaros heterodimers, Helios/Aiolos heterodimers, and methods of using Helios nucleic acids and polypeptides; (c) Daedalos nucleic acids, Daedalos polypeptides, and other related... Agent: Fish & Richardson Pc

20080152643 - Compositions and methods for treatment of autoimmune and related diseases: Compositions and methods are provided for treatment of autoimmune and other related diseases. 3d, a point mutation of the protein uncoordinated-93b (unc-93B), unc-93A, unc-93B, and unc-93C, polypeptides, nucleic acids encoding them and methods for making and using them, for example, to produce transgenic non-human animals.... Agent: Woodcock Washburn LLP

20080152644 - Genes involved in neurodegenerative conditions: The invention discloses suitable gene and polypeptide targets for the development of new therapeutics to treat, prevent or ameliorate neurodegenerative conditions. The invention also relates to methods to treat, prevent or ameliorate said conditions and pharmaceutical compositions therefor, as well as to a method to identify compounds with therapeutic usefulness... Agent: Novartis Corporate Intellectual Property

20080152645 - Genetically encoded multifunctional compositions bidrectionally transported between peripheral blood and the cns: Provided herein are compositions for increasing transport of agents across the blood-brain barrier, in some embodiments in both directions, while allowing their activity once across the barrier to remain substantially intact. The agents are transported across the blood-brain barrier via one or more endogenous receptor-mediated transport systems. In some embodiments... Agent: Wilson Sonsini Goodrich & Rosati

20080152641 - Inhibitors of siderophore biosynthesis in fungi: The present invention relates to methods for screening inhibitors of siderophore biosynthesis in fungi, preferably in Aspergillus species, particularly preferred in Aspergillus fumigatus comprising (a) contacting a cell expressing a fungal siderophore with a compound to be tested; (b) determining whether said cell is capable of siderophore biosynthesis in the... Agent: Foley And Lardner LLP Suite 500

20080152640 - Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer: The present invention relates to the use of at least one inhibitor of at least one ABC-transporter capable of transporting hyaluronan across a lipid bilayer, such as verapamil or valspodar, for the preparation of a pharmaceutical composition for the treatment of a disease which is associated with an excess transport... Agent: Perkins Coie LLP

20080152648 - Compositions and methods for enhancing an adjuvant: Provided herein are compositions and methods for enhancing an adjuvant effect. The methods involve targeting an adjuvant to an antigen presenting cell (APC) using a compound that binds to a cell surface marker of an APC. Such methods are useful for stimulating an immune response in an animal, such as... Agent: Ropes & Gray LLP

20080152646 - Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies: Compositions and methods for treating MM are provided herein.... Agent: Pdl Biopharma, Inc. Attn: Legal Department

20080152647 - Novel antibody recognizing a small subset of human hematopoietic cells: The subject invention pertains to antibodies that have binding specificity for an antigen that is expressed on a subset of human, hematopoietic mononuclear cells, including a hematopoietic stem cell population, but is not expressed on normal, mature myeloid cells. In one embodiment, a monoclonal antibody, MG1, is provided. This antibody... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080152649 - Optimized igf-1r antibodies and methods of using the same: The present invention describes antibodies that target IGF-1R, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification improves the sequence of said antibody and/or alters the effector function of said antibody. Also disclosed are methods of using the antibodies of the invention.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20080152650 - Methods and compositions for specifically targeting human hepatocellular carcinoma cells: Particular aspects of the present invention provide methods and compositions for the targeting and/or treating hepatocellular carcinoma (HCC) cells to affect cancer cell growth or viability. Exemplary methods and compositions relate to cell-associated HCC proteins (e.g., SEQ ID NOS:1-8, corresponding to PGMRCI (prostaglandin receptor membrane component 1), SEMA5A (semaphorin 5A),... Agent: Davis Wright Tremaine, LLP/seattle

20080152651 - Novel polypeptides involved in immune response: Novel polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding said polypeptides, and vectors and host cells for expressing same are also disclosed. The polypeptides, or agonists and antagonists thereof, are used to treat T-cell mediated disorders.... Agent: Amgen Inc.

20080152652 - Ligand for the c-kit receptor and methods of use thereof: A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention.... Agent: Cooper & Dunham LLP

20080152653 - Anti-alpha9 integrin antibody and the use thereof: The present invention provides an anti-mouse α9 integrin antibody, an anti-human α9 integrin antibody, a hybridoma producing any of the antibodies, a method of producing any of the antibodies and the hybridoma, and a pharmaceutical composition comprising any of the antibodies. The anti-α9 integrin antibody of the present invention inhibits... Agent: Foley And Lardner LLP Suite 500

20080152654 - Compositions and methods for sirna inhibition of angiogenesis: Embodiments of methods of using siRNAs targeting VEGF including an siRNA defined by SEQ ID NO: 77 and SEQ ID NO: 78 to stabilize visual acuity in a subject, to inhibit choroidal neovascularization lesions, to treat age-related macular degeneration, to treat diabetic macular edema, and to decrease foveal thickness in... Agent: Pepper Hamilton LLP

20080152655 - Combination therapy with anti-ctla4 and anti-4-1bb antibodies: Methods for screening monoclonal antibodies to CTLA4, monoclonal antibodies to human CTLA4, therapeutic compositions containing the same.... Agent: Calfee Halter & Griswold, LLP

20080152656 - Prevention and reduction of blood loss: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary... Agent: Lowrie, Lando & Anastasi, LLP

20080152657 - Donor specific antibody libraries: The present invention concerns donor-specific antibody libraries derived from a patient donor who has suffered from, or is suffering from one or more diseases discussed herein. The present invention also concerns the method of making and using the donor-specific antibodies. The present invention further concerns the neutralizing antibodies obtained from... Agent: Heller Ehrman LLP

20080152658 - Stabilized anti-hepatitis b (hbv) antibody formulations: The present invention provides liquid formulations of antibodies or fragments thereof that specifically bind to a hepatitis B virus (HBV) antigen, which formulations exhibit stability, low to undetectable levels of aggregations, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long... Agent: Heller Ehrman LLP

20080152659 - Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration: Disclosed are screening methods for determining a human subject's propensity to develop a vascular disorder and/or age-related macular degeneration (AMD), therapeutic or prophylactic compounds for treating disease or inhibiting its development, and methods of treating patients to alleviate symptoms of the disease, prevent or delay its onset, or inhibit its... Agent: Townsend And Townsend And Crew, LLP

20080152660 - Anti-angiogenic compounds: The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.... Agent: Perkins Coie LLP

20080152661 - Polyconjugates for in vivo delivery of polynucleotides: The present invention is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery vehicles. The use of multiple reversible linkages connecting component parts provides... Agent: Mirus Corporation

20080152662 - Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked... Agent: Keown & Zucchero, LLP

20080152663 - Multi-epitope peptide-loaded dendritic cell immunotherapy for cancer: The invention involves peptides of from about 7 to about 50 amino acid residues in length that have epitopes that bind to more than one HLA class II protein and stimulate CD4+ T cells for treatment of cancer from one of three serine proteases overexpressed in ovarian cancer and other... Agent: Hugh Mctavish Cyr & Associates, P.a.

20080152664 - Sperm ligands and methods of use: Identified herein are sperm ligand proteins located in the membrane of sperm, which proteins interact with the membrane of oocytes. Methods of using these proteins, or fragments or derivatives or analogs thereof, are also described. These include methods of increasing (or reducing) successful fertilization, for instance through improved sperm-oocyte binding,... Agent: Utah State University Technology Commercialization Office

20080152665 - Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response: e

20080152666 - Apoptosis-inducing polypeptides: An isolated water-soluble VP1 polypeptide of foot-and-mouth disease virus and a nucleic acid encoding the polypeptide. Also disclosed are a pharmaceutical composition containing the polypeptide or nucleic acid and related methods of inducing apoptosis and treating an apoptosis-related disorder.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080152667 - Methods and compounds for the treatment of mucus hypersecretion: A method of treating mucus hypersecretion, the causative factor in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD, comprises administering a compound that inhibits exocytosis in mucus secreting cells or neurones that control or direct mucus secretion. Also described is a compound, for use in the... Agent: Merchant & Gould Pc

20080152668 - Thymosin alpha 1 peptide/polymer conjugates: A pharmaceutical composition includes a physiologically active conjugate including a Thymosin alpha 1 (TA1) peptide conjugated to a material which increases half-life of the TA1 peptide in serum of a patient when the conjugate is administered to a patient. The material may be a substantially non-antigenic polymer. In a method... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080152669 - Method of stimulating the production of mucin in the eye of a patient: The present invention includes a method of treating a patient comprising mucin deficiency comprising administering to an eye of a patient suffering from mucin deficiency, a composition comprising alginate in an amount effective to increase production of mucin in the mucin deficient patient.... Agent: Bausch & Lomb Incorporated

20080152670 - Novel recombinant feline herpesvirus type i and polyvalent vaccine using the same: An attenuated feline recombinant herpesvirus 1 (FHV-1), which is prepared by identifying gene regions in the genome wherein inserted foreign genes can be expressed without affecting the replication of FHV-1 and has least two types of foreign nucleic acid sequences inserted thereinto, usable as a vector virus or a vaccine.... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080152671 - Novel vaccination: The invention relates to the use of an EBV membrane antigen or derivative thereof in combination with a suitable adjuvant in the manufacture of a vaccine for the prevention of infectious mononucleosis (IM), and to vaccine compositions suitable for prevention of IM.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080152672 - Methods for treating gluteal muscle: Methods for treating a buttock deformity or for preventing development of a buttock deformity by local administration of a Clostridial toxin, such as a botulinum neurotoxin, to a buttock deformity or to the vicinity of a buttock deformity.... Agent: Allergan, Inc.

20080152673 - Desiccated product: A desiccated or preserved product. The product comprises a sugar, a charged material and a sensitive biological component. The sugar forms an amorphous solid matrix.... Agent: Clark & Elbing LLP

20080152676 - Device for delivering antidotes: A device capable of delivering precise amounts of one or more antidotes to treat a victim exposed to biological and chemical agents (biochem agents), and also preferably sensing the presence of biochem agents. The delivery device includes a plurality of reservoirs containing antidotes, a manifold to which the reservoirs are... Agent: Hartman & Hartman, P.c.

20080152675 - Dispersion of polyamino acids in a continuous lipid phase: d

20080152674 - Epilation compositions having high temperature-sensitivity: Embodiments relate to a method of epilating a body surface includes applying to the body surface an epilation composition having a first shear storage modulus and a second shear storage modulus. The first shear storage modulus is less than 0.1% of a second storage modulus. The first shear storage modulus... Agent: Philip S. Johnson Johnson & Johnson

20080152680 - Cosmetic composition containing novel fractal particle based gels having improved optical properties: A method of instantly reducing the appearance of wrinkles and skin imperfections while smoothing the skin, which comprises applying a cosmetic composition in the form of an oil-in-water emulsion comprising a fractal particle based gel and refractive index matching polymers with respect to at least one of the fractal particles.... Agent: Charles J. Zeller, Esq. Avon Products Inc.

20080152681 - Cosmetic composition containing novel fractal particle-based gels: A method of instantly reducing the appearance of wrinkles and skin imperfections while smoothing the skin, which comprises applying a cosmetic composition comprising a fractal particle based gel.... Agent: Charles J. Zeller, Esq. Avon Products Inc.

20080152683 - Cosmetic product: A new application of a component extracted from a Salmonidae fish ovarian membrane is provided. A cosmetic product of the present invention contains a Salmonidae fish ovarian membrane or a component obtained by treating the ovarian membrane with a protease. The cosmetic product can be used as any one of... Agent: Paul A. Guss Paul A. Guss Attorney At Law

20080152679 - Gel-based lipstick having improved rheology: Gel-based lipstick compositions are disclosed comprising an ester terminated poly(ester-amide) (ETPEA) polymeric gellant, a first wax component having a melting point above the sol-gel transition temperature of the ETPEA gellant, a second wax compositions having a melting point equal to of below the sol-gel transition temperature of the ETPEA gellant,... Agent: Joan M. Mcgillycuddy, Esq. Avon Products Inc.

20080152678 - High gloss gel-based lipstick: Gel-based lipstick compositions are disclosed comprising an ester terminated poly(ester-amide) (ETPEA) polymeric gellant, a first wax component having a melting point above the sol-gel transition temperature of the ETPEA gellant, a second wax compositions having a melting point equal to of below the sol-gel transition temperature of the ETPEA gellant,... Agent: Joan M. Mcgillycuddy, Esq. Avon Products Inc.

20080152677 - Oral hygiene formulations in the form of capsules: Oral hygiene formulations in the form of capsules made of gelatin or similar gelling substances suitable for the alimentary use, filled with an oil containing an antiseptic agent for the oral cavity.... Agent: Young & Thompson

20080152682 - Single-crystal platy barium sulfate in cosmetic compositions: A cosmetic composition is provided which includes from 0.01 to 10% of single-crystal platy barium sulfate, from 0.5 to 10% of a water insoluble powdered acrylic polymer in porous particle form and a carrier. The compositions have soft focus optics imparting radiance to the applied skin area without escessive shininess... Agent: Unilever Patent Group

20080152684 - Method for preparing a composition containing bacillus subtilis wg6-14 and related use: The present invention is an isolated Bacillus subtilis WG6-14 (NRRL Accession No. B-30954). The present invention is also related to a composition containing the isolated Bacillus subtilis WG6-14 (NRRL Accession No. B-30954) and a carrier. The present invention is also related to a method for preparing the composition containing Bacillus... Agent: Frenkel & Associates, P.c.

20080152685 - Process for producing an antimicrobial coating: A process for covalently attaching an antimicrobial coating to a polymeric surface. The process comprises contacting the surface of the polymer with a plasma having reactive nitrogen compounds to provide a plasma-treated surface with —NHR groups, wherein R is hydrogen, hydroxyl or C1-2alkyl, reacting the —NHR groups with a surface... Agent: Bausch & Lomb Incorporated

20080152686 - Adding microscopic porosity to the surface of a microcoil to be used for medical implantation: A vasoocclusive microcoil for therapeutic treatment of a patient's vasculature includes a surface with a plurality of voids or pores therein, and a therapeutic or bioactive material disposed within the plurality of voids or pores. The therapeutic or bioactive material within the plurality of voids or pores operates to accelerate... Agent: Fulwider Patton LLP

20080152690 - Biodegradable, anionic polymers derived from the amino acid l-tyrosine: wherein R12 is an alkyl, aryl or alkylaryl group with up to 18 carbon atoms having a pendent carboxylic acid ester group selected from straight and branched alkyl and alkylaryl esters containing up to 18 carbon atoms and ester derivatives of biologically and pharmaceutically active compounds covalently bonded to the... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080152687 - Bone growth particles and osteoinductive composition thereof: A biocompatible synthetic bone growth composition comprising a fibrillar collagen component and a calcium phosphate component. The composition is formed into particles, and then formed into a unitary article that may be provided at the site of a skeletal defect. An osteoinductive component may be further added, either before or... Agent: Wood, Herron & Evans, LLP (zimmer)

20080152689 - Devices containing dna encoding neurotrophic agents and related compositions and methods: Devices useful in the delivery of DNA encoding neurotrophic agents, anti-fibrotic agents, and related compositions are disclosed herein for use in the treatment of central and/or peripheral nervous system injury. Methods of making and using the disclosed devices and DNA are also described. In various embodiments, the invention also discloses... Agent: Seed Intellectual Property Law Group Pllc

20080152688 - Prevention of bacterial contamination: A compound of formula I: wherein R1 is a straight or branched alkyl group containing 8 to 16 carbon atoms at the 2- or 3-position of the morpholino ring, and R2 is a straight or branched alkyl group containing 2 to 10 carbon atoms, substituted with a hydroxy group except... Agent: Marshall, Gerstein & Borun LLP

20080152692 - Controlling resorption of bioresorbable medical implant material: The resorption of a medical implant can be controlled with the use of particles embedded in a resorbable bulk material forming the implant or portion thereof. The implant can be removed from a body of a mammal by natural biological mechanisms after use. The resorption of the implant can involve... Agent: Mayer & Williams Pc

20080152693 - Implants for the treatment of dopamine associated states: Biodegradable implants comprising dopamine modulating compounds are described.... Agent: Lahive & Cockfield, LLP

20080152691 - Malleable implants containing demineralized bone matrix: Described are malleable medical compositions such as pastes or putties that include solids combined with a liquid carrier. The solids can include particulate collagen and particulate demineralized bone matrix. The liquid carrier includes an aqueous medium comprising one or more polysaccharides. Also described are methods for making and using such... Agent: Medtronic Spinal And Biologics

20080152694 - Devices, systems and methods for ophthalmic drug delivery: Devices, systems and techniques for delivering drugs to an ocular tissue are described. In at least some embodiments, a terminal component (e.g., a needle or open end of a catheter) is implanted in an ocular tissue and used to deliver one or more drugs. The delivered drugs may come from... Agent: Banner & Witcoff, Ltd.

20080152695 - Oral/buccal transmucosal delivery methods for electrolyte compositions including xylitol: The present disclosure is an oral/buccal transmucosal delivery method which includes, generally, an edible thin film strip including a predetermined volume of xylitol. The edible thin film strip of the present disclosure is preferably comprised of potassium chloride; trisodium citrate; sodium chloride; glucose, and; xylitol.... Agent: Fellers Snider Blankenship Bailey & Tippens

20080152696 - Use of leptin for the prevention of excess body weight and composition containing leptin: The invention relates to the use of leptin in the preparation of an ingestible composition for children from nursing infants to adolescents, comprising leptin at a concentration greater than 50 ng/kg, for the prevention of excess weight and/or the complications associated therewith. The invention comprises the use of a fully-... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080152698 - Hydrogel: A hydrogel comprises at least 50% by weight of water, at least one gel-forming polysaccharide, at least one acrylic acid derivative and one electrolyte mixture, the electrolyte mixture containing at least two different electrolytes.... Agent: Brinks Hofer Gilson & Lione

20080152697 - Medical dressing comprising an antimicrobial silver compound: A medical dressing comprising a complex of silver and being capable of releasing antimicrobial silver ion activity, said complex comprising silver and a transition element of Group IV of the periodic system of elements enables a controlled release of silver ion activity to a wound bed.... Agent: Jacobson Holman Pllc

20080152699 - Method of treating menopausal women transdermally with testosterone: A method for administering testosterone to a menopausal woman in need of receiving transdermal testosterone therapy wherein the woman is being coadministered estrogen. The type and route of administration of the estrogen are determined and then changed according to the invention. Testosterone is transdermally administered to the woman. Also, a... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080152703 - Epitopes formed by non-covalent association of conjugates: A method for producing and using in treatment a composition for interacting with a ligand, which composition comprises a non-covalent association of a plurality of distinct conjugates, each conjugate comprising a head group and a tail group, wherein the tail groups of the conjugates form a hydrophobic aggregation and the... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080152700 - Methods and compositions for the inhibition of gene expression: The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.... Agent: Miller Canfield Paddock And Stone

20080152701 - Methods and compositions for the treatment and prevention of staphylococcus infections: A biologically pure RNAIII inhibiting peptide (RIP), that includes five contiguous amino acids of the sequence YX2PX1TNF, where X1 is C, W, I or a modified amino acid, and X2 is K or S is provided. The RIP further includes amino acids having a sequence that differs from the sequence... Agent: Jagtiani + Guttag

20080152702 - Releasable linkage and compositions containing same: A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.... Agent: Robins & Pasternak LLP

20080152704 - Dosage forms of palonosetron hydrochloride having improved stability and bioavailability: Provided are solid oral dosage forms of palonosetron hydrochloride, methods of using the dosage forms to treat emesis, and methods of making the dosage forms. The dosage forms have improved stability and bioavailability, and are preferably in the form of liquid filled capsules.... Agent: Clark G. Sullivan Arnall Golden Gregory LLP

20080152706 - Compositions containing coenzyme q-10 and dihydrolipoic acid: The invention describes compositions, including soft gelatin capsules, that include dihydrolipoic acid and the reduced form of coenzyme Qn wherein the dihydrolipoic acid acts as a reducing agent for the coenzyme Qn and also, optionally, as a solvent.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080152705 - Corosolic acid formulation and its application for weight-loss management and blood sugar balance: A soft gelatin capsule and method to deliver an efficable dose of Lagerstroemia speciosa L. (marketed by Soft Gel Technologies under the trademark Glucosol™) for the assistance and maintenance of moderate weight loss through blood sugar maintenance. The product relies on the effects of corosolic acid on blood sugar levels... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080152708 - High viscosity liquid controlled delivery system and medical or surgical device: The present invention relates to novel nonpolymeric compounds and compositions that form liquid, high viscosity materials suitable for the delivery of biologically active substances in a controlled fashion, and for use as medical or surgical devices. The materials can optionally be diluted with a solvent to form a material of... Agent: Thomas P. Mccracken Durect Corporation

20080152707 - Solubilized coq-10 and carnitine: The present invention is directed to compositions and methods of delivery of CoQ-10 and an amino acid solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 and the amino acid, such as carnitine, i.e., carnitine tartrate, in formulations, such... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080152709 - Clonidine composition and method of use: A pharmaceutical composition comprises clonidine or a pharmaceutically acceptable salt or prodrug thereof. The composition, when administered to a patient in an amount delivering a clonidine dose of about 0.1 to about 2 mg/day, exhibits clonidine release properties providing a 24-hour profile of plasma clonidine concentration that (a) does not... Agent: Kv Pharmaceutical Company

20080152710 - Co-beadlet of dha and rosemary and methods of use: The present invention provides improved beadlet formulations useful for inclusion in dietary supplements customized for improving and maintaining ocular nutrition. In particular, the improved beadlets comprise DHA (docosahexaenoic acid); rosemary and/or its components; and excipients.... Agent: Teresa J. Schultz Ip Legal, Tb4-8

20080152711 - Compressible solid particles, procedures for the obtention thereof and procedures for the use of said particles in body-cleansing tablets: Compressible solid tablets comprising from 20 to 38 wt % of an oily or viscous liquid, from 50 to 70 wt % of a cellulose polymer and from 2 to 15 wt % of an hydrophobic coating compound, wherein said particles size is 180 microns or less. For example, the... Agent: Fitch Even Tabin And Flannery

20080152713 - Herbal contraceptive formulation: Disclosed herein are non-synthetic herbal based anti-fertility compositions having high spermicidal activity for in-travaginal administration comprising hydroalcoholic extract of Annona squamosa and pharmaceutically acceptable excipients, in suitably formulated dosage forms for intravaginal administration and a method of contraception in a female subject to prevent pregnancy.... Agent: Bio Intellectual Property Services (bio Ips) Llc

20080152712 - Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist: or a pharmaceutically acceptable salt or hydrate thereof, a polymer such as gelatin, and a matrix forming agent such as mannitol. Systems for effectively buffering the pre-lyophilized suspension are taught, along with methods of treating patients at risk for acute coronary syndrome by administering such a rapidly disintegrating solid dosage... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080152714 - Pharmaceutical formulations: The present invention provides a modified release formulation comprising an active agent in a hydrophilic polymer matrix wherein the active agent is a salt of fenofibric acid wherein the release rate of the formulation in an in vitro dissolution is substantially independent of the ionic strength of the dissolution media.... Agent: Paul D. Yasger Abbott Laboratories

20080152717 - Amorphous valsartan and the production thereof: Valsartan compositions of enhanced bioavailability are described that contain valsartan with at least one solubility-enhancing polymer. Described methods to produce the bioenhanced products comprise solvent spray drying. One aspect of the method includes the steps of providing a mixture comprising valsartan, a solubility-enhancing polymer and a single solvent, a solvent... Agent: International Specialty Products William J. Davis, Esq.

20080152715 - Method for preparing nanoparticles comprising vitamin k and poly-isopropyl-butyl methacrylate-acrylic acid copolymer with supercritical fluid using molecular association theory: The basic concept of the preparation method is as follows. A nanoscaled vitamin K complex is prepared by dissolving vitamin K and a biodegradable polymer in a suitable amount of an organic solvent, spraying the solution into a reactor equilibrated with a supercritical carbon dioxide via a nozzle to obtain... Agent: Greer, Burns & Crain

20080152716 - System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same: A system and method for manufacturing oral osmotic drug delivery devices including the use of a mathematical model in deriving relationships between parameters used in manufacturing the devices for a desired release rate of the active drug substance contained therein. The derived relationship is then used to control the parameters... Agent: Arent Fox LLP

20080152718 - System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same: A system and method for manufacturing oral osmotic drug delivery devices including the use of a mathematical model in deriving relationships between parameters used in manufacturing the devices for a desired release rate of the active drug substance contained therein. The derived relationship is then used to control the parameters... Agent: Arent Fox LLP

20080152719 - Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance: The invention relates to a multiparticulate pharmaceutical form, comprising pellets with a multilayer structure for controlled active ingredient release, comprising a) optionally a neutral core (nonpareilles), b) an inner controlling layer comprising a substance having a modulating effect, which is embedded in a matrix which influences the delivery of the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080152720 - Nanoparticulate tacrolimus formulations: The present invention is directed to pharmaceutical nanoparticulate compositions of an immunosuppressive agent. The pharmaceutical compositions comprise solid particles of an immunosuppressive agent having an effective average particle size of less than about 2000 nm and one or more surface stabilizers associated with the surface of the immunosuppressive agent particles.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20080152721 - Augmentation and repair of spincter defects with cells including adipocytic cells: An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or... Agent: Dardi & Associates, Pllc

20080152722 - Skin care composition: A skin care composition may consist essentially of 2% to 20% by weight glycerin and/or diglycerin, 2% to 20% by weight grapeseed oil and/or soybean oil, 2% to 30% by weight stearic acid, 0.5% to 5% by weight shea butter, 0.5% to 5% by weight bees wax, 0.5% to 5%... Agent: Mark R. Malek, Esquire The Torpy Group, P.l.

20080152723 - Inorganic resorbable bone substitute material: The invention relates in particular to a hydroxyl apatite/silica granular material of defined morphology, a highly porous bone substitute material based on this granular material and a glass ceramic material based in turn thereon as bone substitute material which is characterised by a variable mechanical strength, and shaped bodies of... Agent: Arnold & Porter LLP Attn: Ip Docketing Dept.

20080152724 - Treatment of periodontitis with an injectable slow release iodine: Compositions for the treatment of periodontitis and methods of use thereof are described. The compositions contain a polymer-iodine complex. The polymer-iodine complex can be suspended in a pharmaceutically acceptable carrier in which the complex is stable and the iodine is stable in its elemental form and/or a combined form (e.g.,... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080152725 - Methods and kits for co-administration of nutritional supplements: The present invention relates to methods of co-administration of various vitamin and mineral compositions, and in a specific embodiment, said methods comprise co-administering one composition comprising vitamin A, vitamin D, vitamin C, vitamin E, folic acid, vitamin B1, vitamin B2, vitamin B6, vitamin B12, niacin, calcium, iron, magnesium, zinc, and/or... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20080152726 - Method for reducing the severity of neurological disorders: The present invention relates to the use of polyunsaturated fatty acids and one or more components which have a beneficial effect on total methionine metabolism selected from the group consisting of vitamin B12 and precursors thereof, vitamin B6 and derivatives thereof, folic acid, zinc and magnesium, in the manufacture of... Agent: Young & Thompson

20080152727 - Aqueous composition containing metal composition, and deodorizing agent, antibacterial agent and antifungal agent composed of such aqueous composition: The present invention provides an aqueous composition and an aqueous composition comprising a titanium compound, having a deodorant, antimicrobial or antifungal effect. That is, the present invention relates to an aqueous composition comprising a metal composition comprising iron, aluminum and potassium, and water, where the aqueous composition may contain tetrahydroxytitanium... Agent: Ware Fressola Van Der Sluys & Adolphson, LLP

20080152728 - Noble gas-chlorine mixture effective against micro organisms: A noble gas-chlorine gas mixture having broad-spectrum effectiveness against bacteria, viruses, mold, fungi, algae including spore forming microorganisms, termites, roaches, mice and other organisms. The noble gas, preferably argon/chlorine gas mixture (Chloragon) is introduced into an enclosed area where the bacteria, virus, mold, fungi, etc., are found and allowed to... Agent: Evelyn M. Sommer

20080152729 - Artemisinins in the clinical and veterinary management of kinetoplastid infections: The invention relates to the treatment of kintoplastid infections by administering a pharmaceutical composition containing an extract from the plant Artemisia annua. The invention also relates to isolated, semi-synthetic and synthetic artemisinins that show improved efficacy in treating kinetoplastid infections. This invention also relates to a method of treating kintoplastid... Agent: Caroline Nash Nash & Titus, Llc

20080152731 - Compositions and method for hair loss prevention: The invention encompasses a formulation for hair loss prevention comprising a mixture of water and at least one nonpolar aprotic organic solvent and at least one hair loss preventive ingredient known to inhibit the hormonal mechanism underlying androgenetic hair loss and methods of using the same.... Agent: Kenyon & Kenyon LLP

20080152730 - Novel composition comprising ligustilide and process for their manufacture: Novel purified extracts from Ligusticum species are obtained by submitting crude extracts from Ligusticum species, particularly from Ligusticum wallichii (chuanxiong) containing less than 50 wt.-% of ligustilide to rectification under specific conditions.... Agent: Stephen M. Haracz Bryan Cave

20080152732 - Compositions and methods for increasing adipose metabolism, lipolysis or lipolytic metabolism via thermogenesis: A composition and method for promoting weight loss through the mutual and simultaneously to promotion lipolysis, the expenditure of energy stored in the body as fat, the inhibition of lipolysis as well as affording the body of an individual protection from reactive oxygen species resulting from the β-oxidation of fats.... Agent: Iovate Health Science Research Inc.

20080152733 - Noni juice composition: A novel noni therapeutic juice composition is provided comprising juice of noni fruit possessing substantially improved potency and stability; a blueberry composition; and a coenzyme precursor to tryptophane. A superior and biologically potent noni results which is synergistically enhanced with a blueberry juice composition and a coenzyme precursor to tryptophane.... Agent: Lawrence M. Logsdon Tropical Functional Labs

20080152734 - Anti-inflammatory agent: An anti-inflammatory agent which comprises an oil-soluble licorice extract obtained by extraction treatment of at least either a leguminous plant of the genus Glycyrrhiza or a water extraction residue of a leguminous plant of the genus Glycyrrhiza with an organic solvent, and has at least one effect selected from an... Agent: Arthur G. Schaier Carmody & Torrance LLP

20080152735 - Herbal extract having anti- influenza virus activity and preparation of same: The invention provides a herbal extract having anti-influenza virus activity, by extracting Sophora flavescens Ait, Thesium chinense Turcz, licorice, or mixture thereof with solvent. The herbal extract contains at least one compound selected from the group of compounds represented by following formula (I) or (II) or mixture thereof:... Agent: Wpat, Pc Intellectual Property Attorneys

20080152736 - Lipid fraction of nigella sativa l. seeds: The present invention provides novel compositions comprising a Nigella sativa L. lipid fraction. The Nigella sativa L. lipid fraction is an oily fraction primarily comprised of long chain fatty acids, volatile oils and sterols. The present invention also provides novel methods using compositions comprising the Nigella sativa L. lipid fraction... Agent: Smith Patent Consulting Consulting, Llc

20080152737 - Cancer and inflammatory disorder treatment: Disclosed are extracts, compositions, and methods for treating cancer and inflammatory disorders. Also disclosed are methods for preparing extracts or compounds for treating the disorders.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080152738 - Formulations useful for immunotherapy for cancers containing bacterial component as an active ingredient: An oil-in-water emulsion that comprise a bacterial component as an active ingredient as well as essentially an oil, surfactant, and a stabilizer, and that can be used as an agent for immunotherapy, and the preparation therefor are provided.... Agent: Birch Stewart Kolasch & Birch

20080152739 - Treating a buttock deformity: Methods for treating a buttock deformity or for preventing development of a buttock deformity by local administration of a Clostridial toxin, such as a botulinum neurotoxin, to a buttock deformity or to the vicinity of a buttock deformity.... Agent: Allergan, Inc.

20080145311 - Chelating agents with lipophilic carriers: Compounds useful for associating with nanoparticle or microparticle emulsions to obtain magnetic resonance images permit control of the relaxivity of the signal and readily associate with the particulate components.... Agent: Morrison & Foerster LLP

20080145312 - Methods for rapid screening of mad cow disease and other transmissible spongiform encephalopathies: Methods for diagnosing altered neuropathology in an animal are disclosed, wherein said methods comprise imaging brain, spinal cord, or other neural tissue of the animal, analyzing the appearance of the tissue, and determining whether the appearance of the tissue is altered relative to corresponding unaltered tissue. Also disclosed are methods... Agent: Millen, White, Zelano & Branigan, P.c.

20080145313 - Compositions and methods for the treatment and prevention of neoplastic disorders: Compositions for the treatment and/or prevention of cancer in a mammal by means of RNA interference are provided, together with methods for the use of such compositions. The compositions comprise a small interfering nucleic acid molecule (siNA) that suppresses expression of a target gene that: (a) is involved in an... Agent: Speckman Law Group Pllc

20080145314 - Egfr inhibitors promote axon regeneration: Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron.... Agent: Richard Aron Osman

20080145315 - Protein fragment complementation assays in whole animals applications to drug efficacy, adme, cancer biology, immunology, infectious disease and gene therapy: The instant invention describes a method for detecting protein-protein interactions in living organisms and/or cells, said method comprising: (a) synthesizing probe protein fragments from a protein which enables fluorescent or luminescent detection by dissecting the gene coding for the fluorescent or luminescent protein into a least two fragments; (2) constructing... Agent: Isaac A. Angres

20080145316 - Skin coating with microbial indicator: Skin sealants are usually applied over skin preps to seal the skin and hold any remaining bacteria in place prior to surgical incisions. This sealant is generally left on the skin after surgery. A skin coating is provided that has an indicator that gives a visible color change upon contact... Agent: Kimberly-clark Worldwide, Inc. Catherine E. Wolf

20080145317 - Effervescent formulations of florfenicol for addition in drinking water systems: The invention relates to an effervescent formulation containing florfenicol or an antibiotic of related structure. When introduced into water, the effervescent formulation is dissolved with minimal or no agitation and provides a solution or a homogeneous dispersion of florfenicol. The formulations are typically in the form of free flowing powders,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080145318 - Atomoxetine formulations and associated methods: Methods and formulations for delivering atomoxetine compounds that minimize drug metabolism and thus increase the effectiveness of the drug are disclosed. The in vivo potency of the atomoxetine compound may be maximized by minimizing the in vivo conversion of the atomoxetine compound to an atomoxetine compound metabolite.... Agent: Hedman And Costigan Pc

20080145319 - Compositions comprising extracts from sanguinaria or macleaya: Compositions containing: 1. Anthocyanosides, and/or 2. Procyanidins, 3. Isoquinoline alkaloids extracted from Sanguinaria canadensis, Macleaya cordata or Macleaya microcarpa, and optionally 4. a Zanthoxylum bungeanum and/or Echinacea angustifolia lipophilic extract.... Agent: Jones Day

20080145320 - Antimicrobial compositions: m

20080145321 - Oral care composition with cross-linked polymer peroxide:

20080145322 - Componds, composition and method for controlling biofolms and bacterail infections: The present invention provides compounds and compositions useful for controlling bacterial biofilms as well as for controlling and/or preventing bacterial infections. The compounds of the invention are pentacyclic acid triterpenes. Methods for controlling biofilms and for controlling and/or preventing bacterial infections are also disclosed.... Agent: Thompson Coburn, LLP

20080145323 - Formulation and method for a sunblock for animals: A composition for treating the skin of a mammal in need of protection from sun exposure is provided, the composition including at least one UV absorber, at least one skin conditioner, at least one film former, at least one antioxidant, and at least one fragrance. A method for preparing such... Agent: Dla Piper Us LLP

20080145324 - Uv-photoprotective compositions comprising diebenzoylmethane screening agents and silicon-containing s-triazine compounds substituted with two aminobenzoate or aminobenzamide groups: UV-photostable, topically applicable cosmetic/dermatological compositions contain at least one dibenzoylmethane UV-sunscreen compound and at least one photostabilizing silicon-containing s-triazine compound substituted with two aminobenzoate or aminobenzamide groups.... Agent: Buchanan, Ingersoll & Rooney Pc

20080145325 - Nail varnish comprising at least one resin: The present invention relates to a nail varnish comprising an organic solvent medium, a gelling agent and at least one ketone/aldehyde resin. The present invention also relates to a cosmetic process for making up or for the non-therapeutic care of the nails, comprising the application to the nails of at... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080145326 - Photopatterning of skin: Methods and systems for treating skin for aesthetic or health purposes are described. According to various embodiments, photoresponsive materials and light are delivered in a controlled fashion to produce a patterned distribution of a material in the skin.... Agent: Searete Llc Clarence T. Tegreene

20080145328 - Composition comprising pyrithione or a polyvalent metal salt of a pyrithione and furametpyr: The present invention relates to a composition comprising an effective amount of a pyrithione or a polyvalent metal salt of a pyrithione, an effective amount of furametpyr and an effective amount of a surfactant including a surfactant with an anionic functional group.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080145329 - Fluorosurfactant with disproportinate effect: This invention relates to surfactant compositions comprising a fluorosurfactant and a siloxane surfactant wherein the fluorosurfactant exhibits a disproportionate effect upon the resulting surfactant composition's ability to lower equilibrium surface tension. The fluorosurfactants and siloxane surfactants identified by the present invention exhibit a desirable disproportionate effect from the fluorosurfactant acting... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080145327 - Hair styling composition: The present invention is related to a hair styling composition for keratin fibres especially for hair. The object of the present invention is an aerosol composition for keratin fibres especially for hair based on an aqueous, aqueous-alcoholic or alcoholic medium comprising at least one natural starch and at least one... Agent: Norris, Mclaughlin & Marcus, P.a.

20080145330 - Agent for inhibiting the growth of mammalian hair: The present invention comprises of a composition for post-hair-removal topical application for inhibiting mammalian hair growth & application thereof. The present invention also embraces a method of inhibiting mammalian hair growth by applying an effective amount of the composition to the skin. The composition comprises of a hair growth-inhibiting agent... Agent: Mrinmayee Bhushan Kondhalkar

20080145331 - Compositons and mehtods of inducing hair growth utilizing continus coggygria: This application relates to compositions and methods for inducing hair growth and improving hair quality utilizing extracts of Cotinus coggygria in an amount effective to induce hair growth when applied topically to an area of the skin on which hair growth is desired.... Agent: Philip S. Johnson Johnson & Johnson

20080145332 - Silicone elastomer composite powder, method for producing silicone elastomer composite powder and cosmetics: The present invention provides a silicone elastomer composite powder with excellent flowability and dispersibility. Also, the present invention provides a method for producing a silicone elastomer composite powder, comprising a step of converting a mixture of a silicone elastomer powder and a clay mineral to the composite powder with a... Agent: Rankin, Hill & Clark LLP

20080145335 - Analogs of glycyl-prolyl-glutamate: Embodiments of this invention include novel analogs of Glycyl-Prolyl-Glutamate (GPE) and compositions containing such analogs of GPE. Of these, certain analogs have modified proline residues. Other embodiments of this invention include uses of analogs of GPE to protect neural cells from degeneration and/or death in response to injury or disease.... Agent: Borson Law Group, Pc

20080145334 - Hepatitis c virus inhibitors: b

20080145336 - Isoindoline compounds and methods of their use: Novel isoindoline compounds are disclosed. Methods of treating, preventing and/or managing cancer, diseases and disorders associated with, or characterized by, undesired angiogenesis, and diseases and disorders mediated by PDE 4, using the compounds are also disclosed.... Agent: Jones Day

20080145333 - Method and system to remove soluble tnfr1, tnfr2, and il2 in patients: A method, and system, to induce remission in diseases characterized by excess production of sTNR and interleukin 2 has been developed. In the most preferred embodiment, the system consists of antibodies to sTNFR1, sTNFR2 and sIL2R immobilized in a column containing a material such as SEPHAROSE™. The patient is connected... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080145337 - Method and pharmaceutical composition for treating inflammation: A method of treating an inflammation in a subject in need thereof is disclosed. The method comprises locally or systemically administering to the subject IFN-gamma in an amount so as to achieve an IFN-gamma bulk tissue concentration at a site of inflammation of 1-8,000 units per kilogram body weight, thereby... Agent: Martin D. Moynihan Prtsi, Inc.

20080145338 - Crosslinked, degradable polymers and uses thereof: Acrylate-terminated poly(beta-amino esters) are cross-linked to form materials useful in the medical as well as non-medical field. The polymeric starting material is combined with a free radical initiator, either a thermal initiator or a photoinitiator, and the mixture for cross-linking is heated or exposed to light depending on the initiator... Agent: Choate, Hall & Stewart LLP

20080145339 - Adeno-associated virus aav rep78 major regulatory protein mutants thereof and uses thereof: AAV Rep78 mutants comprising a modified AAV Rep78 protein that possesses different biochemical and biological functions as compared to the wild-type AAV Rep78 protein are disclosed. Particularly, the AAV Rep78 mutants that bind to at least one of a papillomavirus DNA or an AAV DNA or an oncogene or HIV... Agent: Richard C. Peet Foley & Lardner LLP

20080145340 - Neuroactive agents and methods of their use: This invention is related to a method of controlling neurodegeneration by increasing CD 147 receptor signaling. Neuroprotection can be achieved suing cyclophilin A or a functional variant, analog or derivative as a ligand for the CDE 147 receptor administered in various means including gene therapy. Conditions treatable with this method... Agent: Edwards Angell Palmer & Dodge LLP

20080145347 - p-hyde sequences in the rat: This invention provides isolated nucleic acid of the p-Hyde gene, analogs, fragments, mutants, and variants thereof of the p-Hyde family. The invention provides polypeptides, fusion proteins, chimerics, fusion proteins, antisense molecules, antibodies, and uses thereof. Also, this invention is directed to a method of inducing susceptibility to apoptosis with p-Hyde,... Agent: Pearl Cohen Zedek Latzer, LLP

20080145346 - Methods and compounds for altering the load of hepatitis virus: The present invention relates to a method for altering the load of a Hepatitis virus present in an infected host organism. The method involves modulation of the complex formation of a heterogeneous nuclear ribonucleoprotein K (hnRNP K) and the regulatory region of a Hepatitis virus, enhancer II region. Additionally there... Agent: Foley & Lardner LLP

20080145348 - Production of a biological factor and creation of an immunologically privileged environment using genetically altered sertoli cells: The present invention provides a method of providing an individual with a biological factor or intermediate thereof which comprises introducing into the individual Sertoli cells genetically altered to produce the biological factor or intermediate thereof. The genetically altered Sertoli cells are administered in an amount effective to produce the desired... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080145341 - Stabilised compositions comprising probiotics: Stabilised dry bacterial compositions comprising greater than 10% dried bacterial concentrate having a concentration of bacteria of at least 1×108 cfu/g are provided. The compositions have improved stability. Also provided are packaged bacterial compositions, unit-dose compositions and methods of manufacturing the compositions of the present invention.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080145349 - Composition for noxious organisms-controlling agent and method for using the same: wherein R1, R2 and R3 may be the same or different and each represent hydrogen atom, C3-C6 cycloalkyl, -A1-Qp, etc., each of X and Y may be the same or different and represents hydrogen atom, halogen atom, etc., n is an integer of 1 to 4, m is an integer... Agent: Manelli Denison & Selter

20080145342 - Co-transplantation of hepatic stellate cells and graft: A method of inhibiting graft rejection includes isolating Hepatic Stellate Cells from a mammal liver, activating the isolated Hepatic Stellate Cells, and administering a combination of Hepatic Stellate cells and a graft to a mammal.... Agent: Tarolli, Sundheim, Covell & Tummino L.l.p.

20080145343 - Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof: This invention features a method of identifying a compound useful for enhancing efficacy of a therapeutic agent. The method includes incubating a compound in blood cells; separating immune cells from erythrocytic cells; and determining the ratio of the concentration of the compound in the immune cells to the concentration of... Agent: Edwards Angell Palmer & Dodge LLP

20080145345 - Integrated system for on-site cell acquisition, processing and delivery: Numerous embodiments of a system and method for treating cardiac tissue are described. In one embodiment, bone marrow cells are extracted from a patient. The cells are then processed to isolate mononuclear cells, which can then be delivered back near the cardiac tissue of the patient.... Agent: Blakely Sokoloff Taylor & Zafman

20080145344 - Three-dimensional tissue equivalent using macromass culture: The present invention provides a three-dimensional tissue equivalent for in-vivo and in-vitro uses. The three dimensional tissue equivalent of the present invention is a non-contractile cellular sheet cultured over a porous scaffold using a macromass culturing technique, for example where the cellular sheet is entirely on one side of a... Agent: Foley And Lardner LLP Suite 500

20080145350 - Method of curl retention in hair and lashes: The invention relates to a method of retaining, enhancing or imparting curl in a keratinous material which comprises applying to the keratinous material a retention effective amount of a transglutaminase enzyme.... Agent: Karen A. Lowney Estee Lauder

20080145355 - Formulations including monovalent alginate to enhance effectiveness of administered digestive enzymes: Disclosed are alginate formulations that help protect digestive enzymes in the formulations from denaturation during passage through the acidic stomach environment, and from other sources, following ingestion. The formulation changes consistency to permit release of the enzymes in the less-acidic gut. They contain monovalent alginate salts (sodium, potassium and ammonium... Agent: Eric P. Mirabez

20080145351 - Memory influencing protein: The present invention provides methods and compositions for enhancing and/or impairing memory in animals, including humans by the administration of an effective amount of an atypical form of protein kinase C such as protein kinase M zeta (PKMζ) and/or a PKMζ, inhibitor.... Agent: Scully Scott Murphy & Presser, Pc

20080145352 - Method for promoting axonal re-growth and behavior recovery in spinal cord injury: A method for promoting axon re-growth and behavior recovery in a subject suffering from a nerve injury is described. The method includes administering a pharmaceutical composition comprising a safe and effective amount of a chondroitinase ABC (CHABC) to an injury site of the nerve injury in the subject.... Agent: Panitch Schwarze Belisario & Nadel LLP

20080145354 - Pegylation of therapeutic agents: The present invention relates to a method for determining the modification conditions of a therapeutic agent comprising (1) assaying the biological activity of a first modified therapeutic agent after the first modified therapeutic agent has been administered to a subject; (2) assaying the biological activity of the first modified therapeutic... Agent: Foley And Lardner LLP Suite 500

20080145353 - Perhydrolase: The present invention provides methods and compositions comprising at least one perhydrolase enzyme for cleaning and other applications. In some particularly preferred embodiments, the present invention provides methods and compositions for generation of peracids. The present invention finds particular use in applications involving cleaning, bleaching and disinfecting.... Agent: Kamrin T Macknight Genencor International Inc

20080145356 - Enzyme treatment of foodstuffs for celiac sprue: Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.... Agent: Bozicevic, Field & Francis LLP Stanford University Office Of Technology Licensing

20080145357 - Tissue fusion method using collagenase for repair of soft tissue: The present invention provides a method of using locally administered collagenase as a non-invasive means of enhancing cell release from the cartilage or fibrocartilage tissues adjacent to a disease or injury site. The subsequent migration of cells from these tissues into the lesion or wound, followed by deposition of the... Agent: Philip S. Johnson Johnson & Johnson

20080145359 - Imaging, diagnosis and treatment of disease: The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium.... Agent: Wolf Greenfield & Sacks, P.c.

20080145358 - Method for determining responsiveness to chk1 inhibitors: The invention is directed at a method for predicting a patient's responsiveness to a CHK1 inhibitor The method includes providing a sample from a test patient who is being treated with a DNA damaging agent; and determining for the presence of an activated CHK1 signal transduction pathway molecule, wherein the... Agent: Astrazeneca R&d Boston

20080145362 - Antibody combination useful for tumor therapy: Described is a combination of at least two antibodies, characterized by the following properties: (a) it comprises at least two different multivalent antibodies, each one having at least two specificities and being characterized by features (b) and (d) or (b) and (c) as defined below, (b) an antigen-binding domain specific... Agent: Intellectual Property / Technology Law

20080145360 - Immune-derived moieties reactive against lysophosphatidic acid: Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate)... Agent: Biotechnology Law Group C/o Portfolioip

20080145361 - Uses of mammalian cytokine; related reagents: Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.... Agent: Dnax Research Inc. Legal Department

20080145363 - Therapeutic combination of a vegf antagonist and anti-hypertensive agent: Disclosed are compositions and methods for treating a disease or condition related to angiogenesis with a vascular endothelial growth factor (VEGF) inhibitor and one or more anti-hypertensive agent(s). The method of the invention is useful for preventing the development of hypertension and/or reducing hypertension in a subject treated with a... Agent: Regeneron Pharmaceuticals, Inc

20080145364 - Method for high throughput screening for anitbodies and proteins inducing apoptosis: High throughput assays used to identify antibodies and proteins that induce cell death are described herein. It is not necessary to identify the antigens the antibodies are reactive with prior to performing the assays. Instead, libraries of antibodies and proteins, including murine, human, humanized, single chain, and synthetic antibodies, are... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080145365 - Human and mammalian stem cell-derived neuron survival factors: The present invention relates to human, rat and mouse stem cell-derived neuron survival factor polypeptides (SDNSF), a process for producing them, cDNA encoding SDNSF, a vector comprising the cDNA, host cells transformed by the vector, an antibody against SDNSF, pharmaceutical compositions containing SDNSF or the antibody, a method of assaying... Agent: Sughrue-265550

20080145366 - Vascular endothelial growth factor d (vegf-d) antibodies and vectors, and methods of use: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it,... Agent: Marshall, Gerstein & Borun LLP

20080145367 - Methods of treating osteoarthritis with il-6 antagonists: The present invention provides for methods of treating osteoarthritis with IL-6 antagonists such as IL-6 antibodies.... Agent: Pfizer Inc.

20080145368 - Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias: Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and... Agent: Jones Day

20080145369 - Autocrine growth factor receptors and methods: Embodiments of the invention provide methods and compositions for method for diagnosing and treating diseases including cancer. In one embodiment diagnosing tumorigenicity is accomplished by measuring the level of PCDGF receptor expression in a tissue sample suspected of being tumorigenic. In another embodiment, a determination of whether tumorigenic cells will... Agent: Dickstein Shapiro LLP

20080145370 - Synthesis of human secretory igm and the treatment of colstridium difficile associated diseases herewith: A composition for treating a subject is provided. The composition includes dimeric or polymeric secretory IgM therapeutic. Formulating agents are mixed with the dimeric or polymeric secretory IgM to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080145371 - Synthesis of human secretory iga for the treatment of clostridium difficile associated diseases: A composition for treating a subject is provided. The composition includes dimeric or polymeric secretory IgA therapeutic. Formulating agents are mixed with the dimeric or polymeric secretory IgA to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080145372 - Bioreductively-activated prodrugs: The present invention relates to a compound of formula (1), or a pharmaceutically acceptable salt thereof, Formula: (1); wherein: R1 is a substituted aryl or heteroaryl group bearing at least one nitro or azido group or is an optionally substituted benzoquinone, optionally substituted naphthoquinone or optionally substituted fused heterocycloquinone: R2... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080145373 - A-beta immunogenic peptide carrier conjugates and methods of producing same: The present invention is directed to methods of producing conjugates of Aβ peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and... Agent: Townsend And Townsend And Crew, LLP

20080145374 - Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a... Agent: Sughrue Mion, Pllc

20080145375 - Vaccination: The present invention relates to improved nucleic acid vaccines, adjuvant systems, and processes for the preparation of such vaccines and adjuvant systems. In particular, the nucleic acid vaccines and adjuvant systems of the present invention comprise a combination of a nucleotide sequence encoding GM-CSF, or derivatives thereof, and toll-like receptor... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080145376 - Vectors and methods for genetic immunization: Improved DNA vaccine plasmids are disclosed. The improved plasmids eliminate all extraneous sequences, and have superior eukaryotic expression, improved yield and stability during bacterial production, facilitate flexible targeting of antigens to various intracellular destinations, and novel RNA-based functionality. These vectors are utilized in novel immunization methods wherein combinations of immunostimulatory... Agent: Brooks Kushman P.c.

20080145377 - G-csf polypeptides and uses thereof: The present invention relates to G-CSF polypeptides and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080145378 - Means and methods for breaking noncovalent binding interactions between molecules: The present invention concerns multimeric proteinaceous molecules comprising at least two members that bind each other via a region of noncovalent interaction, wherein a first of said members comprises a conditionally reactive group that, when activated, cleaves a covalent bond within said first member. Cleavage of the covalent bond results... Agent: Trask Britt

20080145379 - Recombinant dna molecules encoding aminopeptidase enzymes and their use in the preparation of vaccines against helminth infections: The present invention provides nucleic acid molecules containing nucleotide sequences encoding helminth aminopeptidase enzymes, and antigenic fragments and functionally-equivalent variants thereof, their use in the preparation of vaccines, for use against helminth parasites, and synthetic polypeptides encoded by them.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080145380 - Algae and cancer treatment: A composition for primary prevention, treatment to slow progression of cancer or as an adjuvant therapy in treating cancer is defined by a mixture of a blue-green algae and a brown algae._These algae may be ingested simultaneously or serially. The composition may be formulated as a component of nutritional supplement.... Agent: The Weintraub Group, P.L.C

20080145381 - Multi-subtype fiv vaccines: The subject invention pertains to novel methods and compositions for protecting cats from infection by a broad range of FIV strains using a multi-subtype FIV vaccine. Multi-subtype FIV vaccines comprising either cell free whole virus or cell lines infected with viruses are described. Methods for vaccinating cats with the subject... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080145382 - Recombinant virus expressing foreign dna encoding feline cd80, feline cd86, feline cd28, or feline ctla-4 and uses thereof: The present invention involves a recombinant virus which comprises at least one foreign nucleic acid inserted within a non-essential region of the viral genome of a virus, wherein each such foreign nucleic acid encodes a protein. The protein which is encoded is selected from the groups consisting of a feline... Agent: Morgan & Finnegan, L.l.p.

20080145383 - Method for solubilizing peptide mixtures: Described is a method for making a pharmaceutical preparation comprising the solubilisation of a peptide mixture, characterized in that the peptide mixture is solubilized by an aqueous solution containing at least one organic acid selected from the group consisting of formic acid, acetic acid, propionic acid, butyric acid and halogenated... Agent: Fulbright & Jaworski L.l.p.

20080145384 - Enterohemorrhagic escherichia coli vaccine: Compositions and methods for stimulating an immune response against a secreted enterohemorragic Escherichia coli (EHEC) antigen are disclosed. The compositions comprise EHEC cell culture supernatants.... Agent: Woodcock Washburn LLP

20080145385 - Dna vaccine as immunoprophylaxis against kala-azar: A highly conserved membrane protein present in all species of Leishmania can be used as a vaccine antigen for genetic immunization against visceral leishmananiasis.... Agent: Foley And Lardner LLP Suite 500

20080145386 - Trpv1+ sensory neurons control of beta-cell stress and islet inflammation in diabetes: A process is disclosed for controlling inflammatory tissue access through release of neuropeptides, such as substance P (sP), to insulin-responsive sensory neurons, whereby simultaneous control of insulin sensitivity/resistance is manifested. In models of Type 1 and Type 2 diabetes, sensory afferents, in particular TRPV1, have fundamental roles in insulin/glucose homeostasis,... Agent: Mchale & Slavin, P.a.

20080145387 - Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines: The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is GAP-DMORIE.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080145388 - Product for the targeted release of two-compartment active substances: The invention relates to a product for the targeted release of active substances, especially detergents and/or cosmetic active substances. The inventive product has a layer structure, one layer being impermeable to the active substance and another layer being permeable to the active substance. The two layers define a compartment between... Agent: Frommer Lawrence & Haug

20080145389 - Tooth bleaching compositions: The present invention relates to improved dental compositions and methods for bleaching teeth. More specifically, this invention is directed towards hydrogen peroxide-containing compounds that are maintained at a substantially constant pH range of 6.0-10.0 during the tooth-bleaching procedure in the presence of a calcium chelating agent.... Agent: Discus Dental, Llc

20080145390 - Methods and articles having a high antiviral and antibacterial efficacy: Method and article for providing a rapid, broad spectrum bacterial control, and a rapid and persistent antiviral control on an inanimate surface is disclosed. In the method, a compound or composition capable of lowering surface pH to less than about 4 is applied to the surface, and preferably is allowed... Agent: Marshall, Gerstein & Borun LLP (dial)

20080145391 - Absorbent systems providing antimicrobial activity: An article and process provides a stable technology that reduces the microbial content by providing molecular iodine to the stabilized reagents when at least two reactants are activated by aqueous and/or alcohol materials.... Agent: Mark A. Litman & Associates, P.a. York Business Center, Suite 205

20080145392 - Bone graft: An improved demineralized bone matrix (DBM) or other matrix composition is provided that has been mixed with a stabilizing agent that acts as (1) a diffusion barrier, (2) a enzyme inhibitor, (3) a competitive substrate, or (4) a masking moiety. A diffusion barrier acts as a barrier so as to... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080145394 - Coated implantable medical device: A coated implantable medical device 10 includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract; at least one coating layer 16 posited on one surface of the structure; and at least one layer 18 of a bioactive material posited on... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080145396 - Coated implantable medical device: A coated implantable medical device 10 includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract; at least one coating layer 16 posited on one surface of the structure; and at least one layer 18 of a bioactive material posited on... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080145398 - Coated implantable medical device: A coated implantable medical device 10 includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract, and at least one layer 18 of an immunosuppressive agent posited over at least one surface of the structure 12. Optionally, the device 10 can... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080145399 - Coated implantable medical device: A coated implantable medical device 10 includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract, and at least one layer 18 of an immunosuppressive agent posited over at least one surface of the structure 12. Optionally, the device 10 can... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080145393 - Coating of fast absorption or dissolution: A coating of fast absorption or fast dissolution on an implantable device and methods of making and using of the coating are provided.... Agent: Squire, Sanders & Dempsey LLP

20080145401 - Generation of therapeutic microfoam: Improved therapeutic sclerosing microfoams and methods and devices for making them are provided that have advantage in producing a consistent profile injectable foam with minimal input by the physician yet using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080145400 - Ion bombardment of medical devices: A medical device can include a metal member including a porous first portion with pores extending from a surface of the metal member into the first portion and non-porous second portion. The first portion can have a porosity that varies with distance from the surface of the metal member.... Agent: Fish & Richardson Pc

20080145402 - Medical devices containing rapamycin analogs: A medical device comprises a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such... Agent: Squire, Sanders & Dempsey L.l.p.

20080145395 - Multi-formed collagenous biomaterial medical device: The invention involves a submucosa tissue that has the capability of being shape formed or shape configured. The submucosa involves a purified form of submucosa tissue. Optionally, the submucosa can be packaged in such a manner to permit sterility or maintain sterility of the submucosa.... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080145397 - Multi-formed collagenous biomaterial medical device: The invention involves a submucosa tissue that has the capability of being shape formed or shape configured. The submucosa involves a purified form of submucosa tissue. Optionally, the submucosa can be packaged in such a manner to permit sterility or maintain sterility of the submucosa.... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080145403 - Low temperature processes for making cyclic lipid implants for intraocular use: Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.... Agent: Stephen Donovan Allergan, Inc.

20080145404 - Methods and compositions for regenerating connective tissue: Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well... Agent: Alston & Bird LLP

20080145406 - Devices and methods for ophthalmic drug delivery: Disclosed are ophthalmic drug-delivery devices, comprising a body having a proximal end and a distal end, wherein the body includes a styrene elastomer matrix and a drug in contact with the matrix. Also disclosed are methods of treating or preventing an eye disease in a subject, that involve contacting an... Agent: Alcon

20080145405 - Drug delivery devices: A method for making an ocular drug delivery device, the method comprising providing a drug delivery device comprising a core comprising a therapeutically effective amount of one or more pharmaceutically active agents and a first polymeric material, and a shell covering the core, the shell comprising a second polymeric material... Agent: Bausch & Lomb Incorporated

20080145407 - Methods for reducing neovascularization or edema: Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may... Agent: Allergan, Inc.

20080145409 - Composition for the treatment and prevention of peptic ulcer: The present invention relates to a composition and methods of administering the composition, comprising Citronellol and its analogues and derivatives, to humans and other mammalian animals with peptic ulcers induced by alcohol consumption, H. pylori infection, stress and/or intake of nonsteroidal anti-inflammatory medications.... Agent: Baker & Mckenzie LLP

20080145408 - Dimeric double metal salts of (-) hydroxycitric acid, methods of making and uses of same: The present invention relates to soluble dimeric double metal salt compositions of (−)-hydroxycitric acid (“HCA”), as well as methods for making and using the same. The invention provides dimeric double metal salts of group IA and IIA of HCA (hereinafter, “DDM-HCAs”). The present invention provides methods to make DDM-HCAs of... Agent: Foley & Lardner LLP

20080145410 - Manufacture process: The present invention relates to a new iron containing phosphate adsorbent and its use e.g. for treating hyperphosphataemia.... Agent: Novartis Corporate Intellectual Property

20080145411 - Composition of high absorbability for oral administration comprising oxidized coenzyme q10: The present invention provides a method of increasing the absorbability of oxidized coenzyme Q10 by preparing the oxidized coenzyme Q10 as a composition in the presence of a lysolecithin and an oil and fat. The composition of the present invention comprising oxidized coenzyme Q10, a lysolecithin and an oil and... Agent: Sughrue Mion, Pllc

20080145412 - Method of promoting angiogenesis: The present invention is a method for promoting angiogenesis by administering a formulation comprising an effective amount of a peptidic compound, e.g., a peptide having the sequence TDLQERGDNDISPFSGDGQPFKD (SEQ ID NO: 30), which enhances angiogenesis through the induction of pro-angiogenic factors such as FGF2, TGFβ and fibronectin. Formulations may be... Agent: Bozicevic, Field & Francis LLP

20080145415 - Bioresorbable fillers constituted by phospholipid liposomes and hyaluronic acid and/or the derivatives thereof: The present invention describes a new bioresorbable filler constituted by hyaluronic acid and/or the derivatives thereof structured with/in phospholipid liposomes, which increase the residence time of the starting polymer in situ. Said fillers described herein are substantially intended to increase the soft tissues in aesthetic surgery and dermocosmetics for the... Agent: Hedman & Costigan P.c.

20080145416 - Cross-linked ionic core micelles: The present invention provides polymer micelles with cross-linked ionic cores as delivery vehicles for therapeutics, diagnostics, nucleic acids, proteins, small molecules and the like. The present invention provides additionally methods of synthesis and uses for such micelles.... Agent: Dann, Dorfman, Herrell & Skillman

20080145413 - Lipids and lipid assemblies comprising transfection enhancer elements: This disclosure describes structural elements that enhance fusogenicity of lipids and lipid assemblies (e.g. liposomes) with biological membranes, in particular cell membranes, and use of such structures. The elements are pH sensitive in terms of charge and hydrophilicity and undergo a polar—apolar transition when exposed to low pH.... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo Attn: Patent Intake Customer No. 35437

20080145414 - Method of producing fine particles surface-modified with water-soluble substance: An object of the present invention is to provide a method of easily producing fine particles comprising a lipid, a fatty acid, or a derivative thereof, surface-modified with a water-soluble substance, etc. There are provided a method of producing a fine particles, surface-modified with a water-soluble substance, which contains the... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080145418 - Diindolylmethane for the treatment of hpv infection: New methods and compositions are disclosed that comprise the phytochemical Diindolylmethane, alone or in combination with immune potentiating steroids. These methods and compositions are utilized to treat subjects suffering from common cutaneous warts (verrucae) and Human Papilloma Virus (HPV) related conditions of the oropharynx, larynx, genitalia, and uterine cervix.... Agent: Jones Day

20080145417 - Pharmaceutical formulation for the efficient administration apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof: An efficient pharmaceutical formulation for the treatment of an affliction selected from the group consisting of Parkinson's disease, restless legs syndrome and erectile dysfunction. Said composition comprises at least one member selected from the group consisting of apomorphine, 6aR-(−)-N-propyl-norapomorphine and their derivatives and pro-drugs thereof in the form of the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080145419 - High viscosity liquid controlled delivery system and medical or surgical device: The present invention relates to novel nonpolymeric compounds and compositions that form liquid, high viscosity materials suitable for the delivery of biologically active substances in a controlled fashion, and for use as medical or surgical devices. The materials can optionally be diluted with a solvent to form a material of... Agent: Thomas P. Mccracken Durect Corporation

20080145420 - Human secretory iga for the treatment of clostridium difficile associated diseases: A composition for treating a subject is provided. The composition includes dimeric or polymeric IgA therapeutic. Formulating agents are mixed with the dimeric or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of C. difficile... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080145421 - Stabilized composition: It is intended to provide a pharmaceutical composition which contains a proton pump inhibitor and is stable even if it is stored for a long time. It is also intended to provide a pharmaceutical composition which contains a proton pump inhibitor susceptible to acid, and does not dissolve in the... Agent: Birch Stewart Kolasch & Birch

20080145422 - Galantamine tablet formulation: The present invention relates to a direct compression tablet formulation comprising, as the active ingredient, galantamine, and more specifically, galantamine hydrobromide along with a process of making the same. The tablet formulation is a direct compression tablet and has excellent content uniformity and dissolution properties.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080145423 - Chewable tablet and method of formulating: Processes for preparing a chewable tablet comprising a micronized form of an active ingredient, the method comprising the steps of combining the active ingredient with tablet excipients by geometric dilution to form a final mixture and applying direct compression to at least a portion of the final mixture to form... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080145424 - Sustained release l-arginine formulations and methods of manufacture and use: The present invention provides methods and formulations for the treatment and prevention of cerebrovascular and cardiovascular diseases and disorders. The present invention is based, at least in part, on the discovery that administering to a subject a formulation comprising an agonist of endothelial nitric oxide synthase (eNOS), such as an... Agent: Pepper Hamilton LLP

20080145425 - Pharmaceutical composition of zolpidem: A pharmaceutical composition comprising a Zolpidem hemitartrate starting material comprised of form A, the composition containing less than about 8% by weight of water. The starting material typically comprises less than about 0.1% by weight of forms of Zolpidem other than Form A.... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20080145427 - Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors: A dosage form that includes a cholesteryl ester transfer protein inhibitor in a solubility-improved form and an HMG-CoA reductase inhibitor, wherein the dosage form provides immediate release of the HMG-CoA reductase inhibitor and controlled release and immediate release of the cholesteryl ester transfer protein inhibitor.... Agent: Pfizer Inc.

20080145426 - Microencapsulated delivery vehicle having an aqueous core: Microencapsulated delivery vehicles comprising an active agent are disclosed. The microencapsulated delivery vehicles may be introduced into products such that, upon activation, the product provides a functional benefit to a substrate, such as a user's skin.... Agent: Christopher M. Goff (27839) Armstrong Teasdale LLP

20080145428 - Mascara composition containing shape-memory polymers, gels, and fibers: Cosmetic compositions containing an eyelash curling or branching agent, or a skin-lifting mask or lotion. The mascara composition comprises a SMP, at least one film-forming polymer and at least one wax and leads to a make-up product with good staying power, as well as good coating and curling. The skin-lifting... Agent: Avon Products, Inc.

20080145429 - Dosage form containing oxycodone and naloxone: The present invention concerns a dosage form comprising oxycodone and naloxone which is characterized by specific in vivo parameters such as tmax, Cmax, AUCt value, mean bowel function score and/or duration of analgesic efficacy.... Agent: Duane Morris LLP Patent Department

20080145435 - Composition comprising a volatile solvent, an organic filler and a mineral filler, and uses thereof: e

20080145434 - Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use: Methods of attenuating the toxic or medically undesirable effects of drugs and toxins in a human by administering to a human an injectable formulation comprised of a dispersion of particles comprised of reversed cubic or reversed hexagonal lyotropic liquid crystalline material. The particles absorb or adsorb or otherwise sequester and... Agent: Whitham, Curtis & Christofferson & Cook, P.c.

20080145433 - Darusentan oral dosage form: A solid discrete orally deliverable pharmaceutical dosage form comprises darusentan and one or more pharmaceutically acceptable excipients; wherein (a) the darusentan is in solid particulate form having a mean particle size of about 5 to about 200 μm and is present in the dosage form in an amount of about... Agent: Harness, Dickey, & Pierce, P.l.c

20080145432 - Fine particle and pharmaceutical preparation: s

20080145431 - Medicinal composition and process for producing the same: A production process which comprises (1) a step in which a raw liquid containing a drug is prepared so that the drug is contained in an amount which exceeds the saturation amount thereof as determined at the temperature to be used in a treatment with a high-pressure homogenizer and is... Agent: Birch Stewart Kolasch & Birch

20080145430 - Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor: The present invention is directed to a novel pharmaceutical composition suitable for ophthalmic use comprising nanoparticles dispersed in a liquid dispersion medium, wherein said nanoparticles comprise a cyclooxygenase-2 selective inhibitor having adsorbed on the surface thereof at least one surface stabilizer. The ophthalmic formulation of the present invention is stable,... Agent: Merck And Co., Inc

20080145436 - W/o emulsion: e

20080145438 - Micro- and nano-particulate drugs and methods of making thereof: A micro and nano-particulate drug comprising a drug substance and a surfactant in which the drug and surfactant form a eutectic mixture. The matrix formed between the drug substance and the surfactant has a melting point less than the decomposition temperature of the drug substance and thus provides the advantages... Agent: Thorpe North & Western, LLP.

20080145437 - Reactive chemistries for warming personal care products: Reactive chemistries for warming personal care products are disclosed. In one embodiment, one reactant of the chemistry is encapsulated in a microencapsulated composition. Upon rupture, the microencapsulated composition releases the reactant and the reactant can contact a second reactant in the reactive chemistry, located in either an aqueous solution or... Agent: Christopher M. Goff (27839) Armstrong Teasdale LLP

20080145439 - Nanoparticle drug formulations: A suspension of nanoparticles in a liquid medium provides a mechanism for delivery of gacyclidine base or other drug that is substantially insoluble in the liquid medium.... Agent: Banner & Witcoff, Ltd.

20080145440 - Microparticle preparation and medical composition: According to the present invention, an early-phase release amount of cisplatin (CCDP) is reduced and a release of cisplatin is maintained over a long period of time, such that an anticancer effect against cancer cells is enhanced while side effects are reduced. In this manner, a life prolongation effect for... Agent: Armstrong, Kratz, Quintos, Hanson & Brooks, LLP

20080145441 - Nanoparticles: Materials and methods for studying and modulating the interaction of carbohydrate-containing moieties with other species are described, in particular, small particles, e.g. clusters of metal or semiconductor atoms, which can be employed as a substrate for immobilising a plurality of ligands comprising carbohydrate groups. These “nanoparticles” can then be used... Agent: Edwards Angell Palmer & Dodge LLP

20080145442 - Compositions, methods, and devices for treating liver disease: Described are compositions and methods for treating liver disease, e.g., acute liver disease, using bone marrow-derived stem cells and bone marrow-derived stem cell conditioned media.... Agent: Fish & Richardson Pc

20080145443 - Diaper rash composition and method: A diaper rash composition and a method for treating diaper rash are disclosed. In one embodiment, the diaper rash composition contains a volatile silicone, a silicone elastomer, and a diaper rash agent. Of particular advantage, the diaper rash composition can be formulated so as to only contain the above three... Agent: Dority & Manning, P.a.

20080145444 - Blood product from crocodylian species as a feed supplement for weanling pigs and poultry hatchlings: The present invention is a feed supplement consisting of a blood product from at least one Crocodylian species such as the American alligator (Alligator mississippiensis). The blood product is whole blood, hemolyzed blood, serum or plasma. The feed supplement is a liquid or solid. The feed supplement may be combined... Agent: Perret Doise A Professional Law Corporation

20080145445 - Aspartame and citrate flavored phosphate salt laxative: The present invention provides compositions, kits, and methods suitable for cleansing the colon before colonoscopy. The compositions include a phosphate salt and a flavorant that includes aspartame and a citrate. The kits include the previously mentioned compositions and also may include suitable containers, packaging, relief wipes, and instructions for use.... Agent: Evan Law Group Llc

20080145446 - Multi-purpose hand and/or skin cleaner, sanitizer, drug delivery and exercise system: By providing a reusable support base or carrier which is constructed for being easily held by the user in the person's hand, and incorporating additives, therapeutic agents and/or medicinal components therein, a highly effective and easily employed, multi-purpose hand and/or skin cleaner, sanitizer, drug delivery, and exercise system is realized.... Agent: Melvin I. Stoltz

20080145447 - Inorganic solids that accelerate coagulation of blood: The present invention is a method to accelerate the coagulation of blood through the application of inorganic materials. Any solid that can be used to activate the coagulation of platelet-poor plasma in the APTT clinical test or whole blood in the ACT clinical test has been found to be effective... Agent: Honeywell Intellectual Property Inc Patent Services

20080145448 - Calcium potassium ferrocyanide, a prophylactic mixture comprising this compound and the use thereof for decorporation of radiocesium in subjects affected by nuclear radiation: A new prophylactic mixture is prepared for the effective decorporation of *Cs, *Sr, *I from affected subjects in the event of an accidental release of the radioisotopes in the environment due to any nuclear accident. The prophylactic mixture comprising: 1) Calcium Potassium Ferrocyanide [CaK2Fe(CN)6] 2) Calcium Iodate, and 3) Calcium... Agent: Merchant & Gould Pc

20080145449 - Thiol reactive agents as a therapeutic modality: A patient with a disease associated with a receptor having a cysteine residue is treated with a thiol reactive agent. The diseases include neurodegenerative diseases. Diseases characterized by skeletal muscle atrophy are also treated.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080145450 - Delivery or removal of metals from biological systems: A process for delivering and/or removing metal from a biological system by loading a titanate sorbent with a biometal either before introduction into the system for delivery to a site within the system or after introduction into the system for delivery to a site where there is an excess accumulation... Agent: Mcnair Law Firm, P.a.

20080145451 - Composition for relieving discomfort: The invention relates to a method of controlling feelings of pain in infants or diseased or elderly persons using a complete nutrition or a nutritional supplement. The method comprises administering increased levels of folic acid, vitamin B6 and vitamin B12 or their functional equivalents.... Agent: Young & Thompson

20080145452 - Topical formulations for the prevention of sexually transmitted disease and methods of producing the same: The present invention is directed towards various topical protective formulations which may be used as an adjunct in preventing the spread of a broad range of sexually transmitted diseases. The product is intended to be used as a topical lotion, cream, emulsion, or the like. The film forming excipients and... Agent: Mchale & Slavin, P.a.

20080145453 - Novel dihydropyrimidine derivatives and their use as anti-cancer agents: The invention concerns molecules of formula (I), drugs containing same and their use as anti-cancer agents.... Agent: Alston & Bird LLP

20080145454 - Compositions to alleviate herpes virus symptoms: Compositions and methods of preparing and using such compositions to treat the symptoms of herpes virus.... Agent: Cr Miles, P.c. Craig R. Miles

20080145455 - Combination of inorganic hemostatic agents with other hemostatic agents: Several hemostatic bandages that are commercially available function by tightly sealing a wound so that hemostasis can occur before excessive blood loss takes place. Hemostatic bandages which seal a wound but which do not actually speed the coagulation mechanism include chitosan and chitin-based bandages. Hemostatic gauzes based on chemically modified... Agent: Honeywell Intellectual Property Inc Patent Services

20080145456 - Medicated production for local use based on natural materials: The subject of the invention is a medicated product for local use based on natural materials which said product is suitable for alleviating respectively eliminating pain of different locomotor complaints of the body applying the product through the skin surface. The product according to the invention contains menthol in water... Agent: Millen, White, Zelano & Branigan, P.c.

20080145457 - Methods and compositions for reducing l-pipecolic acid effects in animals: The present invention relates to methods and compositions for reducing L-pipecolic acid concentrations and/or effects in animals. In an embodiment, the invention includes a method of reducing plasma concentrations of L-pipecolic acid in animals including administering an effective amount of a composition including saponins. In an embodiment, the invention includes... Agent: Pauly, Devries Smith & Deffner, L.l.c.

20080145458 - Formulations useful in the treatment of male and female impotence: Pharmaceutical compositions containing: extracts of Tribulus terrestris, Epimedium koreanum, Cinnamon cassia in the weight ratio of 1.5-3.5:1-2:0.1-0.4 respectively; and optionally arginine or a physiologically equivalent ester, salt or precursor thereof. The compositions are useful in the treatment of male and female sexual dysfunctions. A method of treatment using the pharmaceutical... Agent: Young & Thompson 2nd Floor

20080145459 - Methods of treating epiphora: The present invention is related to a method for treating epiphora, the method comprising administering to a nasal area of a subject in need thereof a composition comprising camphor, eucalyptus oil, and menthol, wherein the composition is substantially free of lipids other than the eucalyptus oil.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080145460 - Cosmetology product for skin and hair: The invention provides compositions for external application to the skin and/or hair. The composition may be used to treat burns, particularly minor burns, sunburns, eczema, psoriasis, dry or bleeding cuticles, dry or rough skin, athletes foot, razor rash or razor burn, cold sores, dry or chapped lips, dry or frayed... Agent: Morriss Obryant Compagni, P.c.

20080145461 - Formulation and method of making a topical pain relief composition: A topical pain relief composition for applying to the skin, comprising a mixture of stearic acid, emulsifying polymer, arnica oil, peppermint oil, and distilled water is disclosed.... Agent: Michael A. Shippey, Ph. D.

20080145462 - Compositions and methods for treating parasitic infections: Compositions for treating parasitic infections and methods of using the compositions to treat subjects with parasitic infections are provided. Methods of selecting compositions for use in treating parasitic infections are further provided.... Agent: Sonnenschein Nath & Rosenthal LLP

20080145463 - Blood type checking reagent containing lectin: Lectin for checking a blood type is extracted from seeds of bitter gourd, balsam pear, or Momordica charantia. A blood type checking reagent includes the lectin. The lectin extracted from seeds of bitter gourd preferably has a molecular weight between 100,000 and 170,000 measured with poly-acrylamide gel electrophoresis in existence... Agent: Kubotera & Associates, Llc

20080145464 - Anti-tumor and anti-inflammatory extracts of plant biomass and their uses: Extracts from an indigenous Jamaican plant that exhibit an anti-tumor activity and/or an anti-inflammatory activity and, more particularly, an extract of Jamaican Ball Moss (Tillandsia Recurvata) that has a therapeutic pharmacological activity, in particular an anti-cancerous activity by inducing tumorous cell death by apoptosis, and active compounds isolated thereof are... Agent: Ober/kaler C/o Royal W. Craig

20080145465 - Sesquiterpene lactone extract from artemisia leucodes for reducing inflammation and down-regulating pro-inflammatory gene expression: The sesquiterpene lactone extract from Artemisia leucodes is a potent anti-inflammatory agent in vivo. Methods of obtaining the anti-inflammatory extract and methods of treating inflammation with the extract are disclosed. A product comprising the Artemisia leucodes total sesquiterpene lactone extract is useful for treatment of inflammation.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.a.

20080138276 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.a.

20080138275 - Hybridoma cell line g250 and its use for producing monoclonal antibodies: This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G250 as well as derivatives thereof such as chimeric and humanized G250 antibodies.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080138277 - Delivery systems and methods for diagnosing and treating cardiovascular diseases: The invention relates to the treatment and prevention of atherosclerosis and cardiovascular diseases associated with atherosclerosis. The invention further relates to methods of diagnosing atherosclerosis and cardiovascular diseases associated with atherosclerosis. In certain embodiments, the invention provides biological systems and methods for delivering a therapeutic agent or an imaging agent... Agent: Ropes & Gray LLP

20080138278 - Conjugates of rgd peptides and porphyrin or (bacterio) chlorohyll photosynthesizers and their uses: Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and normeoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080138279 - Method of imaging cell death in vivo: A method of imaging apoptosis in vivo, using radiolabeled annexin, is described.... Agent: Lahive & Cockfield, LLP

20080138280 - Composition and methods for inhibiting cell survival: The present invention is directed to compositions and methods of making and using compositions that are useful for treating cells or conditions caused or exacerbated by cell survival mechanisms of the body, particularly conditions exacerbated by cell survival mechanisms involving NF-KB. The compositions and methods of the present invention comprise... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080138281 - Radioactive tyrosine derivative, method for producing same, labeling agent for positron imaging and medical agent for assessing grade of malignancy of tumor respectively composed of radioactive tyrosine derivative, and method for detecting tumor: e

20080138282 - Radiolabeled arylsulfonyl compounds and uses thereof: The present invention relates to Radiolabeled Arylsulfonyl Compounds and methods of use thereof as imaging agents for the COX-2 enzyme using positronemission tomograpy (PET). Methods of making the Radiolabeled Arylsulfonyl Compounds and pharmaceutical compositions comprising an effective amount of a Radiolabeled Arylsulfonyl Compound are also disclosed.... Agent: Wilmerhale/columbia University

20080138283 - Radiolabeled compounds and uses thereof: The present invention relates to Radiolabeled Compounds and methods of use thereof for treating or preventing a psychiatric disorder in a subject, for stabilizing the mood of a subject having a mood disorder, or as imaging agents for a serotonin receptor. Compositions comprising an imaging-effective amount of a Radiolabeled Compound... Agent: Wilmerhale/columbia University

20080138287 - 3-substituted-2(arylalkyl)-1- azabicycloalkanes and methods of use thereof: The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds, and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is... Agent: Womble Carlyle Sandridge & Rice, Pllc

20080138285 - Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound: A steroid ester compound of a terminally-fluorinated alkyl fatty acid, a steroid compound having bis(trifluoromethyl)phenyl group, a phosphatidylserine compound having a terminally-fluorinated alkyl group, a glyceride compound having bis(trifluoromethyl phenyl group, or a glyceride compound having a terminally-fluorinated alkyl group. A vascular lesion can be selectively imaged by using a... Agent: Sughrue Mion, Pllc

20080138286 - Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption: Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption.... Agent: Jones Day

20080138284 - Novel peptides that promote lipid efflux: Disclosed herein are peptides with domains that promote lipid efflux from cells and optionally possess at least one anti-inflammatory domain or a domain that stimulates LCAT activity. Provided herein are methods of using the peptides to treat or inhibit diseases including dyslipidemic disorders, stroke and myocardial infarction. Also provided are... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080138288 - Combinations for treatment of neovasculature: Long-term treatment of conditions associated with neovasculature is effected by combining targeted acute antiangiogenic agent treatment with chronic treatment with an additional drug.... Agent: Morrison & Foerster LLP

20080138292 - Sensors for fluorescence and magnetic resonance imaging: The present invention generally relates to agents and compositions having MRI and/or optical signals, and methods for their use in the determination of an analyte. In some cases, an optical, MRI, or other signal produced by the agent or composition may be affected by the presence of an analyte. Some... Agent: Wolf Greenfield & Sacks, P.c.

20080138289 - Systems and methods for detecting infrared emitting composites and medical applications therefor: Medical applications for an infrared emitting composite are provided. The infrared emitting composite includes an infrared emitting agent dispersed in a matrix material, where the composite emits light of a wavelength range substantially non-absorbent to animal fluid or tissue. A system and method for detecting an infrared emitting composite are... Agent: Kenyon & Kenyon LLP

20080138290 - Fluoro-carbon emulsion enhancement agent for high intensity focused ultrasound treatment and use thereof: The present invention discloses a fluorocarbon emulsion enhancement agent for HIFU treatment, which can increase acoustic energy deposition at the target location during HIFU treatment. The enhancement agent comprises a discontinuous phase comprising of a core material encapsulated by a membrane-forming material and a continuous phase comprised of aqueous medium;... Agent: The Webb Law Firm, P.c.

20080138291 - Sulfonamide derivatives having carbonic anhydrase inhibiting activity and their use as therapeutic and diagnostic agents: The present invention discloses sulfonamide A-(Q)n—Ar—SChNHR which are CA IX-selective inhibitors, which selectively bind to the enzyme under hypoxic conditions and are able to reverse the tumor acidification mediated by the enzyme. These compounds are useful in anticancer therapies based on tumor-associated CA isozyme inhibition as well as for hypoxic... Agent: Young & Thompson

20080138295 - Bechet's disease using cyclopropyl-n-carboxamide: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of... Agent: Jones Day

20080138293 - Cosmetic and pharmaceutical foam: The invention relates to an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a foam adjuvant agent, a surface-active agent and a water gelling agent. The cosmetic or pharmaceutical foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable... Agent: Wilmerhale/boston

20080138294 - Systems and methods for effecting cessation of tobacco use: The invention relates generally to a system and method for treating conditions responsive to nicotine therapy. More specifically, the invention relates to pulmonary administration of a nicotine containing formulation to effect smoking cessation.... Agent: Bozicevic, Field & Francis LLP

20080138296 - Foam prepared from nanoemulsions and uses: The present invention provides a foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable oil in water nano emulsion composition includes: (a) a nano oil globule system, comprising substantially... Agent: Wilmerhale/boston

20080138297 - Pyran derivatives, process of preparation and use thereof in perfumery and flavouring: Y is a 5-, 6- or 7-membered ring, preferably a 5-membered ring, methyl or ethyl mono- or polysubstituted, and optionally unsaturated, and R1, R2, R3, R4 are, each independently, a hydrogen atom or a linear or branched C1-5 alkyl or C2-5 alkenyl group, and X is present or absent; when... Agent: Young & Thompson

20080138298 - Oral care compositions comprising zinc and phytate: i

20080138299 - Oral pharmaceuticals or oral hygiene products comprising licorice flavonoid extract: The present invention relates to the use of a compound Licochalone A (5-(1,1-Dimethylallyl)-4,4′-dihydroxy-2-methoxychalcone)) as well as Glycyrrhiza inflate Betal flavonoid extract, Glycyrrhiza glabra L. flavonoid extract, Glycyrrhiza kansuensis (Chang et Peng) flavonoid extract, a flavonoid extract of a mixture of two to three of the above licorices, or a mixture... Agent: Baker & Mckenzie LLP

20080138302 - Cosmetic composition comprising at least one volatile ester: e

20080138303 - Photoprotective cosmetic compositions comprising silicon-containing s-triazine compounds substituted with two aminobenzoate or aminobenzamide groups and non-silicon-containing lipophilic triazine compound uv-screening agents: and (b) at least one non-silicon-containing lipophilic 1,3,5-triazine compound UV-screening agent, such compositions having improved photoprotective effectiveness in the UV-B range and the 1,3,5-triazine compound(s) being improvedly soluble therein.... Agent: Buchanan, Ingersoll & Rooney Pc

20080138301 - Pyrrolidone-carboxylic modified polysiloxanes having aqueous and detergent solubilities and water-in-oil emulsion capability: The properties of 2-pyrrolidone-4-carboxylic substituted polysiloxanes can be dramatically altered by increasing the presence of the carboxylic-substituted pyrrolidone monomer of the polysiloxane, such that the amidopolysiloxane has an acid equivalent weight of about 3:00-3,000 daltons and a molecular weight average Mw of about 1,000-60,000 daltons resulting in enhanced detergent and... Agent: Jones Day

20080138304 - Depilatory compositions having high concentrations of alkali metal ions: A depilatory composition including a keratin degrading compound; one or more alkali metal ions in a total alkali metal ion concentration by weight of at least about 2.5%; a cation that forms a partially-soluble hydroxide; and one or more hydrophobic compounds is provided.... Agent: Philip S. Johnson Johnson & Johnson

20080138306 - Hair treatment method: A hair treatment method in which a hair treatment agent including (A) water, (B) a hydrophobic silicone, (C) 0.5% by weight or more of a lower alcohol and (D) a surfactant is applied to the hair, and immediately thereafter the hair is bundled and secured with a holding device.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080138305 - Pretreating agent in hair dyeing: To provide a pretreatment agent for use in hair dyeing which is not thick and easy to be applied to scalp and little inhibits hair dyeing. A pretreatment agent for use in hair dyeing comprises polysiloxane, Vaseline and liquid paraffin as essential ingredients.... Agent: Kratz, Quintos & Hanson, LLP

20080138307 - Use of high molecular weight crosslinked, water-soluble cationic polymers in hair care formulations: High molecular weight, crosslinked, water-soluble cationic polymers, such as poly(diallyldialkyl ammonium) halides, give superior performance to conventional polymers in hair care applications, particularly as conditioning agents for hair together with or after a beautification treatment such as relaxing, waving, perming, coloring, straightening or bleaching.... Agent: Joann Villamizar Ciba Corporation/patent Department

20080138308 - Anhydrous hair conditioning composition: A base composition comprising non-ionic surfactant and cationic surfactant is provided. The base composition is prepared by heating the surfactant mixture in the substantial absence of other ingredients. The base composition is a simple composition which is suitable for use in preparing a hair conditioner composition by mixing with water... Agent: Unilever Intellectual Property Group

20080138309 - Use of aminodithiol as a reducing agent for hair perming: The present invention relates to the use of aminodithiols as reducing agents for hair perming. It further relates to a hair perming method using these aminodithiols.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080138310 - Use of peo-pbo block copolymers in ophthalmic compositions: The use of poly(oxyethylene)-poly(oxybutylene) block copolymers in pharmaceutical compositions useful for modifying the surfaces of contact lenses and other medical devices is disclosed. The present invention is based in-part on a discovery that this class of compounds is particularly efficient in wetting hydrophobic surfaces, such as the surfaces of silicone... Agent: Alcon

20080138311 - Allergen-inhibiting method, allergen-inhibiting fiber and allergen-inhibiting sheet: The allergen inhibitor of this invention comprises at least one compound selected from the group consisting of an aromatic hydroxy compound, an alkali metal carbonate, alum, lauryl benzene sulfonate, lauryl sulfate, polyoxyethylene lauryl ether sulfate, and a divalent or more sulfate having either or both of a polyoxyethylene chain and... Agent: Kubovcik & Kubovcik

20080138312 - Biostatic polymer: Methods and compositions effective for at least a week for prevention of microbial colony growth on a surface, for example an inanimate surface, where the surface is covered with a dry or substantially dry film formed from a composition comprising a polyvinyl alcohol and a quaternary ammonium compound. The film... Agent: Wolf Greenfield & Sacks, P.c.

20080138315 - Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an ugtiai substrate: The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention... Agent: Paul D. Yasger Abbott Laboratories

20080138313 - Methods and compositions based on diphtheria toxin-interleukin-3 conjugates: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388... Agent: Jones Day

20080138314 - Use of il-22 for the treatment of conditions of metabolic disorders: The use of IL-22 for the treatment of metabolic disorders including hyperlipidemia, obesity, hyperinsulinemia and diabetes. IL-22 may also be used in combination with insulin for diabetes.... Agent: Eagle Ip Limited

20080138316 - Use of a combination of cyclosporine and pegylated interferon for treating hepatitis c (hcv): A method of treating a patient having a HCV infection which method comprises administering to said patient a cyclosporin A or a cyclosporin A derivative in association with a conjugate of interferon to a water-soluble polymer in an amount effective to alleviate or eliminate one or more of the signs... Agent: Novartis Corporate Intellectual Property

20080138317 - Use of biocompatible amphiphilic polymers as an anti-inflammatory agent: The present invention relates to the use of bioabsorbable and biocompatible amphiphilic polymers as an anti-inflammatory agent. In particular, the present invention provides methods of treating inflammatory diseases or conditions by employing an amphiphilic polymer made of a polybasic acid or a derivative thereof, a monoglyceride and a polyether.... Agent: Philip S. Johnson Johnson & Johnson

20080138319 - Bone-marrow derived neurogenic cells and uses thereof: Disclosed are cellular compositions, grafts and pharmaceutical products made from bone marrow (BM) cells useful for a wide array of cell-based therapies for diseases and disorders of the nervous system. Transgenic cells in accord with the invention express therapeutic or reporter genes encoded in viral vectors. The cells are capable... Agent: Edwards Angell Palmer & Dodge LLP

20080138318 - Compositions comprising viruses and methods for concentrating virus preparations: A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 20° C. to 27° C. Methods for concentrating and purifying virus preparations are also disclosed.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080138325 - Particle-mediated transformation of animal tissue cells: A method of transferring a gene to vertebrate cells is disclosed. The method comprises the steps of: (a) providing microprojectiles, the microprojectiles carrying polynucleic acid sequences, the sequences comprising, in the 5′ to 3′ direction, a regulatory sequence operable in the tissue cells and a gene positioned downstream of the... Agent: Bingham Mccutchen LLP

20080138321 - Method for enhancing stem cell trafficking: Consumption of blue-green algae, or extracts thereof, enhances trafficking or homing of stem cells in animals by inducing a transient increase in the population of stem cells present in the animal's circulatory system. The animal may be healthy or suffering some disease or physiological condition.... Agent: Klarquist Sparkman, LLP

20080138320 - Method of using a probiotic agent for the treatment of diarrhea: Disclosed is a method of manipulating the rate of gastrointestinal transit in a mammalian subject. Also disclosed is the use, in the manufacture of a medicament for the treatment of constipation, of a selective inhibitor of methanogensis, a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of... Agent: Davis Wright Tremaine LLP/los Angeles

20080138322 - Methods and reagents for the enhancement of virus transduction in the bladder epithelium: Agents and methods for enhancing recombinant virus transduction in the bladder epithelium are described. A first method involves contacting the luminal surface of the bladder with a composition comprising a transduction enhancing agent and an oncolytic virus. Alternatively, the luminal surface of the bladder can be contacted first with a... Agent: Ropes & Gray LLP

20080138324 - Hair mesenchymal cells: An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or... Agent: Dardi & Associates, Pllc

20080138323 - Methods of promoting cardiac repair using growth factors fused to heparin binding sequences: The present invention is directed to proteins in which a heparin binding peptide is fused to a growth factor that promotes cell growth and survival. The compound thus formed is bound to the surface of cells which are then administered to damaged tissue. The growth factor is thereby maintained at... Agent: Law Office Of Michael A. Sanzo, Llc

20080138326 - Method for cancer treatment, carcinogenesis suppression or mitigation of adverse reactions of anticancer agents: Provided is a method for suppressing carcinogenesis, treating cancer, or mitigating adverse reactions of anticancer agents, with low prevalence of adverse reactions by administering an effective amount of a reduced coenzyme Q as an active ingredient. In the method, the reduced coenzyme Q can be administered in the form of... Agent: Sughrue Mion, Pllc

20080138327 - Substantially dry disposable device for creating ready-to-use solutions for cleaning and inhibiting the formation of biofilms on surfaces: A substantially dry disposable device for creating ready-to-use solutions effective in cleaning and inhibiting the growth and formation of biofilms on surfaces and methods of manufacturing the same are disclosed. The device is impregnated with a concentrated formulation comprising a fermentation supernatant as obtained from the fermentation of Saccharomyces cerevisiae,... Agent: Evelyn M. Sommer

20080138328 - Novel use of the kinases rsk4 and pak5: Type 2 diabetes is one of the most common diseases. In the year 2030 366 million patients are expected, which is a doubling in comparison to the year 2000. Besides a defective regulation of the glucose metabolism patients suffer from diseases of the kidney and the brain, which are named... Agent: Buchanan Ingersoll & Rooney Pc

20080138329 - Inhibitors of dna methylation in tumor cells: or a pharmaceutically acceptable salt thereof, and which lend themselves for the manufacture of drugs useful in the inhibtion of DNA methylation, the inhibition of DNA methyltransferases, and may therefore be useful for the manufacture of pharmaceuticals for the treatment of developmental disorders such as Prader-Willi-Syndrome, Angelman-Syndrome (Happy Puppet Syndrome),... Agent: Foley And Lardner LLP Suite 500

20080138300 - Composition cosmetique comprenant un polymere acrylique: an organic solvent phase comprising at least one first organic solvent, the said phase being free of lower monoalcohol containing from 1 to 5 carbon atoms or of C3-C4 ketone, or containing them in a weight content, relative to the total weight of the composition, of less than or equal... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080138331 - Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors: A method is described for the diagnosis of an ovarian or endometrial tumor or for a prognosis, characterized in that the L1 level is determined in a patient sample, preferably via an anti L1 antibody, the presence of L1 being an indication of the presence of an ovarian or endometrial... Agent: Intellectual Property / Technology Law

20080138330 - Methods and compositions for treating conditions involving abnormal angiogenesis: The present invention features methods and compositions for preventing, reducing, or treating hypoxia and, pathological disorders involving abnormal angiogenesis. Thus, the present invention is useful for treating, reducing, or preventing ischermic conditions (characterized by a reduced blood flow or reduced angiogenesis, e.g., a myocardial infarct) and hypervascular conditions (characterized by... Agent: Clark & Elbing LLP

20080138339 - Anti human ovarian cancer-anti cd3 bispecific antibody: The present invention provides an anti-ovarian cancer bispecific antibody. Said antibody includes two polypeptide domains connected by a polypeptide linker, one is anti-ovarian cancer antibody, or its Fab fragment, single complementarity determining region (CDR) antibody or single chain Fv (scFv) and the other is anti-CD3 antibody, or its Fab fragment,... Agent: Jones Day

20080138341 - Anti-cd70 antibody and its use for the treatment of cancer and immune disorders: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological... Agent: Townsend And Townsend And Crew LLP

20080138337 - Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation: The present invention provides methods and compositions for the inhibition of proliferation rate of target cells, for example tumor cells. In particular, a nucleic acid encoding a connexin protein, fragment, derivative or analog thereof can be incorporated into a target cell. Expression of the nucleic acid sequence encoding the connexin... Agent: Townsend And Townsend And Crew, LLP

20080138336 - Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and... Agent: Johnathan Klein-evans

20080138334 - Immune-derived moieties reactive against bioactive lipids, and methods of making and using same: Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate)... Agent: Biotechnology Law Group C/o Portfolioip

20080138333 - Internalizing anti-cd74 antibodies and methods of use: The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which... Agent: Faegre & Benson LLP Patent Docketing

20080138340 - Methods and compositions for modulating the immune system of animals: Methods and compositions are disclosed for modulating the immune system of animals. Applicant has identified that oral administration of immunoglobulins purified from animal blood can modulate serum IgG levels for treatment of immune dysfunction disorders, potentiation of vaccination protocols, and improvement of overall health and weight gain in animals, including... Agent: Schwegman, Lundberg & Woessner, P.a.

20080138332 - Methods and compositions for the treatment and prevention of staphylococcus aureus infections through interference with opuc operon interaction with trap: The bacterial protein OpuCA, an intracellular part of an ABC transporter, has been shown to interact directly with TRAP. The present invention provides methods and compositions directed at interfering with the interaction between OpuCA and TRAP. The resulting inhibition of TRAP advantageously will reduce pathogenesis of all bacteria that utilize... Agent: Jagtiani + Guttag

20080138342 - Methods of treating pre-eclampsia and eclampsia: Disclosed herein are methods for diagnosing pre-eclampsia and eclampsia. Also disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1—are also disclosed herein for the treatment... Agent: Clark & Elbing LLP

20080138338 - Polypeptide variants: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For... Agent: Genentech, Inc.

20080138335 - Stabilized human igg2 and igg3 antibodies: It is intended to provide highly stable variants of human antibody IgG2 and IgG3 subclasses. The present invention provides an IgG heavy chain comprising the constant region of a human IgG2 heavy chain having at least a substitution of Y for F at the 300th position, L for V at... Agent: Foley And Lardner LLP Suite 500

20080138343 - Anti-cd70 antibody and its use for the treatment of cancer and immune disorders: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological... Agent: Townsend And Townsend And Crew LLP

20080138344 - Identification and engineering of antibodies with variant fc regions and methods of using same: The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to... Agent: Edell, Shapiro & Finnan, Llc

20080138346 - Antibodies to a chemokine expressed in inflamed adenoid: The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (ADEC) from inflamed adenoid tissue. The present invention also provides for antisense molecules to the nucleotide sequences which encode ADEC, expression vectors for the production of purified ADEC, antibodies capable of binding specifically... Agent: Foley And Lardner LLP Suite 500

20080138345 - Compositions and methods for treatment of cancer: The present invention concerns compositions and methods for the treatment of disorders characterized by the overexpression of an LIV-1. More specifically, the compositions include DNA and amino acid sequences of an LIV-1, antibodies to an LIV-1, and methods for the treatment of a mammal susceptible to or diagnosed with cancer... Agent: Heller Ehrman LLP

20080138347 - Dsp-10 dual-specificity phosphatase: Compositions and methods are provided for the treatment of conditions associated with cell proliferation, cell differentiation and cell survival. In particular, the dual-specificity phosphatase DSP-10, and polypeptide variants thereof that stimulate dephosphorylation of DSP-10 substrates, are provided. The polypeptides may be used, for example, to identify antibodies and other agents... Agent: Seed Intellectual Property Law Group Pllc

20080138348 - G-protein coupled receptor ligands and methods: The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080138349 - Identification and engineering of antibodies with variant fc regions and methods of using same: The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region... Agent: Edell, Shapiro & Finnan, Llc

20080138350 - Process for use of fluoroquinolones to reduce or modulate inflammation due to eye disease or ophthalmic surgery: The present invention provides a safer and more effective way to treat ophthalmic disease and to perform ophthalmic surgeries while reducing the risk of vision loss due to the inflammatory response in the eye. The invention generally relates to the use of fluoroquinolones to reduce inflammation due to ophthalmic disease... Agent: Sheppard, Mullin, Richter & Hampton LLP

20080138351 - Liposome treatment of viral infections: One can treat a viral infection such as hepatitis B (HBV), hepatitis C (HCV), and bovine viral diarrhea virus (BVDV) infections via the delivery of pH sensitive liposomes directly into the endoplasmic reticulum (ER) membrane. Two exemplary liposome formulations are DOPE/CHEMS (DC liposomes) and DOPE/CHEMS/PEG-PE (DCPP liposomes). DC and DCPP... Agent: Foley And Lardner LLP Suite 500

20080138352 - Identification and characterization of novel proline racemases and hydroxyproline-2-epimerases, uses thereof, and methods of identifying proline racemases and hydroxyproline-2-epimerases: This invention provides identification and characterization of racemases and epimerases and definition of protein signatures of those racemases and epimerases. This invention also provides identification of nucleic acid molecules encoding a peptide consisting of a motif characteristic of the protein signatures, and to the peptides consisting of these motifs. Antibodies... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080138353 - Alpha b-chrystallin as a therapy for inflammation: The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods... Agent: Bozicevic, Field & Francis LLP Stanford University Office Of Technology Licensing

20080138354 - Cytomegalovirus vaccine: This specification discloses a Cytomegalovirus vaccine which employs nuclear localization signal knock-out to improve vaccine immunogenicity and antigen presentation in a combined DNA and recombinant adeno-associated viral vector vaccination (rAAV) system.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080138355 - Modified leukotoxin gene and protein: The present invention provides nucleic acid sequences encoding a modified leukotoxin protein, wherein the modification comprises the removal of nucleic acid sequences encoding amino acids within hydrophobic transmembrane domains of full length leukotoxin protein, preferably from Mannheimia haemolytica. The modified leukotoxin proteins are useful in vaccine compositions effective against Mannheimia... Agent: Bereskin And Parr

20080138356 - Pili from mycobacterium tuberculosis: The present invention relates to pili obtained from Mycobacterium tuberculosis, methods of producing the pili and the use of the pili for inducing an immune response against Mycobacterium tuberculosis. The present invention also provides proteins and peptides which are constituents of the pili. Antibodies which bind to the pili are... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080138357 - Vaccines against neisseria meningitidis: Various polypeptides, or a variant or fragment thereof or a fusion of these are described which are useful in a vaccine. The polypeptide may be a polypeptide comprising the amino acid sequence selected from any one of SEQ ID Nos (2, 4, 6, 8, 10, 12, 14, 16, 18, 20,... Agent: Sheldon Mak Rose & Anderson Pc

20080138358 - Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in the method: The invention relates to an ex vivo animal or challenge model as a method to identify protective (recombinant) proteins and rapidly measure protective immunity in intestinal segments directed against parasites and vaccines directed against parasitic infections. The invention further relates to vaccines directed against infection with parasites, such as Fasciola... Agent: Trask Britt

20080138359 - Neisseria meningitidis lgtb los as adjuvant: The present invention relates to Neisserial Lipo-Oligo-Saccharides (LOS) that comprise a tri-saccharide outer core that shows increased binding to the DC-SIGN receptor on dendritic cells, as a result of which the Neisserial LOS's of the invention have increased immunostimulatory activity. The tri-saccharide outer core of the Neiserial LOS's combined with... Agent: Morgan Lewis & Bockius LLP

20080138360 - Vaccine composition against hepatitis c virus: A vaccine composition for the therapeutic and prophylactic treatment of Hepatitis C, containing as components the Hepatitis C virus structural proteins in certain proportions and having an enhancer effect in the development of the immune response against the Hepatitis C virus. Combined vaccines against pathogenic entities including this vaccine composition... Agent: Hoffmann & Baron, LLP

20080138362 - Cell strain capable of being cultured without ingredients derived from animals, method of producing the same, method of producing virus using the same, and method of producing vaccine: [Abstract] The invention relates to a cell strain induced from MDCK cells as dog kidney-derived cells, and being able to be cultured without ingredients derived from animals. The cell strain is produced by adapting a MDCK cell to a medium without a serum but with a cell growth factor; and... Agent: Nath & Associates

20080138361 - Optimized expression of hpv 45 l1 in yeast: Synthetic DNA molecules encoding the HPV45 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV45 L1 protein, wherein said polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV45 virus-like particles (VLPs), and to produce vaccines... Agent: Merck And Co., Inc

20080138363 - Attenuated chimeric flavivirus bearing attenuated japanese encephalitis virus gene as backbone: A nucleic acid molecule containing nucleotide sequences that encode the capsid protein, pre-membrane protein and non-structural protein of Japanese encephalitis virus, and a nucleotide sequence that encodes the envelop protein of a second flavivirus, wherein the nucleotide sequence(s) that encode(s) the pre-membrane protein and/or non-structural protein of Japanese encephalitis virus... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080138364 - Neuropathic pain treatment method: Methods for treating a non-spasm caused pain by peripheral administration to a patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin.... Agent: Allergan, Inc.

20080138365 - Tumor antigens bfa5 for prevention and/or treatment of cancer: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of... Agent: Patrick J. Halloran, Ph.d., J.d

20080138368 - Anhydrous care of make-up composition containing fibers and polyols: An anhydrous care or make-up composition for keratin substances such as the skin, the lips or superficial body growths, containing fibers which are compatibilized with a fatty phase by at least one polyol that is liquid at room temperature, wherein this composition is, in particular, a foundation or a lipstick... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080138366 - Cosmetics: The present invention provides a cosmetic comprising a spherical resin particle having many recesses on the surface thereof. According to the present invention, a cosmetic which is excellent in spreadability and a touch feeling at application, and an effect such as a moist feeling, a wet feeling, a dry feeling... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20080138369 - Dentifrice containing functional film flakes: A dentifrice composition comprising an orally acceptable vehicle having distributed therein a water hydratable film flakes having a matrix comprised of a water soluble hydroxy alkyl cellulose polymer and a starch, and having entrained therein a constituent selected from therapeutic cosmetic and decorative materials.... Agent: Colgate-palmolive Company

20080138367 - Micronized vitamin c formulation: Stable vitamin C (L-ascorbic acid) compositions for topical application, comprising micronized L-ascorbic acid in a substantially non-aqueous carrier having a pH greater than that of skin, and preferably not lower than approximately 5.5 and not greater than approximately 7.5, are described. The composition may consist essentially of L-ascorbic acid and... Agent: Keown & Zucchero, LLP

20080138371 - Aqueous insecticidal compositions and the use thereof for protecting lignocellulose-containing materials: The invention relates to aqueous insecticidal compositions embodied in the form of an aqueous polymer fine particle dispersion containing at least one type of organic insecticidal active substance whose water solubility is equal to or less than 5 g/l at 25° C./1013 mbar and a polymer particle average size, determined... Agent: Birch Stewart Kolasch & Birch

20080138370 - Solid formulation comprising a phytosanitary product: The invention relates to a solid formulation containing a liquid composition containing a water-insoluble solid phytosanitary product. The invention especially relates to a solid formulation enabling the formation of nanoparticles of the phytosanitary product during a dispersion in water.... Agent: Hunton & Williams LLP Intellectual Property Department

20080138372 - Method and composition for attracting arthropods by volatilizing an acid: The invention is a method for attracting mosquitoes by producing a volatilized acid by combining an acid precursor with water to produce the humidified vapor acid attractant, preferably hydrogen chloride. The humidified volatilized acid can be further combined with carbon dioxide, or carbon dioxide can be simultaneously produced to attract... Agent: Alston & Bird LLP

20080138373 - Anti-microbial substrates with peroxide treatment: An oxidizing anti-microbial treatment and products containing such treatment are described. The treatment involves, in part, preparing a substrate to accept an attachment of charged moieties, and a number of stabilized peroxide compounds on at least part of a surface of said substrate. When microbes, such as bacteria, having a... Agent: Dority & Manning, P.a.

20080138381 - Bone implant composite: A bone implant composite comprising a collagen matrix and a calcium-based mineral, the calcium-based mineral having a particle size of 25-2000 μm and being interspersed in the collagen matrix; wherein the bone implant composite contains 3-60% by weight the collagen matrix and 40-97% by weight the calcium-based mineral, and has... Agent: Occhiuti Rohlicek & Tsao, LLP

20080138378 - Cell seeded expandable body: Devices, systems and methods for treating medical conditions using cell therapy via body lumens. Localized delivery is achieved with the use of a stent-like expandable body seeded with cells. The expandable body is expanded to contact at least a portion of the inner walls of the body lumen and the... Agent: Medtronic Vascular, Inc. Attn: Kim S. Grigg

20080138375 - Macrocyclic lactone compounds and methods for their use: v

20080138379 - Methods, treatments, and compositions for modulating hedgehog pathways: The present invention relates to prevention of congenital deformations The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events gene expression during prenatal development, post-natal development and during... Agent: Irving M. Fishman C/o Cohen Tauber Spievack And Wagner

20080138374 - Molecular plasma deposition of bioactive small molecules: Substrates coated with several classes of bioactive agents, including antimicrobial agents, are described. The coating technique is based on a molecular plasma discharge deposition method such that the deposited materials retain biological activity and/or structure. The deposited biomaterials can be selected for a variety of medical uses, including coated implants... Agent: Daniel M. Storey

20080138376 - Preparation of therapeutic foam: A device is described for facilitating the preparation of therapeutic foam e.g. for the treatment of varicose veins. A pressurised vial contains a sclerosant liquid, e.g., polidocanol solution, and a sterile gas which is readily absorbed by the body, e.g., carbon dioxide, oxygen or a mixture of these gases. The... Agent: Nixon & Vanderhye, Pc

20080138380 - Use of dermatan sulfrates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses: Dermatan sulfates and/or O-desulfated heparins useful in treating and preventing heparinoid-induced autoimmune responses, in particular heparin-induced thrombocytopenia (HIT) and its associated disease states. The dermatan sulfates comprise repeating disulfated and/or trisulfated disaccharide units of L-iduronic acid and N-acetyl-D-galactosamine. The O-desulfated heparins comprise heparin molecules selectively O-desulfated at the 2-O and/or... Agent: Jagtiani + Guttag

20080138377 - Vasodilator eluting luminal stent devices with a specific polyphosphazene coating and methods for their manufacture and use: The present invention is directed to luminal stent devices including vascular devices that comprise a specific polyphosphazene and the capability of releasing nitric oxide or other smooth muscle relaxant compounds in vivo or into stored or transient flowing blood to achieve vascular dilatation, reduce adverse reactions, reduce thrombosis, and/or to... Agent: Sutherland Asbill & Brennan LLP

20080138382 - Sustained release intraocular implants and related methods: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable... Agent: Stephen Donovan Allergan, Inc.

20080138383 - Compositions and methods for treating seizures: This invention relates generally to pharmaceutical compositions for treating seizures, and, more particularly, to pharmaceutical compositions that are bioadherent to oral and/or nasal mucosa, comprise one or more anti-acute seizure agents, and can be used to treat one or more conditions selected from the group consisting of acute seizure, repetitive... Agent: Kv Pharmaceutical Company

20080138384 - Oral hair growth stimulants comprising orthosiphon: Disclosed is a hair growth stimulant for oral use comprising at least one member selected from the group consisting of plants of the genus Orthosiphon in the family Lamiaceae, plants of the genus Vitex L. in the family Verbenaceae, and extracts thereof; and a food comprising the hair growth stimulant... Agent: Knobbe Martens Olson & Bear LLP

20080138385 - Antibacterial composition, antibacterial molding, solution containing antibacterial composition, detergent, surface of tatami mat and tatami mat: An antibacterial composition containing an organic antibacterial agent and an inorganic antibacterial agent is provided. Zirconium phosphate having supported thereon silver or copper or a salt thereof may be used as the inorganic antibacterial agent, and 2-mercaptopyridine-N-oxide sodium, carbendazim (methyl 1H-2-benzimidazole carbamate), or thiabendazole (2-(4-thiazolyl)-1H-benzimidazole) may be used as the... Agent: Millen, White, Zelano & Branigan, P.c.

20080138386 - Crosslinkable saccharide-siloxane compositions, and networks, coatings and articles formed therefrom: The invention provides a cross-linkable composition comprising a saccharide-siloxane copolymer according to a specified structural formula, a crosslinking agent, and, optionally, solvent. Cross-linked polymeric networks, cured coatings, and articles of manufacture formed from the inventive compositions are also provided, as well as processes and methods of manufacturing the inventive cross-linkable... Agent: Dinsmore & Shohl LLP

20080138387 - Hemostatic sponge and article: A hemostatic article, e.g., a sponge is pretreated with predetermined quantities of selected hemostatic agents to assist hemostasis in surgical or traumatic wounds. The hemostatic article is provided with a visible marking/indication of the strength of the hemostatic agent. The visible indication may be color coding, or, the marking could... Agent: Rama Nath

20080138388 - Transdermal absorption patch: It is intended to provide a transdermal absorption patch which is highly excellent in transdermal absorption properties and long-lasting drug effect even in the case where a drug-effect component contained in the transdermal absorption patch is a basic drug hardly soluble in a pressure-sensitive adhesive base, has a high stability... Agent: Edwards Angell Palmer & Dodge LLP

20080138389 - Transdermal therapeutic system for treating parkinsonism: A substantially solvent-free matrix layer containing (−)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol is produced by adding an active substance to an adhesive solution, coating the resultant active substance-containing adhesive solution onto a suitable sheet, and removing the solvents in a drying process to give said substantially solvent-free matrix layer.... Agent: Harness, Dickey, & Pierce, P.l.c

20080138391 - Skin-friendly drug complexes for transdermal administration: The present invention generally relates to pharmaceutical compositions for the treatment of various diseases and disorders, in particular the use of novel complexes of amine drugs with polyacrylic acid carbomer polymers. The compositions of the present invention can be administered transdermally or transmucosally to patients in need thereof for a... Agent: Winston & Strawn LLP Patent Department

20080138390 - Transdermal delivery system for use with basic permeation enhancers: The present invention includes transdermal delivery systems having a polymeric active agent reservoir fabricated from an admixture of polyisobutylene and an insoluble hydrophilic polymer in powdered form, which provide numerous advantages in the transdermal delivery of active agents using basic enhancer compositions. For example, the systems of the invention provide... Agent: Intellectual Property Group Fredrikson & Byron, P.a.

20080138394 - Composite for liver-specific delivery and release of therapeutic nucleic acids or drugs: The inventive composite having a nanoscale particle size can specifically deliver therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects without inducing any enzymatic abnormalities or pathological damage to the normal liver function, when administered together with the therapeutic... Agent: Sughrue Mion, Pllc

20080138401 - Delivery vehicle comprising a modified mscl protein channel: The invention relates to the field of drug delivery, in particular, to compounds and methods for the chemical modification of a proteinaceous channel to be used in pharmaceutical delivery vehicles for controlled and/or localized release of therapeutic molecules (e.g., small molecules, peptides, proteins or other macromolecules). Provided are drug delivery... Agent: Trask Britt

20080138398 - Dual release nicotine formulations, and systems and methods for their use: This invention relates generally to a method to provide habitual tobacco users with products, methods and apparatus to reduce and eventually terminate their dependence on nicotine containing products. More specifically, the invention relates to a nicotine-based medicament that is formulated in such a way as to effectively reduce or eliminate... Agent: Bozicevic, Field & Francis LLP

20080138399 - Dual release nicotine formulations, and systems and methods for their use: This invention relates generally to a method to provide habitual tobacco users with products, methods and apparatus to reduce and eventually terminate their dependence on nicotine containing products. More specifically, the invention relates to a nicotine-based medicament that is formulated in such a way as to effectively reduce or eliminate... Agent: Bozicevic, Field & Francis LLP

20080138400 - Liposomal curcumin for treatment of diseases: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2... Agent: Chalker Flores, LLP

20080138392 - Liposome containing cardiolipin for improvement of mitochondrial function: Disclosed herein is a composition comprising a liposome, a cardiolipin, and at least one antioxidant, wherein the composition is useful for improving, maintaining, or restoring a mitochondrial membrane and/or mitochondrial function. In one example, the liposome is primarily composed of phosphatidylcholine, the cardiolipin is tetraoleoyl-cardiolipin, and the at least one... Agent: In Re: Alticor Inc. 28533 Brinks, Hofer, Gilson & Lione

20080138395 - Pharmaceutical composition for the prevention and control of cancer: A pharmaceutical composition for the prevention and control of cancer containing, as pharmaceutically active substances, reduced glutathione and/or S-methyl glutathione and/or S-ethyl glutathione and/or S-acetyl glutathione and/or S-phosphoric glutathione and/or monomethyl glutathione ester and/or monoethyl glutathione ester and/or monoacetyl glutathione ester and/or monophosphoric glutathione ester and/or isopropyl glutathione ester, and... Agent: Thomas & Raring, P.c.

20080138397 - Processes for taste-masking of inhaled formulations: The present invention provides novel processes and methodologies to minimize the bitter or otherwise unpleasant taste, to minimize the tendency to stimulate the cough reflex, or to minimize oropharyngeal deposition of medically-active compounds administered by the pulmonary/inhalation route and to deliver hydroxychloroquine (HCQ) either singularly or in combination with an... Agent: Bozicevic, Field & Francis LLP

20080138396 - Treatment and diagnosis of macrophage mediated disease: where the group Ab comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for... Agent: Barnes & Thornburg LLP

20080138393 - Water soluble extract of spinach for prevention and repair of dna damage: Compositions comprising a water soluble spinach extract, compositions comprising a water soluble spinach extract, a liposome, a cardiolipin, and at least one antioxidant, compositions comprising a water soluble spinach extract, an extract of Arabidopsis thaliana or of the mustard (Brassica) plant, a liposome, a cardiolipin, and at least one antioxidant,... Agent: In Re: Alticor Inc. 28533 Brinks, Hofer, Gilson & Lione

20080138402 - Highly inhibited starch fillers for films and capsules: The invention provides the addition of highly inhibited starch filler to gelatin-free films and soft capsules. The addition of the highly inhibited starch filler raises the solid levels during processing without substantially increasing the melt viscosity. The resultant films and capsules are transparent.... Agent: National Starch And Chemical Company

20080138403 - Pharmaceutical dosage forms of oxcarbazepine: A pharmaceutical dosage form comprising a mixture of a therapeutically effective amount of oxcarbazepine having median particle size ranging from about 15 μm to about 26 μm and one or more hydrophilic polymers, said mixture being formed by subjecting a suspension comprising said oxcarbazepine and a hydrophilic polymer in a... Agent: Sughrue Mion, Pllc

20080138404 - Extended release formulations of carvedilol: An improved controlled release dosage form for once-daily administration of carvedilol is described. The controlled release dosage form comprises a therapeutically effective amount of carvedilol and/or a pharmaceutically acceptable salt thereof; one or more hydrophilic polymers; one or more pharmaceutically acceptable excipients; and a polyoxyalkylene block copolymer, a solid dispersion... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080138405 - Sirolimus nanodispersion: The present invention relates to a nanodispersion composition comprising sirolimus and a surface modifier wherein effective average particle size of Sirolimus is more than 400 nm and process for preparation thereof.... Agent: Jayadeep R. Deshmukh, Esq. Ranbaxy Inc.

20080138407 - Capsule medication administration system and medication administration method: A capsule medication administration system includes: a first capsule for internal body marking; a second capsule for medication; a marking device which makes a marking within a living body; a drug retention section which retains a drug; a release device which releases the drug; a detection device which detects the... Agent: Scully Scott Murphy & Presser, Pc

20080138406 - Composition for treatment of pain in bones and joints: The present invention is a composition delivering effective amounts of Glucosamine, Devils Claw, and SAM in a single dosage unit.... Agent: Robert M. Schwartz, P.a.

20080138408 - Drug delivery system and method: A system for delivering a therapeutic dose of a drug is disclosed. The system includes a delivery medium with therapeutic units attached thereto. The delivery medium is preferably a polymeric hydrogel matrix that has therapeutic units incorporated therein or metal nanoparticles with therapeutic units complexed thereto. The therapeutic units include... Agent: Haverstock & Owens LLP

20080138409 - Olanzapine pharmaceutical composition: An olanzapine pharmaceutical composition such as a tablet is made using anhydrous lactose as an excipient.... Agent: Synthon Ip Inc

20080138410 - Oral drug delivery system: An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a composition selected from... Agent: Sughrue Mion, Pllc

20080138413 - Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof:

20080138411 - Modified release formulations of selective serotonin re-uptake inhibitors: The present invention relates to modified release pharmaceutical compositions for oral administration and more particularly to modified release pharmaceutical compositions of a form of at least one selective serotonin re-uptake inhibitor selected from the group consisting of a selective serotonin reuptake inhibitor, racemic mixtures thereof, enantiomers thereof, pharmaceutically-acceptable salts thereof... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080138412 - Sustained release alfuzosin hydrochl formulation and method for their production: A sustained release alfuzosin hydrochloride formulation contains alfuzosin hydrochloride as about 1% to about 5% by weight of the formulation, hydrophilic polymers as about 35% to about 75% by weight of the formulation, hydrophobic polymers as about 10% to about 30% by weight of the formulation, disintegrating agents as 10%... Agent: Andrews & Kurth, L.l.p.

20080138414 - Methods of regenerating cartilage: The present disclosure relates to methods of regenerating cartilage. In an embodiment, a method includes initiating a release of precursor cells, including bone marrow cells and progenitor cells, into a cartilage defect; and applying a population of exogenous cells to the cartilage defect. The exogenous cells, selected from a group... Agent: Norman F. Hainer, Jr. Smith & Nephew, Inc.

20080138415 - Composition and method for producing composition for constructing tissue, and tissue construct: A cellular composition comprising a mesenchymal stem cell product and a biogel with methods for preparing and for using the composition. Tissue constructs made with the composition are also disclosed.... Agent: Ladas & Parry LLP

20080138416 - Method and systems for using biopolymer-based beads and hydrogels: Compositions comprising biopolymers such as alginates and cell attachment peptides are disclosed. Compositions may optionally further comprise cells. Methods for repairing or treating a tissues and organs with such compositions and systems for providing such compositions to tissues and organs, and methods for delivering desired proteins to individual with such... Agent: Patent Administrator

20080138422 - Analgesic compositions: The present invention relates to pharmaceutical compositions comprising an analgesic agent and providing controlled release of the agent for improved treatment and prevention of pain and pain-related conditions, such as pain-related sleep disturbance. The present invention is particularly concerned with self-administered compositions.... Agent: Davidson, Davidson & Kappel, Llc

20080138419 - Method for preparing an orally administrable formulation for controlled release: The present invention provides a method for preparing an orally administrable formulation comprising a biologically active ingredient for controlled release in a neutral or basic environment, which comprises the steps of: (a) dispersing powder ethylcellulose with an average diameter from about 0.1 μm to about 300 μm in an aqueous... Agent: Ladas & Parry LLP

20080138420 - Microencapsulation product and process: Microcapsules possessing Lewis acid-Lewis base salt walls incorporate water-immiscible materials, such as N,N-diethyl-m-toluamide (DEET), as a core component. Such microcapsules, or similar microcapsules incorporating other core components, may be made by emulsifying a water-immiscible core component in an aqueous solution of one wall-forming reactant, such as the Lewis base, and... Agent: Ratnerprestia

20080138418 - Nanoparticles composed of alkyl-cyanoacrylate polymers: The role of nanoparticle composition as biodegradable carriers for variously therapeutical drugs is disclosed. Nanoparticles are synthesized by anion emulsion polymerization of two alkyl-cyanoacrylate monomers with adjusted content ratio. By modulating the compositions, particle size, hydrophobicity and degradation rate of the copolymers is controlled. Hence, to encapsulate wide range of... Agent: Joe Mckinney Muncy

20080138424 - Nanoparticulate fibrate formulations: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20080138421 - Pharmaceutical compositions comprising fesoterodine: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group... Agent: Kenyon & Kenyon LLP

20080138423 - Systems and methods for effecting cessation of tobacco use: The invention relates generally to a system and method for treating conditions responsive to nicotine therapy. More specifically, the invention relates to pulmonary administration of a nicotine containing formulation to effect smoking cessation.... Agent: Bozicevic, Field & Francis LLP

20080138417 - Topical composition and method of forming: The present invention provides a topical composition for use in treating medical conditions such as fungal epithelial infections, carpal tunnel syndrome, tendonitis, and arthritis. The topical composition includes a mineral component including a source of calcium and a source of potassium, a vitamin component including a source of ascorbic acid,... Agent: Howard & Howard Attorneys, P.c.

20080138427 - Method for producing granules: In a production process of granules containing a biologically active substance, variation in the elution profile of the biologically active substance is reduced by heating the temperature of granules to about 50° C. or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed... Agent: Hamre, Schumann, Mueller & Larson, P.c.

20080138425 - Method for the preparation of a stable lactate metal salt in powder form and stable metal lactate salt: The invention relates to a method for the preparation of a stable lactate metal salt in powder form, the product of said preparation, functional pre-mixes for foodstuff comprising said stable, lactate metal salt powder, and foodstuffs comprising said stable lactate metal salt powder. In the method according to the invention,... Agent: Oliff & Berridge, Plc

20080138426 - Remedies for sex hormone dependent disease: A combination agent containing an LHRH receptor agonist or antagonist and an androgen receptor agonist, which is useful as an agent for the prophylaxis or treatment of hormone-dependent diseases and the like, is provided.... Agent: Foley And Lardner LLP Suite 500

20080138429 - Coated particles and pharmaceutical dosage forms: The present invention relates to coated particles and pharmaceutical dosage forms comprising the active substances sensitive to environmental influences. The coating of the present invention provides stability and protection of the active substance to environmental influences and in particular from oxidation and/or environmental humidity by coating.... Agent: Novartis Corporate Intellectual Property

20080138428 - Fast-disintegrating microporous binders: A highly porous, fast-disintegrating binder suitable for pharmaceutical applications and methods of making the same are disclosed, the binder comprising microporous particles of an aqueous-soluble cellulosic polymer and a wicking agent. Pharmaceutical compositions and fast-disintegrating dosage forms containing the binder are also disclosed.... Agent: Chernoff, Vilhauer, Mcclung & Stenzel

20080138431 - Pharmaceutical composition: A microparticle composition comprising a biodegradable polymer, an immunogenic single-stranded ribonucleic acid (ss-RNA) material, a biologically active macromolecule and a stabilising agent wherein the outer surface of the resulting microparticle is free from adsorbed molecules is described. The composition is effective in providing an immune response in dendritic cells, in... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080138430 - Temperature-sensitive nanoparticles for controlled drug delivery: The present invention generally relates to controlled drug delivery. More specifically, the present invention relates to novel device/system and extracorporeally-controlled method of drug delivery. In some embodiments, the present invention provides a system comprising a thermally-active metal nanoshell; and a temperature-responsive interpenetrating polymer network having at least one therapeutic agent... Agent: Baker Botts, LLP

20080138432 - Acute inflammatory condition treatment: This invention provides a method for prophylaxis or treatment of an acute inflammatory disorder, comprising administering to a patient an aliquot of the patient's blood extracted from the patient and treated ex vivo with at least two stressors selected from the group consisting of an oxidizing agent, an electromagnetic emission... Agent: Foley & Lardner LLP

20080138434 - Methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood: Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce... Agent: Ryan Kromholz & Manion, S.c.

20080138433 - Vasodilator eluting blood storage and administration devices with a specific polyphosphazene coating and methods for their manufacture and use: The present invention is directed to medical devices including blood storage and handling products that comprise a specific polyphosphazene and the capability of releasing nitric oxide or other smooth muscle relaxant compounds in vivo or into stored or transient flowing blood to achieve vascular dilatation, reduced adverse reactions, reduced thrombosis,... Agent: Sutherland Asbill & Brennan LLP

20080138435 - Nutritional supplement with colostrum and epa or dha or gla: The invention relates to a nutritional composition comprising colostrum and a fat blend that is particularly suited the treatment of intestinal dysfunction in HIV patients.... Agent: Foley And Lardner LLP Suite 500

20080138436 - Food supplement composition suitable for promoting iron absorption: Use of a composition comprising cartilage or chondroitin sulphate and absorbable zinc for the preparation of a food supplement or a drug suitable for promoting iron absorption in patients suffering from lack of iron.... Agent: Roylance, Abrams, Berdo & Goodman, L.l.p.

20080138437 - Antitumor agent: Due to the toxicity of antitumor agents, use of antitumor agents is limited, and thus, it is desirable to develop auxiliary agents or antitumor agents that have the effect of reducing toxicity while maintaining the antitumor effect of antitumor agents. The present invention provides antitumor agents mixed with particulate hydroxyapatite... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080138438 - Compositions having a high antiviral and antibacterial efficacy: Antimicrobial compositions having a rapid and persistent antiviral and antibacterial effectiveness are disclosed. The antimicrobial compositions contain (a) a divalent zinc salt, (b) an optional disinfecting alcohol, (c) an optional antimicrobial agent, and (d) an optional organic acid, wherein the composition has a pH of about 5 or less.... Agent: Marshall, Gerstein & Borun LLP (dial)

20080138439 - Cosmetic composition enriched with 1h216o: The present invention relates to production of cosmetic composition enriched with 1H216O in comparison with typical cosmetic composition. This is provided by addition to cosmetic composition a highly pure light water comprising 1H216O from about 99.76% to about 99.999% by weight of water, while the content of 1H216O in typical... Agent: Notaro And Michalos

20080138440 - Methods of diagnosing and alleviating gadolinium toxicity: The present invention relates to novel methods of treating or reducing the likelihood of developing gadolinium toxicity by administering to a patient a metal chelator before, concurrently with, or after exposure to gadolinium. The novel methods comprise, inter alia, the use of iron chelators to aid patients at increased risk... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080138441 - Composition comprising zinc-containing layered material with a high relative zinc lability: The present invention relates to a composition comprising an effective amount of zinc-containing layered material, an effective amount of a surfactant including a surfactant with an anionic functional group, wherein the zinc-containing layered material has a relative zinc lability of greater than about 15%.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080138442 - Personal care compositions comprising a zinc containing material in an aqueous surfactant composition: Disclosed are compositions comprising an effective amount of a zinc containing material having an aqueous solubility within the composition of less than about 25% by weight at 25° C.; from about 5% to about 50% of a surfactant; and from about 40% to about 95% water; wherein the pH of... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080138443 - Carnitine-containing peritoneal dialysis solution having improved biocompatibility: The protective effect on peritoneum of L-carnitine and its lower alkanoyl derivatives, both in the form of inner or pharmaceutically acceptable salts is disclosed. Concentrations of carnitine from about 0.02 to 0.5% w/v are suitable for preparing a solution for peritoneal dialysis having higher biocompatibility and protecting peritoneum from toxic... Agent: Lucas & Mercanti, LLP

20080138444 - Method for treating bronchoconstriction and pulmonary vaso-constriction: This invention relates to the treatment and prevention of asthma or other forms of broncho-constriction or reversible pulmonary vasoconstriction in a mammal.... Agent: Bayer Health Care Llc

20080138445 - Pharmaceutical mixture for hepatitis treatment and its preparation method: A pharmaceutical mixture for the treatment of hepatitis and its preparation method are disclosed. The method includes the following steps: pulverize the plants, macerate and extract the plant with water, concentrate the aqueous extract as the first concentrate; add ethanol to form a precipitate, collect and concentrate the liquid phase... Agent: Bacon & Thomas, Pllc

20080138446 - Herbal composition: The invention relates to a herbal composition comprising extracts from Thuja, Poke, Sweet violet, Red clover, Greater celandine and Calendula; formulations containing the herbal composition; and use of the herbal composition for preventing and/or treating skin conditions and/or abnormalities.... Agent: Needle & Rosenberg, P.c.

20080138448 - Composition for improving blood flow in working muscles: A nutritional composition and method is provided for increasing blood flow to skeletal muscle in an individual by supporting the biological activity of nitric oxide comprising therapeutically effective amounts of L-arginine, Crataegus extract and Artichoke flavonoids.... Agent: Torys LLP

20080138447 - Method for administering appetite suppressant and composition thereof: A composition, which includes Guarana extract 36%, Hoodia 20:1, Cha de bugre 4:1, Ginseng, Citrus Auratium, Magnolia bark extract, and black pepper, for suppressing appetite as well as a method for the weight reduction of a body by administering a dosage of the composition, are disclosed. The composition, which is... Agent: Seyfarth Shaw LLP

20080138449 - Composition and method for supporting thermogenesis and lipid oxidation: A nutritional composition and method is provided for promoting weight loss or weight maintenance in an individual by supporting and enhancing thermogenesis and lipid oxidation comprising therapeutically effective amounts of yohimbine or derivatives thereof, an effective amount of Evodia rutaecarpia extract and a source of an effective amount of L-carnitine... Agent: Torys LLP

20080138450 - Process for the recovery of a phytolipid composition: Disclosed is a process for the recovery of a phytolipid composition from a vegetable oil by-product. The phytolipid composition produced comprises squalene, phytosterols, mixed tocopherols and tocotrieneols, and vegetable wax and is useful as an emollient. The phytochemical composition may be applied directly to the skin to provide emolliency. Alternatively,... Agent: Brett L. Nelson Eastman Chemical Company

20080138451 - Dermatological composition: Dermatological compositions containing a humectant, e.g., at least one of urea, ammonium lactate, and glycerin, and an emollient, e.g., at least one of Shea or cocoa butter, glycine soja sterol and hybrid sunflower oil. The compositions of the invention may be utilized for treatment or amelioration of skin disorders or... Agent: Intellectual Property / Technology Law

20080138452 - Hepatocurative effect of emblica officinalis against cyp 450 bio-activation hepatotoxicity of drugs: The present invention relates to a composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and method of treating drug induced hepatotoxicity... Agent: Smith, Gambrell & Russell

20080138453 - Chickpea extracts as therapeutic agents and foods in the treatment and prevention of obesity and non-insulin-depenent diabetes: This invention discloses the uses of chickpea (Cicer arietinum) extract in the preparation of food for the prevention and treatment of obesity and non-insulin-dependent diabetes (NIDD). The invention provides a therapeutic agent and food containing chickpea extract for the prevention and treatment of obesity and NIDD. In this invention, the... Agent: Matthias Scholl

20080131362 - Radiopharmaceutical dispensing, administration, and imaging: Apparatus is provided for use with at least one labeled radiopharmaceutical agent, the apparatus including a container (22) containing the at least one labeled radiopharmaceutical agent, and a portable computer-communicatable data carrier (120, 24) associated with the container (22), the data carrier (120, 24) containing imaging protocol information for use... Agent: Wolf, Block, Shorr And Solis-cohen LLP

20080131365 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.a.

20080131363 - Rs7 antibodies: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins... Agent: Faegre & Benson LLP Patent Docketing

20080131367 - Composition for diagnosing amyloid-related diseases: A composition for diagnosing amyloid-related diseases, which comprises a flavone derivative, a chalcone derivative, a styrylchromone derivative, or a coumarin derivative, is provided. These compounds have high binding specificity to an amyloid β protein, high permeability to a blood-brain barrier, and ability to rapidly disappear from sites other than cerebral... Agent: Birch Stewart Kolasch & Birch

20080131366 - Folate receptor gene modulation for cancer diagnosis and therapy: A method of diagnosing and treating a patient with or suspected of having at least one solid tumor that produces folate receptor type α includes administering a biologically effective amount of at least one folate receptor α inducer, specifically steroid receptor ligands, with or without aid from at least one... Agent: Patrick P. Pacella Emch Schaffer Schaub & Porcello Co.

20080131368 - N4 chelator conjugates: The present invention provides tetra-amine chelator conjugates with biological targeting moieties, linked via a linker group and technetium complexes thereof as radiopharmaceuticals. The linker group is such that the chelator is mono-functionalised at the bridgehead position and provides both flexibility and a lack or aryl groups, to minimise lipophilicity and... Agent: Ge Healthcare, Inc.

20080131369 - Compositions and methods for enhancing contrast in imaging: Example compositions of liposomes with hydrophilic polymers on their surface, and containing relatively high concentrations of contrast-enhancing agents for computed tomography are provided. Example pharmaceutical compositions of such liposomes, when administered to a subject, provide for increased contrast of extended duration, as measured by computed tomography, in the bloodstream and... Agent: Benesch, Friedlander, Coplan & Aronoff LLP Attn: Ip Department Docket Clerk

20080131373 - Fragments of antibodies to epidermal growth factor receptor and methods of their use: Antibody Fab fragments specific for the EGF receptor are disclosed, as are compositions and kits comprising these Fab proteins. The Fab proteins may be conjugated to drugs or other therapeutic agents or to diagnostic agents. Also disclosed are methods for diagnosing and treating diseases such as tumors and cancer in... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20080131371 - Oligonucleotide non-viral delivery systems: Low molecular weight low molecular weight chitosan oligomers were able to self-assemble siRNA into nanosized particles, provide protection against enzymatic degradation, and mediate gene silencing that is stable over a long period of time in vitro. The control of structural variables in formulating complexes of siRNA with low molecular weight... Agent: Patent Administrator Fmc Corporation

20080131370 - Screening method: The present invention provides a method for screening for a prophylactic or therapeutic drug for apoptosis or an inflammation-associated disease, diabetes and complications thereof or a chronic obstructive pulmonary disease (COPD), namely, a method for screening for a prophylactic or therapeutic drug for apoptosis or an inflammation-associated disease, diabetes and... Agent: Edwards Angell Palmer & Dodge LLP

20080131372 - Sustained release intraocular implants and methods for preventing retinal dysfunction: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix,... Agent: Allergan, Inc.

20080131375 - Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis: Although it can be farnesylated, the mutant lamin A protein expressed in Hutchison Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters... Agent: Klarquist Sparkman, LLP

20080131374 - Uses and compositions for treatment of rheumatoid arthritis: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for... Agent: Lahive & Cockfield, LLP

20080131376 - Carboranylporphyrins and uses thereof: The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity carborane-containing porphyrin compounds with halide, amine, or nitro groups and methods for their use particularly in boron... Agent: Brookhaven Science Associates/ Brookhaven National Laboratory

20080131377 - Pharmaceutical aerosol compositions: An aerosol formulation comprising a biodegradable microsphere comprising a non-living reagent, such as a sub-unit vaccine, that produces a protective immune response in a mammal to whom it is administered. Nebulizers and inhalers containing such formulations are also described and claimed.... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080131378 - Aerosol cream mousse and method of treating hair: The present invention provides stable aerosol cream mousse composition, preferably hair care composition, that can provide enhanced touch, combability, alignment and volume reduction to the hair, with low or reduced greasy, oily hair feel, while being formulated having a thick, rich, creamy, mousse-type rheology with excellent spreading, perception of spreading,... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080131379 - Compressed chewing gum tablet: The present invention relates to a compressed chewing gum tablet possessing tooth brush properties, which compressed chewing gum tablet comprises at least gum base and a) at least one whitening agent, b) at least one fresh-breath agent, c) at least one anti-plaque agent, d) at least one anti-gingivitis agent, e)... Agent: Sughrue Mion, Pllc

20080131380 - Methods of whitening teeth: The present invention relates to improved dental compositions and methods for bleaching teeth. More specifically, this invention is directed towards hydrogen peroxide-containing compounds that are maintained at a substantially constant pH range of 6.0-10.0 during the tooth-bleaching procedure in the presence of a calcium chelating agent.... Agent: Discus Dental, Llc

20080131381 - Methods for photostabilizing ingredients within cosmetics, personal care and household products and compositions obtained therefrom: The present invention relates to methods and compositions for using photostabilizer compounds for stabilizing formulation ingredients, like flavors, fragrances, colors, antioxidants, polymers, within cosmetics, personal care and household products, against degradation from sun light, heat and air oxidation resulting in improvement in storage stability, viscosity, and maintenance of color of... Agent: Millen, White, Zelano & Branigan, P.c.

20080131382 - Novel resorcinol derivatives for skin: n represents 0, 1. When n=0, the ring is a cyclopentyl with or without one heteroatom from O, N or S and/or with or without one double bond. When n=1, the ring is a cyclohexyl with or without one heteroatom from O, N or S and/or with or without one... Agent: Unilever Intellectual Property Group

20080131383 - Cosmetic composition for obtaining a cosmetic coating with a metallically glossy appearance, artificial fingernails and use of pvd aluminum pigments: The invention relates to a cosmetic composition comprising a liquid phase and a PVD aluminum pigment, wherein the cosmetic composition contains a PVD aluminum pigment at a pigmentation level of from 0.05 to 5.0% by weight, based on the total weight of the cosmetic composition, and at least one leafing... Agent: Ostrolenk Faber Gerb & Soffen

20080131384 - External preparation for skin whitening, whitening agent, whitening method and method of production of external preparation for skin whitening: An external preparation for skin whitening containing 0.001 to 20.0 mass % of an extract of at least one plant selected from the group consisting of Pilea cavaleriei (Urticaceae), Saururus chinensis (Saururaceae), Streptocaulon griffithii (Asclepiadaceae), Toddalia asiatica (Rutaceae) and Tadehagi triquetrum (Leguminosae).... Agent: Snider & Associates

20080131385 - Mixture of self-invertible inverse latex and a powder for cosmetic or pharmaceutical use; use as texturizer: A texturizing composition and method utilized for foundations, makeup powders, mascaras, lipsticks, emulsions, lotions, gels, sprayable formulations, and solution impregnated on fabrics, paper, towelettes or complexion corrector papers comprising at least one self-invertible inverse latex, and powder.... Agent: Young & Thompson

20080131386 - Topical product formulations containing strontium for reducing skin irritation: Topical formulations containing aqueous-soluble divalent strontium cation in a suitable topical formulation vehicle, and methods of using these formulations to inhibit skin irritation, are disclosed.... Agent: Nath & Associates

20080131387 - Liquid stick antiperspirant: One embodiment of the invention described herein includes a method for improving stability of an antiperspirant. The method includes preparing a blend that comprises dibenzylidene sorbitol; adding an antiperspirant active to the blend, to make an antiperspirant blend; and adding one or more alkaline earth silicate salts to the antiperspirant... Agent: Schwegman, Lundberg, Woessner & Kluth, P.a.

20080131388 - Cosmetic product: A cosmetic product is provided, which is directed at improving infrared radiation effects, charged particle emission and ultraviolet blocking effects. Diamond powder formed by shockwaves is suitably blended with a cosmetic product and specific infrared wavelengths and charged particle emission characteristics generated by the semiconductor characteristics thereof are used. An... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080131393 - Block polymers, compositions and methods of use for foams, laundry detergents, shower rinses and coagulants: The present invention relates to a block polymeric material. Typically the block polymer comprises units capable of having an average cationic charge density of about 15 or less, preferably 5 or less, more preferably from about 0.05 to about 5, even more preferably from about 0.05 to about 2.77, even... Agent: Dickinson Wright Pllc

20080131391 - Compositions containing a quaternary ammonium polymer, a fatty quaternary agent and a nonionic surfactant: A composition and process for treating a keratinous substrate involving contacting the keratinous substrate with a composition containing: a) at least one quaternary ammonium polymer; b) at least one fatty quaternary agent; c) at least one nonionic surfactant; and d) optionally, at least one ceramide, and wherein the composition is... Agent: L'oreal Usa/ Patent Department

20080131392 - Conditioning composition for keratin fibres: The present invention relates to a conditioning composition for keratin fibres especially human hair comprising as special cationic polymer. The present inventor has surprisingly found out that an aqueous hair conditioning composition comprising at least one fatty alcohol, at least one emulsifier and Polyquaternium-70 improves hair combability, smoothness shine, elasticity... Agent: Norris, Mclaughlin & Marcus, P.a.

20080131390 - Hair treatment product containing anionic surfactants and cationic polymers: The invention relates to a hair treatment product, especially shampoo, containing al) alkyl ether sulfate or a) alkyl sulfate or the mixture thereof, b) secondary alkane sulfonate, c1) betaine or c2) ether carboxylate or the mixture thereof, d) at least one non-ionic surfactant, and e) a cationic polymer from the... Agent: Clariant Corporation Intellectual Property Department

20080131389 - Hair relaxer: A hair relaxer includes at least one specific mercapto compound such as 2-methoxyethyl 3-mercaptopropionate, 2-mercapto-4-butanolide and 2-mercapto-4-butyrolactam. The hair relaxer can achieve an excellent effect of shaping and relaxing hair over a wide range of pH values from weak acidity to weak alkalinity. In particular, the hair relaxer displays a... Agent: Sughrue Mion, Pllc

20080131394 - Natural cleanser having antioxidant composition: The invention relates to a soluble product extracted from coffee cherries to water, which soluble product is used either as such or concentrated as a fat-removing cleanser having antioxidant effects at the same time. Further, the product may be advantageously used as an antioxidant for zest oils of citrus fruits... Agent: Ladas & Parry LLP

20080131395 - Controlled gas release from a melt processable compatible polymer blend: The invention relates generally to compatible polymer blends that can be extruded or injection molded into films or other objects that will generate and release a gas such as sulfur dioxide, carbon dioxide, or chlorine dioxide upon contact with moisture.... Agent: Senniger Powers LLP

20080131397 - Beta-2-glycoprotein 1 is an inhibitor of angiogenesis: The present disclosure provides a method of inhibiting angiogenesis within a tissue of interest by providing either intact or nicked β-Glycoprotein 1 (β2GP1) to cells associated with the tissue. The presence of β2GP1 inhibits angiogenesis within the tissue, in part by preventing neovascularization into the tissue. The disclosure also provides... Agent: Vinson & Elkins, L.l.p.

20080131396 - Method for altering the cd4/cd8 ratio and the mononuclear cellular infiltrate into a tumor: A method for altering the CD4/CD8 ratio and the mononuclear cellular infiltrate into a tumor that results in significant modulation of the infiltrating immune cells shown by a decrease in CD8+ T cells and a significant increase in tumor infiltrating CD4+ T cells. A dose of 800 IU/day as IL-2... Agent: Hahn & Voight Pllc

20080131398 - Combination therapy for treatment of viral infections: One can treat a viral infection by first administering at least one first antiviral compound for a first time period and then, after the end of the first time period, concurrently or subsequently administering the at least one first antiviral compound and at least one second antiviral compound for a... Agent: Foley And Lardner LLP Suite 500

20080131399 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encodings the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the intention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080131400 - Vector system: Provided is a method of treating motor neuron disease using a lentiviral vector system to transduce a target site, wherein the vector system is or comprises at least part of a rabies G envelope protein or a mutant, variant, homologue or fragment thereof, and a nucleotide of interest (NOI), and... Agent: Frommer Lawrence & Haug

20080131411 - Identification of the gene causing the mouse scurfy phenotype and its human ortholog: Isolated nucleic acid molecules are provided which encode Fkhsf, as well as mutant forms thereof. Also provided are expression vectors suitable for expressing such nucleic acid molecules, and host cells containing such expression vectors. Utilizing assays based upon the nucleic acid sequences disclosed herein (as well as mutant forms thereof),... Agent: Davis Wright Tremaine, LLP/seattle

20080131401 - Alteration of microbial populations in the gastrointestinal tract: Method of enhancing a resident population of microorganism in a selected site of the gastrointestinal tract of an animal, the method comprising providing to the animal a selected modified or unmodified resistant startch or mixtures thereof in combination with one or more probiotic microogranisms such that upon ingestion the starch... Agent: Robert L. Price Mcdermott, Will & Emery

20080131402 - Controlled production and delivery of biologically active agents by gut bacteria: The invention provides gut commensal bacteria that have been modified to express one or more biologically active polypeptides or protiens, the bacteria includes a promoter, such as a xylanase promoter, which is induced in response to the presence of xylan in the diet and which regulates the expression of the... Agent: Myers Bigel Sibley & Sajovec

20080131412 - Isoflavone-containing composition: This invention provides a composition comprising a daidzein-containing substrate and a strain of micro-organism capable of metabolizing daidzein to equol as essential ingredients. This composition is effective in the prevention and alleviation of unidentified clinical syndrome inclusive of menopausal syndrome in middle-aged to elderly women for which no effective means... Agent: Sughrue, Mion, Zinn, Macpeak & Seas, Pllc

20080131413 - Method for preventing or treating the development of respiratory allergies: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.... Agent: Bristol-myers Squibb Company - Mead Johnson

20080131414 - Use of selected lactic acid bacteria for reducing infantile colic: The invention herein provides certain strains of lactic acid bacteria selected for their capability of promoting production of IL-10 and consequently proliferation of CD4+CD25+ TR cells, for prophylaxis and/or treatment of infant colic, a method of selecting such strains, and products containing such strains.... Agent: Lynn E Barber

20080131403 - Recombinant adeno-associated virus expressing human antisense gene cyp2j2 and its preparation methods: A recombinant adeno-associated virus expressing antisense human CYP2J2 gene and preparation method thereof are provided, the recombinant adeno-associated virus is prepared through cloning human CYP2J2 cDNA (1509 bp, which encode the protein containing 503 amino acids) from human leucocyte DNA by PCR, cotransfecting three plasmids by the calcium phosphate precipitation... Agent: Matthias Scholl

20080131406 - Angiotensin i derivatives: The present invention relates to angiotensin I derivatives. In particular, the present invention relates to the use of angiotensin I derivatives, excluding des-aspartate-angiotensin I, for the treatment and/or prevention of cardiac hypertrophy, and/or neointima formation.... Agent: Marshall, Gerstein & Borun LLP

20080131405 - Composition for treating a disease caused by neuronal insult comprising a human umbilical cord blood-derived mesenchymal stem cell as an active ingredient: Provided is a composition for treating nerve damage-related diseases. The composition includes a human umbilical cord blood-derived mesenchymal stem cell as an active ingredient. The mesenchymal stem cell isolated and incubated from the human umbilical cord blood migrates to an injured area to be differentiated into a nerve cell or... Agent: Thelen Reid Brown Raysman & Steiner LLP

20080131407 - Differentiation of bone marrow cells into neuronal cells and uses therefor: The present invention relates to methods of inducing differentiation of mammalian bone marrow stromal cells into neuronal cells by contacting marrow stromal cells with a neuronal differentiation-inducing compounds. Neuronal differentiation-inducing compounds of the invention include anti-oxidants such as, but not limited to, beta-mercaptoethanol, dimethylsulfoxide, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid,... Agent: Seed Intellectual Property Law Group Pllc

20080131404 - Hepatocytes: The invention relates to the production of hepatocyte cell lines useful in toxicology screens or therapy. A mammalian hepatocyte comprises, as a single polypeptide, a fusion protein comprising a c-myc protein and an oestrogen receptor, or functional fragments thereof.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080131408 - Mammalian myeloid progenitor cell subsets: A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided into specific myeloid progenitor subsets, including a common myeloid progenitor cells (CMP), megakaryocyte/erythroid progenitor cells (MEP) and... Agent: Bozicevic, Field & Francis LLP

20080131409 - Methods and compositions for the treatment of medical disorders: In general, the invention relates to marrow-derived adult progenitor cells (MAPCs) and their use in methods of treating various medical disorders, typically caused by or involving loss of cells or loss of cell function. These cells, when administered, e.g., intranasally, can cross the blood brain barrier and terminally differentiate into... Agent: Clark & Elbing LLP

20080131410 - Placental stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells: The present invention provides compositions and methods of using placental stem cells that originate from a postpartum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the... Agent: Jones Day

20080131415 - Adoptive transfer of cd8 + t cell clones derived from central memory cells: The present invention provides a method of carrying out adoptive immunotherapy in a primate subject in need thereof by administering the subject a cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount. The method comprises administering as the CTL preparation a preparation consisting essentially of an in vitro expanded primate... Agent: Myers Bigel Sibley & Sajovec

20080131416 - Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders: Treatment and/or prophylaxis, in mammalian patients, of neurodegenerative and other neurological medical disorders is effected by administering to the patient effective amounts of apoptotic bodies and/or apoptotic cells, preferably those derived from the patient's own white blood cells, e.g. by extracorporeal treatment of the patient's blood cells to induce apoptosis... Agent: Foley & Lardner LLP

20080131417 - Microarray-based analysis of rheumatoid arthritis markers: A microarray and method of screening for rheumatoid arthritis (RA) in a mammal is disclosed. The method comprises contacting a sample from the mammal to an immobilized polypeptide or fragment thereof homologous to at least a portion of an RA marker protein, and detecting binding of an antibody from the... Agent: Knobbe Martens Olson & Bear LLP

20080131418 - Diagnostics and therapeutics for macular degeneration-related disorders: The invention relates to methods for diagnosing and treating macular degeneration-related disorders. The invention also related to methods for identifying genes that cause macular degeneration-related disorders.... Agent: Townsend And Townsend And Crew, LLP

20080131419 - Recombinant human t2 rnase and uses thereof: The cloning and heterologous expression of human T2 RNase6PL are disclosed. Further disclosed are methods for preventing, inhibiting and/or reversing cell motility, actin filament assembly or disassembly, proliferation, colonization, differentiation, accumulation and/or development of abnormal cells in a subject is disclosed. The methods are effected by administering to the subject... Agent: Martin D. Moynihan Prtsi

20080131420 - Methods and compositions for treating mucosal inflammation: Disclosed herein are methods for treating mucositis (e.g., Alternaria-activated mucositis) that involves the direct mucoadministration of an active agent that is antifungal and antibacterial in an amount and for a duration effective to treat mucositis.... Agent: Lahive & Cockfield, LLP

20080131423 - Anti-trem-like transcript-1 (tlt-1) antibodies, methods and compositions: The present invention relates to methods and compositions for modulating platelet activity, and methods and compositions for treating a disease or disorder associated with platelet activity in a subject, comprising administering a single chain anti-TREM-like transcript-1 (TLT-1) antibody or a functional fragment or variant thereof in an amount effective to... Agent: Edwards Angell Palmer & Dodge LLP (client Reference No. 47992)

20080131425 - Biomolecular coating for implants: Methods and compositions are provided for improving tissue growth and device integration in vivo. Substrates and devices coated with an α2β1 or α5β1 integrin-specific ligand are provided. The substrates and devices coated with an α2β1 or α5β1 integrin-specific ligand are shown to have greater tissue formation on the surface relative... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080131422 - Human anti-amyloid beta peptide antibody and fragment of said antibody: A human anti-amyloid β peptide (hereinafter referred to as “Aβ”) antibody that binds to Aβ to thereby inhibit aggregation of Aβ molecules, and a fragment of said antibody are provided. The antibody and a fragment thereof according to the present invention, comprising a variable region of a human-derived anti-Aβ antibody,... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080131424 - Method of treatment and agents useful for same: The present invention relates generally to a method for the treatment and prophylaxis of inflammatory conditions. The present invention is predicated in part on the identification of cells of the monocyte/macrophage lineage being critical for inflammation and, in particular, chronic inflammation. In accordance with the present invention, it is proposed... Agent: Proskauer Rose LLP

20080131421 - Neisserial antigens: The invention provides proteins from Neisseria meningitidis (strains A & B) and from Neisseria gonorrhoeae, including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.... Agent: Novartis Vaccines And Diagnostics Inc.

20080131426 - Prevention and reduction of blood loss: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary... Agent: Fish & Richardson Pc

20080131429 - Cytotoxicity mediation of cells evidencing surface expression of cd44: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a... Agent: Mchale & Slavin, P.a.

20080131428 - Cytotoxicity mediation of cells evidencing surface expression of trop-2: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a... Agent: Mchale & Slavin, P.a.

20080131427 - Whole genome evolution technology applied to improve protein and antibody yields by cells: Whole Genome Evolution Technology can be considered a broad tool for supporting the needs for scaleable manufacturing of therapeutic antibodies. Its random nature and in vivo mode of action separate this process from other complementary technologies, thus providing alternative solutions to improve a host cell's manufacturing performance. The speed with... Agent: Woodcock Washburn LLP

20080131431 - Cd47 related compositions and methods for treating immunological diseases and disorders: Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing... Agent: Seed Intellectual Property Law Group Pllc

20080131432 - Method of treating the chemotoxic effects of chemotherapeutic drugs on brain tissue: This invention is related to a novel method of treating the chemotoxic effects on the central nervous system of chemotherapeutic drugs, namely Adriamycin, by administering a therapeutically effective amount of anti-Tumor Necrosis Factor-α antibody to a patient to alleviate the symptoms of the effects. The antibody operates to decrease the... Agent: Crowell & Moring LLP Intellectual Property Group

20080131430 - Therapeutic administration of the scrambled anti-angiogenic peptide c16y: Unregulated angiogenesis is associated with a variety of pathological conditions. Tumor growth and metastasis is dependent on the development of new blood vessels. The development of new blood vessels in the eye, or ocular neovascularization, has been implicated in a variety of serious ocular diseases. For instance, choroidal neovascularization is... Agent: Woodcock Washburn LLP

20080131434 - Compositions and methods for diagnosing and treating cancer: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080131433 - Fc receptor homolog antibodies and uses thereof: Provided herein are antibodies having the same epitope specificity as an antibody produced by the hybridoma cell line deposited with the American Type Culture Collection as hybridoma 4-2A6, 1-5A3, or 1-3B4. Further provided herein are methods of identifying and selecting cells that express FcRH1 or FcRH4. Methods of diagnosing and... Agent: Fish & Richardson P.c.

20080131435 - Identification and engineering of antibodies with variant fc regions and methods of using same: The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to... Agent: Edell, Shapiro & Finnan, Llc

20080131438 - Antibodies to non-functional p2x7 receptor: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.... Agent: Townsend And Townsend And Crew, LLP

20080131436 - Polypeptide compounds for inhibiting angiogenesis and tumor growth: In certain embodiments, this present invention provides polypeptide compositions (e.g., antibodies and antigen binding portions thereof that bind to EphB4), and methods for inhibiting EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.... Agent: Ropes & Gray LLP

20080131437 - Use of soluble cd164 variants in inflammatory and/or autoimmune disorders: The present invention relates to sCD164 variants and therapeutic uses thereof, in particular for treating or preventing inflammatory or autoimmune disorders.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080131440 - Method of treating a pathological syndrome and a pharmaceutical agent: Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a... Agent: Houston Eliseeva LLP - Ru

20080131439 - Methods of diagnosing inflammatory bowel disease: The present invention provides methods, systems, and code for accurately classifying whether a sample from an individual is associated with inflammatory bowel disease (IBD) or a clinical subtype thereof. In particular, the present invention is useful for classifying a sample from an individual as an IBD sample using a statistical... Agent: Townsend And Townsend And Crew, LLP

20080131441 - Methods of using foxp3 levels to predict the outcome of organs undergoing acute rejection: A method for assessing risk of losing a transplanted organ by a patient having an episode of acute rejection of the transplanted organ is described. The method includes obtaining from the patient a cell sample from the transplanted organ or peripheral blood, determining a level of FOXP3 in the cell... Agent: Hoffmann & Baron, LLP

20080131442 - Igy antibodies to human telomerase reverse transcriptase: IgY antibodies which specifically bind to human telomerase reverse transcriptase (hTERT) can be used to detect hTERT and thereby diagnose cancer. Preparations of the antibodies can be used to reduce hTERT reverse transcriptase activity in in vitro assays and can be used as in vivo therapeutics to treat cancer.... Agent: Banner & Witcoff, Ltd.

20080131443 - Method and composition for reconforming multi-epitopic antigens to intiate an immune response: The invention concerns methods and compositions for initiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen.... Agent: Ropes & Gray LLP

20080131445 - Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs: The invention provides methods of isolating CD127lo/− immunosuppressive regulatory T cells which can be greatly enriched for FoxP3, methods of expanding the isolated cells, pharmaceutical compositions of such cells, and methods of their use in the treatment of autoimmune and other immune system mediated disorders.... Agent: Townsend And Townsend And Crew, LLP

20080131444 - Recombiant protein expression systems and applications thereof: The invention relates to a transitory expression system of recombinant proteins in a plant, characterized in that it comprises a viral expression vector comprising a ubiquitous constitutive promoter upstream from a gene of interest or a reporter gene placed downstream from the viral vector or a gene that is adapted... Agent: Wilmerhale/boston

20080131446 - Vaccine composition: e

20080131448 - Cancer immunotherapy: A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an... Agent: Akerman Senterfitt

20080131447 - Polypeptides for inducing a protective immune response against staphylococcus aureus: m

20080131450 - Immunogenic complexes, preparation method thereof and use of same in pharmaceutical compositions: The present invention relates to a method of improving the immunogenicity of an immunogen, by means of coupling with a small support peptide. More specifically, the present invention relates to a method of preparing an immunogenic complex, as well as the complexes that can be obtained by one such method,... Agent: Birch Stewart Kolasch & Birch

20080131449 - Polypeptides from african swine fever virus as vaccines for preventive and therapeutic use: The present invention generally relates to the use of selected polypeptides from African Swine Fever virus for the prevention and therapy of African Swine Fever infections as well as other infections, including immune deficiencies in mammals and humans.... Agent: Inhouse Ip

20080131451 - Epitope escape mutations: The present invention provides methods for predicting epitope escape mutations arising during the course of HIV disease using an algorithm that predicts the difficulty with which and the manner in which HIV may escape from a CTL response. Thus, the invention is useful for the development of effective therapeutic or... Agent: Ingrid A. Beattie, Ph.d., J.d. Mintz Levin Cohn Ferris Glovsky & Popeo, P.c.

20080131452 - Hepatitis virus core proteins as vaccine platforms and methods of use thereof: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.... Agent: Christine A Lekutis Medlen & Carroll

20080131453 - Campylobacter jejuni outer membrane protein immunogenic composition: The field of this invention is the development of therapeutic agents having immunogenic efficacy against Campylobacter. The present invention is directed to a method of producing monoclonal antibodies that are highly specific for epitopes of Campylobacter jejuni outer membrane proteins; to specific monoclonal antibodies made by using the epitopes; and... Agent: Sutherland Asbill & Brennan LLP

20080131454 - Methods and compositions for the treatment of rhinovirus infections with carrageenan: The present invention provides the use of carrageenan or mixtures thereof for the manufacture of an antiviral pharmaceutical composition for the treatment of rhinovirus infections.... Agent: Fulbright & Jaworski L.l.p.

20080131455 - Antigen delivery compositions and methods of use: The present invention provides antigen delivery compositions and methods of using same to prevent or to treat cancers and other infectious diseases.... Agent: Wood, Herron & Evans, LLP

20080131456 - Antibiotic resistance free vaccines and methods for constructing and using same: The present invention provides Listeria strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.... Agent: Pearl Cohen Zedek Latzer, LLP

20080131457 - Use of alpha-toxin for treating and preventing staphylococcus infections: Vaccines comprising an S. aureus alpha-toxin antigen and a pharmaceutically acceptable carrier are provided, and are useful for treating and preventing infections. The S. aureus alpha-toxin antigen may contain at least two alterations that reduce its toxicity and/or may be conjugated to or co-administered with another bacterial antigen. The vaccines... Agent: Foley And Lardner LLP Suite 500

20080131459 - Full-length infectious cdna clone for porcine reproductive and respiratory syndrome virus(prrsv) and uses thereof: The present invention relates to a novel full-length infectious cDNA clone for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), derivatives therefrom and uses thereof Particularly, the present invention relates to a full-length PRRSV genomic RNA represented by SEQ. ID. No 27 and the genetically stable full-length infectious PRRSV cDNA clone... Agent: Jhk Law

20080131458 - Vaccine adjuvants: Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at... Agent: Darby & Darby P.c.

20080131460 - Method of immunization against the 4 serotypes of dengue fever: c

20080131461 - Malaria prime/boost vaccines: The invention relates to novel vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from Plasmodium falciparum and purified recombinant protein vaccines such as RTS,S, in the context of appropriate adjuvants.... Agent: Trask Britt

20080131462 - Lactic acid bacteria strains useful against gastrointestinal pathogens and compositions containing same: The invention relates to a method for preventing or treating gastrointestinal infections in humans, which comprises administering a pharmaceutical preparation comprising, in combination with a pharmaceutically acceptable or food grade carrier, a therapeutically effective amount of at least one lactic acid bacteria strain of the genus L. acidophilus, L. crispatus,... Agent: Winston & Strawn LLP Patent Department

20080131463 - Vaccination method for controlling coccidiosis in fowl: A method for protecting fowl against coccidiosis includes the steps of inoculating the fowl with coccidial oocysts from a strain of Eimeria that is at least partially resistant to an ionophore and subsequently administering to the fowl the ionophore and at least one chemotherapeutic anticoccidial agent. In particular, the ionophore... Agent: Venable LLP

20080131464 - Vaccines: A vaccine formulation for the prevention or amelioration of plasmodium infection in humans is provided. The vaccine comprises a malaria antigen, especially a protein which comprises a portion of the CS protein of P. falciparum fused in frame via a linear linker to the N-terminal of HBsAg, and an immunostimulatory... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080131465 - Group a streptococcus crge protein: The invention provides methods of screening utilising the CrgE protein and the Streptococcus pyogenes bacterium expressing crgE. The invention also provides bacteria where the crgR and/or the crgE gene has been knocked out. The invention also provides fusion proteins comprising the polypeptide encoded by Spy1542 (crgE) and pharmaceutical compositions comprising... Agent: Novartis Vaccines And Diagnostics Inc.

20080131466 - Vaccine composition containing synthetic adjuvant: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from... Agent: Seed Intellectual Property Law Group Pllc

20080131467 - Film-coated solid dosage form: The invention provides a film coated solid oral dosage form. The coated form comprises a solid core and at least two separately applied coatings or layers. The first layer, which is a seal coat, contains a swellable polymer, such as hydroxypropyl methyl cellulose. The second layer, which is a release... Agent: Linda A. Vag Agent For Applicant

20080131469 - Aqueous composition for cosmetics and cosmetic including the same: The invention provides an aqueous composition that can alleviate at least one of the problems that conventional aqueous compositions for cosmetics have (e.g., insufficient temporal stability, insufficient viscosity increase, being incapable of being used in a variety of pH ranges and being incapable of providing sufficient thixotropy). The aqueous composition... Agent: National Starch And Chemical Company

20080131468 - Isocyclomaltooligosaccharide (s) , isocyclomaltooligosaccharide-forming enzyme, their preparation and uses: e

20080131470 - Eyelid scrub composition: An eyelid scrub composition comprising polyhexamethylene biguanide (PHMB), 1,2-hexanediol, 1,2-octanediol, and a pH stabilizing surfactant solution present in an amount effective to control the pH level of the composition between 5.5 and 7.5. The composition can further comprise moisturizers and foam stabilizers. The composition can be combined with a fabric... Agent: D'ambrosio & Associates, P.l.l.c.

20080131471 - Method of transferring bacteriostatic properties to a product in an aqueous solution: Textiles and also dishes and other household implements which are cleaned in laundry machines or dish washing machines can be afforded protection from an increasing colonization by bacteria when the textiles or the dishes are washed together with a microbicidal repository including a solid fiber composite of ion-exchanger particles loaded... Agent: Edell, Shapiro & Finnan, Llc

20080131473 - Cell-independent fabrication of tissue equivalents: This invention relates to cell-independent processes which mimic cellular bioremodelling and produce organised biomaterials which have mechanical properties and viable cell densities suitable for use as functional tissue implants. The biomaterials are produced by providing a gel comprising a matrix of scaffold fibres of and an interstitial fluid; and plastically... Agent: Nixon & Vanderhye, Pc

20080131476 - Cultured cell sheet, production method and tissue repair method using thereof: It is intended to provide a cultured cell sheet with excellent tissue adherence and flexibility. The above object can be achieved by culturing cells on a support for cell culture in which a surface of a substrate is coated with a temperature-responsive polymer whose lower or upper critical solution temperature... Agent: Nixon & Vanderhye, Pc

20080131474 - Methods of therapy with thrombin derived peptides: The present invention relates to a method for promoting cardiac tissue repair comprising administering to the cardiac tissue a therapeutically effective amount of an angiogenic thrombin derivative peptide and/or inhibiting or reducing vascular occlusion or restenosis. The invention also relates to methods of stimulating revascularization. In yet another embodiment, the... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080131475 - Methods of use of dual ppar agonist compounds and drug delivery devices containing such compounds: The present invention relates to uses of dual PPAR agonist compounds and delivery devices containing such compounds. The compounds are useful as pharmaceuticals for the treatment and/or prevention of VSMC proliferation, e.g., stenosis and restenosis, especially restenosis in diabetic patients.... Agent: Novartis Corporate Intellectual Property

20080131472 - Sulfated depolymerized derivatives of exopolysaccharides (eps) from mesophilic marine bacteria, method for preparing same, and uses thereof in tissue regeneration: The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerisation of said native EPSs followed by... Agent: Marshall, Gerstein & Borun LLP

20080131477 - Device and method for tissue engineering: A device and method for tissue engineering is disclosed. More particularly this invention relates to a bioabsorbable device and a method of its use which promotes controlled new tissue in-growth into voids or cavities occupied by the device as portions of the device are selectively absorbed within a host thereby... Agent: Philip S. Johnson Johnson & Johnson

20080131478 - Methods for encapsulation of biomacromolecules in polymers: A method for encapsulating a biomacromolecule in a pore-containing polymer comprising the steps of providing an encapsulating solution containing the biomacromolecule and the pore-containing polymer; contacting the biomacromolecule with the pore-containing polymer for a time sufficient for the biomacromolecule to enter the pores of the pore-containing polymer; and rearranging the... Agent: Calfee Halter & Griswold, LLP

20080131479 - Endoprosthesis with three-dimensional disintegration control: The present invention comprises a medical device having a support structure made from alternating layers. One or more layers may be made by direct metal laser sintering. One or more layers may be made by introducing nitrogen into a previously formed layer via excimer laser nitriding.... Agent: Fish & Richardson P.c.

20080131481 - Hypotensive lipid-containing biodegradable intraocular implants and related methods: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.... Agent: Stephen Donovan Allergan, Inc.

20080131482 - Hypotensive lipid-containing biodegradable intraocular implants and related methods: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.... Agent: Stephen Donovan Allergan, Inc.

20080131480 - New polyarylates for drug delivery and tissue engineering: Biocompatible polyarylates of diphenol compounds and poly(alkylene oxide) dicarboxylic acids, articles formed therefrom and therapeutic uses are disclosed.... Agent: Synnestvedt Lechner & Woodbridge LLP

20080131483 - Enhancement of drug delivery to the central nervous system: A method for targeting the central nervous system, for use in the treatment and/or prevention of central nervous system disorders and/or states, comprising administering to a subject in need of treatment an effective amount of a pharmaceutical composition by the ocular route of drug delivery.... Agent: Muhammad Abdulrazik

20080131484 - Intraocular drug delivery systems: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 10 days and one year or longer.... Agent: Allergan, Inc.

20080131485 - Sustained release intraocular implants and methods for preventing retinal dysfunction: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix,... Agent: Allergan, Inc.

20080131486 - Sustained release intraocular implants and related methods: Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable... Agent: Stephen Donovan Allergan, Inc.

20080131487 - Chymosin for the prevention and treatment of gastrointestinal disorders: The present invention is directed to medical or dietary treatments comprising administration of a zymogen such as chymosin or other rennins. Embodiments of the invention are directed to treating infant colic, heartburn, gastro-esophageal reflux (GER), gastro-esophageal reflux disease (GERD), irritable bowel syndrome, and recurrent abdominal pain. The invention is also... Agent: James Remenick Novak Druce & Quigg, LLP

20080131489 - Composite structure including a low vinyl acetate layer: A composite structure suitable for making transdermal delivery devices includes in sequence: (a) a liner film layer; (b) a containment layer having from zero to 15 wt. % content of vinyl acetate repeating units, the layer including either a thermal bonding copolyester resin or a combination of an ethylene-vinyl acetate... Agent: Ratnerprestia

20080131488 - Medical tape preparation: A medical tape preparation which comprises a support and, superposed on one side thereof in the following order, a pressure-sensitive adhesive layer and a release liner. The pressure-sensitive adhesive layer can contain a large amount of an oleophilic oily matter. The tape preparation is excellent in adhesion, cohesiveness, and stability... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20080131491 - Percutaneously absorbable preparation: The present invention provides a percutaneously absorbable preparation for percutaneous absorption of donepezil or its hydrochloride which is stable and resistant to loss of cohesiveness of the pressure-sensitive adhesive layer while attached and resistant to adhesive transfer due to cohesive failure during removal by peeling. The percutaneously absorbable preparation comprises... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080131490 - Stabilized donepezil-containing patch preparation: A donepezil-containing patch preparation is provided whereby production of donepezil-related substances in the pressure-sensitive adhesive layer is suppressed. A stabilizer comprising at least one or more species selected from the group consisting of ascorbic acid, metal salts or esters thereof, isoascorbic acid or metal salts thereof, ethylenediamine tetraacetic acid or... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080131494 - Dermal penetration enhancers and drug delivery systems involving same: The invention relates to a method for treatment or prophylaxis of a disease or condition in an animal comprising administering to a mucosal membrane of said animal in need of such treatment a therapeutically effective amount of a drug delivery system comprising at least one physiologically active agent or prodrug... Agent: Foley And Lardner LLP Suite 500

20080131492 - Dosage forms for movement disorder treatment: The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug compositions and dosage forms comprising said drug composition. Another aspect of the invention relates to methods of manufacturing the drug compositions... Agent: Ropes & Gray LLP

20080131493 - Method and multilayered device for controlled topical delivery of therapeutic agents to the skin: A multilayered composite sheet for delivering one or more therapeutic agents to the skin is disclosed. The composite sheet comprises a flexible porous polymer with open cells of a sufficient size for holding a therapeutic agent, an encapsulating agent for encapsulating the flexible porous polymer and therapeutic agent, and an... Agent: Vedder Price Kaufman & Kammholz

20080131497 - Formulations of dnase and methods of use thereof: Compositions comprising DNase encapsulated in a liposome are provided. Additionally, provided are compositions comprising a free enzyme and empty liposomes, compositions comprising a free enzyme and an antiinfective encapsulated in a liposome, compositions comprising a free enzyme, a free-antiinfective, and empty liposomes, compositions comprising a free enzyme, a free antiinfective,... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080131499 - Method and composition for solubilising a biologically active compound with low water solubilty: Compositions for forming molecular associates with lipophilic compounds and an improved method of loading lipophilic biologically active compounds into previously formed, aqueous suspensions of lipid particles. A preferred embodiment for injection purposes comprise lipid particles having sizes below 1000 nm in diameter, in a vial or other suitable container are... Agent: Buchanan, Ingersoll & Rooney Pc

20080131495 - Mucinous glycoprotein (muc-1) vaccine: The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1 based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.... Agent: Foley And Lardner LLP Suite 500

20080131498 - Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof: Pharmaceutically acceptable liposome-encapsulated busulphan formulations for parenteral administration are provided, as well as such formulations furthermore comprising glutathione and/or at least one glutathione precursor and a process for manufacture of the preparations. The formulations are stable, have improved biodistribution and significantly reduced side effects over those produced by oral administration... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080131496 - Topical application of melatonin directly or in liposomes for the amelioration of itching and histamine and non histamine related inflammatory skin changes: The invention is a topical therapeutically effective amount of melatonin encapsulated in a liposome applied topically to an area of skin affected by immunologic response, radiation treatment induced dermatitis, acne, insect bite or other irritant stimulus such as sunburn in order to reduce itching. The invention also proposes a topical... Agent: Brooke Schumm Iii Daneker, Mcintire, Schumm, Prince, Goldstein Et Al

20080131500 - Methods and compositions for rapid inactivation of proteins: Disclosed are methods of inactivating a protein, such as cleaving a disulfide bond of a protein, that involve contacting the protein with a reducing agent, a denaturant, and a hydroxide ion, wherein the pH of the composition is about 10.0 to about 14.0. Also disclosed are methods of treating or... Agent: Fulbright & Jaworski L.l.p.

20080131501 - Enhanced immediate release formulations of topiramate: The present invention provides enhanced immediate release formulations of topiramate, in which 80% of the active ingredient is released in the period of time of not more than 30 min. These formulations may be advantageously used for the treatment of acute neurological conditions, such as migraine.... Agent: Foley And Lardner LLP Suite 500

20080131502 - Capsule medication administration system and medication administration method: A capsule medication administration system includes: a first capsule for internal body marking; a second capsule for medication; a marking device which makes a marking within a living body; a drug retention section which retains a drug; a release device which releases the drug; a detection device which detects the... Agent: Scully Scott Murphy & Presser, Pc

20080131503 - Stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor: A pharmaceutical composition for oral administration comprising a fixed dose combination of a first solid pharmaceutical composition containing fenofibrate as the active substance and second solid pharmaceutical composition containing an HMG-CoA reductase inhibitor such as a statin as the active substance, wherein the first and the second pharmaceutical compositions are... Agent: Darby & Darby P.c.

20080131505 - Co-processed microcrystalline cellulose and sugar alcohol as an excipient for tablet formulations: A particulate co-processed composition comprising microcrystalline cellulose and at least one sugar alcohol is disclosed. A preferred sugar alcohol is mannitol. The composition has an improved compactability profile, lubricant sensitivity, and ejection profile compared to microcrystalline cellulose and the at least one sugar alcohol, either alone or in combination as... Agent: Fmc Corporation

20080131504 - Short term slow release drug delivery system: The present invention is directed to a novel short term slow release drug delivery system, preferably for solid oral dosage forms of water-soluble, alkaline salts of alkali metals and alkaline earth metals comprising polyvinylpyrrolidone and CPAA and preferably a wax component.... Agent: Fulbright & Jaworski, LLP

20080131507 - Method of forming a tablet: A method of forming a tablet includes the steps of pre-blending an active pharmaceutical ingredient susceptible to tackiness and a blending additive with a first mixing effort to form a pre-blend mixture, wherein the first mixing effort and a second mixing effort, resulting from mixing at least one excipient with... Agent: Ratnerprestia

20080131506 - Tablets comprising a biologically active substance and an excipient containing calcium carbonate: Tablet comprising at least one biologically active substance and an excipient, in which the excipient contains calcium carbonate and at least one additive selected from fatty acids, their salts, their esters, lipid materials, polysaccharides, polyvinylpyrrolidone and polyvinylpyrrolidone derivatives, acrylic compounds, mono-, di- or triglyceride esters, animal proteins, and mixtures of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080131508 - Oral transmucosal nicotine dosage form: The invention described herein relates to an oral transmucosal solid dosage form useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the invention transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of... Agent: Cephalon, Inc.

20080131510 - Composition and method for providing localized delivery of a therapeutic agent: The present invention is a composition for providing localized delivery of a therapeutic agent to a subject. The instant composition is a hydrophilic matrix-based prodrug system, wherein a protease substrate peptide acts as extracellular protease degradable spacer binding the therapeutic agent to a hydrophilic matrix. Release of the therapeutic agent... Agent: Licata & Tyrrell P.c.

20080131509 - Methods and compositions for treating tissue using silk proteins: Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized... Agent: Blakely Sokoloff Taylor & Zafman

20080131511 - Pharmaceutical composition for treatment of tear and salivary fluid drying: m

20080131512 - Biodegradable hydrogels: A prepolymer comprises polymerisable macromolecules, each polymerisable macromolecule comprises a polysaccharide backbone and at least two side units, wherein each of the at least two side units comprises a polymerisable group which is connected to the backbone via at least one group which is hydrolysable under physiological conditions; wherein the... Agent: Morrison & Foerster LLP

20080131515 - Emulsion composition, and foods and cosmetics containing the emulsion composition: An emulsion composition having a small particle size of emulsified particles and excellent emulsion stability is provided. The emulsion composition includes a phospholipid, an oil-based component and a surfactant, wherein the content of the surfactant exceeds 0.5 times by weight the content of the oil-based component, and exceeds 5 times... Agent: Birch Stewart Kolasch & Birch

20080131514 - Preservation of bioactive materials by spray drying: This invention provides methods and compositions to preserve bioactive materials in a matrix of powder particles. Methods provide high-pressure gas spraying and/or near supercritical spraying of formulations followed by drying in a stream of conditioned gas to form stable powder particles containing bioactive materials.... Agent: Quine Intellectual Property Law Group, P.c.

20080131513 - Sustained-release microspheres and methods of making and using same: Provided, among other things, are compositions and methods for making sustained-release microspheres, as well as a microsphere delivery system for the sustained release of an active agent. The microsphere delivery system comprises a homogeneous mixture of biodegradable polymer, active agent, and a so-called release-modifying agent (including a pH-stabilizing agent), and... Agent: Morrison & Foerster LLP

20080131516 - Granule formation: The present invention relates to oral granules of montelukast sodium.... Agent: Merck And Co., Inc

20080131517 - Time-sustained-release formulations comprising a beta-blocker: The present invention relates to compositions and methods of treating human subjects with a beta-adrenergic receptor blocking agent (“beta-blocker”) provided in a time-sustained-release delivery system. The time-sustained-release drug delivery systems includes at least three populations of beads, where each population of beads includes a beta-blocker. The beads may be selected... Agent: Arent Fox LLP

20080131518 - Process for preparing a medicament: The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080131519 - Novel antiviral and immune stimulant pharmaceutical composition: The invention relates to a novel antiviral and immune-simulating pharmaceutical composition, containing as active ingredient 20-85 mass % of a ω-3-polyunsaturated fatty acid ester, in fish oil concentrate containing 20-70 mass % of a 5,8,11,14,17-eicosapentaenic acid ester and a 4,7,10,13,16,19-docosahexaenic acid ester, further 1-lysine of a salt thereof, optionally a... Agent: Young & Thompson

20080131520 - Biodegradable biopolymers, method for their preparation and functional materials constituted by these biopolymers: A biodegradable biopolymer material consists of silk fibroin from domesticated silkworm; silk fibroin from wild silkworm; a composite material comprising silk fibroin from domesticated silkworm and silk fibroin from wild silkworm; or a composite material comprising either silk fibroin from domesticated silkworm or silk fibroin from wild silkworm and at... Agent: Arent Fox LLP

20080131521 - Methods for preventing or treating bone disorders: The present invention relates to a method of preventing or treating a bone disorder in a mammal, comprising administering to the mammal a therapeutically effective amount of a peptide having ability to modulate lipid metabolism but having no appreciable effect on IGF-1.... Agent: Foley And Lardner LLP Suite 500

20080131522 - Use of placental biomaterial for ocular surgery: The present application is directed to a method of performing ocular surgery using biomaterial from placenta and/or umbilical cord, wherein the biomaterial is contacted with a tissue of the eye, or tissue surrounding the eye, affected by the surgery. The biomaterial is also used in surgery performed to repair trauma... Agent: Jones Day

20080131523 - Composition and therapeutic uses thereof: A physiologically ingestible composition with microstructured water having a negative oxidation reduction potential of at least −40, and uses thereof are provided. The composition may further included dissolved oxygen, which may be present in an amount of 20 ppm to 150 ppm. The physiologically ingestible composition may be administered to... Agent: The Fleshner Group, Pllc

20080131524 - Compositions for treatment of viral-induced skin lesions and methods of using same: A composition and method for treatment of viral-induced skin lesions, such as warts, are described. The composition is comprised of tea tree oil and/or derivatives from tea tree oil and one or more minerals, such as iodide and/or selenium. The composition is used to prepare medicaments for the treatment of... Agent: Perkins Coie LLP

20080131525 - Therapeutic nutrient compositions or combinations and methods of their use: The invention may be summarized as follows. A combination to be parenterally delivered to a critically ill patient or for the purpose of improving mitochondrial function. The combination comprises a glutamine precursor molecule and an antioxidant in sufficient concentrations to be clinically effective. The combination may be prepared in the... Agent: Arent Fox LLP

20080131526 - Akt sensitization of cancer cells: Most human tumors find ways to resist anticancer drug monotherapy. Akt is considered a likely peptide providing such monotherapy drug resistance. Data indicates that Akt chemoresistance is induced in a p53-dependent manner and that inhibition of Akt may be an effective means of overcoming chemoresistance in cancer cells expressing wild-type... Agent: Smith Hopen, Pa

20080131527 - Topical analgesic composition: This invention concerns a synergistic combination of a topical anesthetic and wound barrier forming agent capable of providing extended analgesia of ‘significant open wounds’ (that being, for example, a laceration, surgical incision, abrasion, ulcer or burn, but not being a minor cut, scratch, sting, burn or abrasion) in which conventional... Agent: Stefan Kirchanski

20080131529 - Chinese traditional medicine composition for treatment of avian influenza, method for preparation and application thereof: A Chinese traditional medicine composition for prevention and treatment of avian influenza is provided. Its active ingredients are consisted of: herba houttuyniae 21.4 wt. %, Caulis lonicerae japonicae 17.9 wt. %, radix isatidis 14.3 wt. %, male fern rhizome 10.7 wt. %, radix et rhizoma sophorae tonkinensis 7.1 wt. %,... Agent: Ladas & Parry LLP

20080131528 - Methods and compositions for treating or preventing neurodegenerative diseases: The present invention provides novel compositions and methods for pharmaceutical or nutraceutical use in an animal, preferably in a human. In one aspect, compositions and methods are provided for treating or preventing neurodegenerative diseases, such as Alzheimer's disease, by restoring function of nerve tissues.... Agent: Wilson Sonsini Goodrich & Rosati

20080131530 - Composition comprising the extract of crude drug complex having neuroprotective activity for preventing and treating stroke and neurodegenerative diseases: The present invention relates to a composition comprising an extract of crude drug complex comprising Panax ginseng C. A. Meyer, Acanthopanax senticosus HARMS, Angelica sinensis DIELS, Scutellaria baicalensis GEORGI, prevention and treatment of stroke and neurodegenerative diseases such apoplexy, Alzheimer's disease (AD), Parkinson's disease (PD), Pick's disease, Creutzfeldt-Jakob disease and... Agent: Lucas & Mercanti, LLP

20080131531 - Konjac mannan and ginseng compositions and methods and uses thereof: Described are a number of compositions, namely a konjac mannan mixture, a ginseng composition, and a composition comprising konjac mannan and American ginseng. Methods of use of these compositions are described including their use for reducing blood glucose in non-diabetic and diabetic individuals, as well as reducing postprandial blood glucose... Agent: Bereskin And Parr

20080131532 - Fast asleep: An herbal composition for inducing sleep while simultaneously enhancing memory, Fast Asleep's oral strips contain a unique blend which provides hormone, natural herb and plant alkaloid. The blend consists of Kava-Kava extract (standardized to 30% kavalactones), Melatonin and Huperzine-A. The hormone and the sleep-inducing natural herb are in a range... Agent: Lorn Leitman

20080131533 - Compositions and methods for protection of harvested fruits from decay: Methods and compositions comprising essential oils or components thereof for protecting harvested fruits against decay caused by a specific pathogenic fungus are provided, such as Cinnamon cassia oil for protection of persimmons against Alternaria alternata, strawberries against Botrytis cinerea, or mandarins against Penicillium italicum or Penicillium digitatum.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080131534 - Use of a plant extract or plant juice: The present invention provides methods for increasing peroxisome proliferator-activated receptor-gamma (PPARγ) activity and/or endothelial nitric oxide synthase (eNOS) activity in a subject by administering to the subject a plant extract or plant juice from thyme, oregano, clove, nutmeg, red clover, bay leaves, red onion or grapes.... Agent: Fulbright & Jaworski L.l.p.

20080131535 - Skin protection composition: The present invention provides a method comprising suppressing the growth of a microorganism selected from the group consisting of anthrax bacteria and a virus selected from the group consisting of herpes simplex virus and influenza virus by providing an object containing or impregnated with a composition comprising Sasa extract, and... Agent: Sughrue Mion, Pllc

20080131536 - Drug for treatment of complications of diabetes mellitus: The method is used to treat diabetic complications such as neuropathy, peripheral neuritis, cataract and retinopathy have shown improvement with flavonoids present in licorice. The improvement was found to be due to the prevention of transformation of glucose to sorbitol by inhibiting aldose reductase enzyme, thus avoiding the accumulation of... Agent: Pyle & Piontek Attn: Thomas R. Vigil

20080131537 - Composition for treating asthma: The present invention relates to a composition for treating asthma in an individual comprising extracts of aniseed, thymus and inula, a method for treating asthma in an individual comprising the step of administering said composition, and the use of said composition as a medicament.... Agent: Knobbe Martens Olson & Bear LLP

20080131538 - Starch foam microparticles: The present invention relates to starch foam microparticles having a porous structure, and which typically have a diameter of less than or equal to about 50 microns. The present invention also relates to novel uses for the starch foam microparticles in beekeeping and in the pharmaceutical, plastics and fragrance industries.... Agent: Usda-ars-office Of Technology Transfer Patent Advisors Office